Radiation Protection Guidance for the United States (2018)



Radiation Protection Guidance for U.S.

- NCRP Council Committee 1 (CC-1)
- Update NCRP Guidance for Radiation Protection in the U.S.
- NCRP Scientific Committee 1-25 (SC 1-25) • Evaluate current science for Linear-Nonthreshold (LNT) as model
- for radiation protection applications. • NCRP Scientific Committee 1-23 (SC 1-23)
- Guidance on Radiation Dose Limits for the Lens of the Eye.
- See <u>ncrponline.org</u> for ongoing status updates.

NCRP Council Committee 1 CC-1 will update NCRP • Chair – Kenneth Kase guidance for radiation at No. 114 protection. Co-Chair – Don Cool LIMITATION OF EXPOSURE TO IONIZING RADIATION Stakeholders

- Current draft is early work in progress.
- AAPM input will be crucial for relevance, clarity, and usefulness.
- Co-Chair John Boice
- Agencies/Regulators Exposed Individuals

Public and Private

NCRP CC-1 Framework

- Provide framework for appropriate protection against detrimental effects without limiting beneficial uses/results.
- Update the bases of System of Protection for U.S.
- Include sources and exposures not previously addressed:

4

40

- · Patients exposed in medical imaging and radiation therapy;
- Caregivers for such patients;
- · Voluntary participants in medical research; and • Exposures of nonhuman species in the environment.
- Prudent guidance for adequate protection.



Build a Culture of Protection Characterize exposures.

- Establish Dose Criteria and ID exposures that warrant specific attention to reduce magnitude.
- Influence the entire dose distribution and shift exposures towards lower values.
- Reduce inequity.
- Enable stakeholder engagement and action.





NCRP CC-1 Science/Ethics/Communication

- Development based upon scientific information, ethics, and expert opinion derived from experience.
- Ethical considerations
 - Provide transparency about the values that underlie the system.
 - Principles: Benificence: provide more good than harm.
 - Non-maleficence: prevent harm.
 - · Autonomy: self determination.
 - Justice: act fairly (ensure equity).
- Communicating NCRP system to Stakeholders Establish and maintain Trust and Confidence



NCRP CC-1 Considerations

- Adverse Health Outcomes from Radiation Exposure
- Tissue Reaction (severity increases with dose)
- Stochastic Effect (probability increases as function of dose)
 - Cancer Incidence and Mortality
 - Site specific, sex/age, special exposure groups, new RERF data, large-scale worker study data coming available. Non-Cancer Detriments
- Significant Uncertainty at low dose and dose rates
- Require judgment for model selection
- Radiation protection purposes



NCRP CC-1 Recommendations

- Similar, but likely not identical, to those made previously by NCRP and ICRP.
- Restricting dose to skin will be based on NCRP Report #130 and NCRP Statement #9.
- · Restricting dose to lens will be based on conclusions of NCRP SC 1-23.
- Restricting dose for emergency exposure will be based on NCRP Report #165 and recommendations of NCRP SC 3-1.

NCRP CC-1 Recommendations

- Occupational and public exposure categories dose criteria for exposure situations will be similar to NCRP Report #116 and ICRP Publication #103.
- Special considerations for certain medical staff, emergency responders, and the embryo/fetus.
- Dose criteria for comforters/caregivers will be based on recommendations of previous NCRP reports.
- Dose criteria for human research subjects will be based on recommendations of NCRP SC 4-7.

NCRP CC-1 Schedule and Info

- Draft materials are under review with NCRP PACs.
- Discussions of proposals at IRPA, CRCPD, HPS, AAPM, and other professional societies.
- ICRP Task Group providing consultation.
- Revised draft for Council consideration in 2017.
- For copies of current working draft or other information:
- Ken Kase: <u>krkase539@gmail.com</u>
 Marvin Rosenstein: <u>smrmr@msn.com</u>



NCRP Scientific Committee 1-25 SC 1-25 on LNT Recent epidemiologic studies and implications for the Linear-Nonthreshold Model for Radiation Protection Purposes Chair – Roy Shore Co-Chair – Larry Dauer Commentary in support of CC-1 by 2017.

NCRP SC 1-25 Purpose

- Prepare a commentary reviewing recent epidemiologic studies and evaluate whether the new observations are strong enough to support or modify the LNT model as used in radiation protection today.
- Will include recent (within ~5y) epidemiologic studies with extensive study and adequate dosimetry. Ecological studies will not be included.
- Studies Integration of New Findings –
- Implications on RP –

Improved communication to broader audiences.



葫

榭

NCRP SC 1-25 Epidemiological Studies



Cancer studies: atomic bomb survivors, Chernobyl, CT exams, INWORKS, 15 country study(summary), Mayak, other worker studies, Atomic Veterans, Techa River, U.S. Radiologic Technologists, Million Person Study, high natural background, Taiwan.

Cardiac/circulatory: atomic bomb survivors, TB/Fluoro, other worker studies.

- Other considerations genetics, children, prenatal, noncancer effects (hypothyroidism).
- Assessment of strength of Dosimetry and Statistical models.

NCRP Scientific Committee 1-23

- SC 1-23 Guidance on Radiation Dose Limits for the Lens of the Eye.
- Review radiogenic cataract mechanisms.
- Evaluate epidemiological evidence to date.



Co-Chair – Larry Dauer
Commentary in

support of CC-1 by 2016.



7/27/16













NCRP SC 1-23 Epidemiology

- Many populations studied to date. Large variations. Only a few investigate low dose effects. Many with poor dosimetry. Method of scoring endpoints differ. Confounders exist.
- General conclusions:
- Strong likelihood of an association between exposure to ionizing radiation and initiation or development of various opacifications and/or cataracts.
- Recognize large uncertainty.
- A lower threshold or no threshold *may* be an appropriate model for radiation cataractogenesis risk.

20

NCRP SC 1-23 Draft Conclusions

- Should radiation-induced cataracts be characterized as stochastic or deterministic effects?
 - Best epidemiology still indicates a threshold, not possible to make a specific quantitative estimate with available data.
- Effects of LET, dose rate, acute/protracted dose delivery on cataract induction and progression?
 - Need high-quality epi and mechanistic studies with better dosimetry and scoring to answer.

2:

NCRP SC 1-23 Draft Conclusions

- How should detriment be evaluated for cataracts?
 - Cataracts not life threatening but may affect individual's ability to carry out their occupations or other daily tasks.
 SC 1-23 encourages NCRP-168 recommendation to regard eye
 - exposures in much the same way as whole-body exposures. Thus, ensure exposures are consistent with ALARA principles. This includes careful justification and optimization in exposure situations with doses to the lens of the eye.



NCRP SC 1-23 Draft Conclusions

- Based on current evidence, should NCRP change the recommended limit for the lens of the eye at this time?
- A threshold model should continue to be used for radiation protection purposes.
- While some epi evidence points to a threshold for visionimpairing cataracts for doses on the order of 1-2 Gy, a specific quantitative estimate of lens effect thresholds can not be made at this time.
- It is prudent to reduce the current recommended annual lens of eye occupational dose limit from 150 mSv to 50 mGy. (Note - these considerations are under final review)

NCRP SC 1-23 Recommendations

- Urgent need for comprehensive evaluation of overall effects of radiation on the eye.
- New RERF studies being initiated for A-Bomb Survivors.
- Need for new, high-quality epidemiology and basic research on mechanisms of action.
- Ongoing opportunity for dose-sparing optimization and dneed for more education and accurate dose assessment.
- · Need additional information on pediatric effects.
- Longitudinal studies.
- Stakeholder Workshop on August 29th in NYC.

Radiation Protection Guidance for U.S.

- NCRP Council Committee 1 (CC-1)
 Update NCRP Guidance for Radiation Protection in the U.S.
- Update NCRP Guidance for Radiation Protection in the
 NCRP Scientific Committee 1-25 (SC 1-25)
 - Evaluate current science for Linear-Nonthreshold (LNT) as model for radiation protection applications.
- NCRP Scientific Committee 1-23 (SC 1-23)
- Guidance on Radiation Dose Limits for the Lens of the Eye.
- See <u>ncrponline.org</u> for ongoing status updates and for information on the August 29th Stakeholder Workshop in NYC on Lens of Eye.

NOT TO BE DISSEMINATED OR REFERENCED

NCRP DRAFT CC 1 Report

Working Draft (4-12-16) [Awaiting PACs, ICRP and Member input] ... added Fleming (4-10/11-16)

General Comments

RADIATION PROTECTION GUIDANCE FOR THE UNITED STATES (2018)

April 2016

Note: Copyright permission is being sought for the figures and tables requiring such permission prior to their use in the final NCRP publication.

National Council on Radiation Protection and Measurements7910 Woodmont Avenue, Suite 400, Bethesda, Maryland 20814

Comment [M1]: Preston ... I really did not have any major concerns except the usual of length of section not necessarily being representative of relative importance to the task.

Comment [M2]: Bushberg ... Suggest robust use of hyperlinks to dentitions in the glossary and (if necessary) the larger NCRP glossary

6 **Preface**

7 In the first quarter of 2014, a proposal to write a National Council on Radiation Protection 8 9 and Measurements (NCRP) report on Radiation Protection Guidance for the United States was approved by the Board of Directors. Council Committee 1 (CC 1) was formed in the second 10 quarter of 2014. The current Report updates and expands on the 1993 NCRP Report No. 116, 11 Radiation Protection Guidance for the United States (NCRP, 1993a). The first meeting of CC 1 12 was held on September 3-4, 2014. 13 14 Since 1993, substantial advances in radiation effects knowledge, as well as radiation 15 protection understanding and culture, have occurred. New knowledge has been obtained on 16 radiation effects at doses lower than apparent in 1993. Noncancer effects such as cardiovascular 17 disease and cataracts are emerging as potentially important concerns. Discussion of ethical 18 foundations had not been introduced Ethics has not been applied and the severity of health 19 outcomes have not been addressed in a context of radiation protection. The Fukushima nuclear 20 reactor accident and the ever-rising increase in population exposure to radiologic imaging 21 examinations [computed tomography (CT) examinations, positron emission tomography scans, 22 and nuclear medicine procedures] have increased the awareness of the importance of radiation 23 protection guidance in the United States. 24 25 In 2007, the International Commission on Radiological Protection (ICRP) published an 26 update of their recommendations (Publication 103) (ICRP, 2007). Subsequently an important 27 ICRP report on tissue reactions (previously called deterministic effects) and noncancer effects 28 29 was published in 2013 (Publication 118) (ICRP, 2013). While the goals for radiation protection 30 in the United States are the same as those for the international community, there are some 31 differences in the specific approaches taken to obtaining these goals {i.e., in implementing the three pillars of radiation protection of justification, optimization [the as low as reasonably 32 33 achievable (ALARA) principle}, and dose limitation] (Kase, 2016). These differences will be

34 discussed in this Report.

35

Comment [M3]: Fleming edit

Comment [CD4]: Cool ... I would change this to "medical use of radiation". I think we must be careful to not just be focused on radiology.

36	A review of recent radiation epidemiologic studies by NCRP Scientific Committee SC 1-25	
37	(in progress) will address dose-response models in general, including threshold models, and their	
38	applicability to radiation protection guidance.	
39		
40	CC 1 considered numerous radiation protection issues. It was particularly important that this	
41	Report point out where there is consistency with current U.S. and international radiation	
42	protection guidance and where there are other points of view for issues where the NCRP	
43	guidance is unique for the United States and the rationale for such differences. This Report	
44	represents the guidance for the United States at the time of publication of this Report, which is	
45	projected to be completed and published in 2018. An illustrative listing of issues is given below	
46	whose roles in the overall radiation protection system were examined. However, it should be	
47	recognized that all relevant areas (more than those listed below) were reviewed and that the	
48	listing below is only a partial illustrative list.	
49		
50	Noncancer effects such as cardiovascular disease and cataracts	
51	• Effect of age at exposure	
52	• Effect of sex	
53	Genetic susceptibility	
54	• Severity of the radiation effect	
55	•Treatability of the radiation effect	
56	• The ethical bases for justification, ALARA (optimization), and dose limits	Comment [M5]: Fleming addition
57	• The ALARA principle	
58	• A risk-based versus a dose-based system	
59	• The appropriate situations when the effect has a threshold	
60	• Dose and dose-rate effectiveness factor (DDREF), dose-rate effectiveness factor (DREF),	
61	and low-dose effectiveness factor (LDEF)	
62	Biologically-based dose-response models	
63	Risk assessment for U.S. radiation-exposed populations	
64	• Energy-dependent radiation weighting factors for low linear-energy transfer radiation	
65	• Weighting factors for specific radionuclides or classes of radionuclide emitters 3	

66	Clarity of radiation quantities and units	
67	Reporting and recording doses and units	
68	Skin dose and hot particles	
69	Patient protection in medical practice	
70	Revision or reassessment of NCRP Report No. 115 (<u>Risk Estimates for Radiation</u>	
71	Protection) (NCRP, 1993b): two Scientific Committees were formed to assist this	
72	process, one on Guidance on Radiation Dose Limits for the Lens of the Eye (SC 1-23)	
73	and the other on Recent Epidemiologic Studies and Implications for the Linear Non-	
74	Threshold Model (SC 1-25)	
75	 Radiation protection for nonhuman species 	
76	• Clarification of the philosophical basis for radiation protection (e.g., anthropomorphism)	Comment [M6]: Fleming addition
77		
78	Unique aspects of the manner in which CC 1 has operated include:	
79		
80	• It was the first Committee formed under the direct oversight of the Council as	
81	opposed to oversight by one of the NCRP Program Advisory Committees (PACs).	
82	• All the PACs participated in the development and review of the recommendations.	
83	• The 2015 NCRP Annual Meeting was on "Changing Regulations and Radiation	
84	Guidance: What Does the Future Hold?" and addressed the rulemaking activities	
85	ongoing within the NRC, U.S. Environmental Protection Agency (EPA) and U.S.	
86	Department of Energy (DOE) for which the CC 1 guidance should prove useful	
87	(<mark>Cool, 2016</mark>).	
88	• An extensive effort was made to consult with and present to numerous national and	
89	international stakeholder groups during both the development and review phases of	
90	this work, including to name just a few: ICRP, the International Radiation Protection	
91	Association (IRPA), the Health Physics Society (HPS), the Radiation Research	
92	Society (RRS), the American Association of Medical Physics (AAPM), and the	
93	American College of Radiology (ACR).	
94		
95	This Report was prepared by Council Committee 1 (CC 1) on Radiation Protection	

- 96 Guidance for the United States. Serving on Council Committee 1 and the PAC Advisors were:
- 97 [bios (to be added at the end) will include other relevant NCRP and radiation organization roles]

98

99

100 101

102 103

104 105

106

107

108

109 110

111

112

113

114 115 116

117 118

NOT TO BE DISSEMINATED OR REFERENCED

Jo National Council c	
Ke	

John D. Boice, Jr, <u>Co-Chair</u> National Council on Radiation Protection and Measurements Bethesda, Maryland

> Kenneth R. Kase, <u>Co-Chair</u> Palo Alto, California

Members

Armin Ansari Centers for Disease Control and Prevention Atlanta, Georgia

Jerrold T. Bushberg U.C. Davis School of Medicine Sacramento, California

Donald A. Cool Electric Power Research Institute Charlotte, North Carolina

Lawrence T. Dauer Memorial Sloan Kettering Cancer Center New York, New York

Darrell R. Fisher Dade Moeller Health Group Richland, Washington

Patricia A. Fleming Saint Mary's College Notr<u>e</u> Dame, Indiana

Kathryn Higley Oregon State University Corvallis, Oregon Randell N. Hyer Center for Risk Communication Stevensville, Maryland

William E. Irwin Vermont Department of Health Burlington, Vermont

Fred A. Mettler, Jr. Albuquerque, New Mexico

Donald L. Miller Food and Drug Administration Rockville, Maryland

R. Julian Preston Chapel Hill, North Carolina

Gayle E. Woloschak Northwestern University Chicago, Illinois

Consultants

S. James Adelstein Harvard Medical School Boston, Massacusetts

Ralph L. Andersen Burke, Virginia

Michael A. Boyd U.S. Envirnonmental Protection Agency Washington, D.C.

NOT TO BE DISSEMINATED OR REFERENCED

119	
120	PAC 7 Liaison
121	
122	John E. Till Disk Assessment Computing
123	Nisk Assesssment Corporation
124	Neeses, South Carolina
126	PAC Advisors
127	
128	Kathryn D. Held (PAC1)
129	Kathryn H. Pryor (PAC 2)
130	John W. Poston, Sr. (PAC 3)
131	James A Brink (PAC 4)
132	S.Y. Chen (PAC 5)
133	Steven I. Simon (PAC 6)
134	Faul A. LOCKE (FAC 7) Stavan Baskan (BAC 7)
135	Sieven Deckei (FAC 7)
137	NCRP Secretariat
138	
139	Marvin Rosenstein, Staff Consultant
140	Cindy L. O'Brien, Managing Editor
141	Laura J. Atwell, Office Manager
142	David A. Smith, <u>Executive Director</u>
143	
144	
145	The Council expresses appreciation to the Committee members for the time and effort
146	devoted to the preparation of this Report. NCRP would also like to thank the many colleagues
147	not on the Committee, and some not on the Council, who provided critical reviews and guidance
148	in a very timely manner when asked about specific areas of the Report. NCRP also gratefully
149	acknowledges the financial support provided by the U.S. Nuclear Regulatory Commission
150	(NRC) under Grant No. NRC-HQ-60-14-G-0012 and the Centers for Disease Control and
151	Prevention (CDC) under Grant No. 5UE1EH000989. The contents of this Report are the sole
152	responsibility of NCRP, and do not necessarily represent the views of NRC or CDC.
153	
154	John D. Boice, Jr.
155	President
156	

7

NOT TO BE DISSEMINATED OR REFERENCED

References (Preface) 157

- 158 159 Cool (2016). Health Phys. 110(2):233-7.
- ICRP (2007a). ICRP Publication 103 ICRP (2013). ICRP Publication 118 160
- 161
- Kase (2016). Health Phys. 110(2):127-45. 162
- NCRP (1993a). NCRP Report No. 116, <u>Radiation Protection Guidance for the United States</u> NCRP (1993b). NCRP Report No. 115 (<u>Risk Estimates for Radiation Protection</u>) 163
- 164

165	Contents
166	
167	Preface
100	Executive Summery (Bonding)
109	Executive Summary (rending)
171	1 Introduction 12
172	1. Introduction 12
173	1.2 Effects of Concern in Radiation Protection
174	1.3 Determination of Radiation Effects
175	1.3.1 Introduction
176	1.3.2 Epidemiologic Studies of Radiation Effects
177	1.3.2.1 Types of Studies
178	1.3.2.2 Limitations
179	1.4 Developing the System for Radiation Protection
180	1.5 The Basis and Structure of the System for Radiation Protection
181	1.6 Summary
182	
183	2. Exposure Situations and Categories of Exposure
184	2.1 Exposure Situations
185	2.1.1 Planned Exposure Situations
186	2.1.2 Emergency Exposure Situations
187	2.1.3 Existing Exposure Situations
188	2.2 Categories of Exposure
189	2.2.1 Occupational Exposure
190	2.2.1 Public Exposure
191	2.2.3 Medical Exposure
192	
193	3. The Ethical Foundations of the System for Radiation Protection
194	3.1 Moral Significance
195	3.1.1 Anthropocentrism
196	<u>3.1.2 Anthropomorphic Extensionism</u>
197	$3.1.3 \pm $ Biocentrism
198	3.14.3 ECOCENTRISM
199	3.2 Ethical Found Theories Virtue
200	2.2.2 Ethioal Energies
201	2.2.2 Ethics and the Eurodemontal Dringinles of Rediction Protection
202	5.2.5 Eules and the Fundamental Finiciples of Kadiation Flotection
203	1 The NCRP System for Radiation Protection 32
204	4. The focker system for Kadiation Protection
205	4.1.1 Addition or Removal of a Source
200	4.1.2 Medical Exposures
208	4.2. Optimization
209	4.2.1 Public
210	4.2.2 Occupational
211	4.2.3 Medical
212	4.3 Restriction of Individual Dose
213	4.3.1 Occupational
	9

214	4.3.2 Public
215	4.3.3 Medical
216	4.3.3.1 Imaging Procedures
217	4.3.3.2 Radiation Oncology
218	
219	5. Quantities, Units, and Measurements 44
220	5.1 Introduction
221	5.2 Base Quantities
222	5.2.1 Energy Imparted by Ionizing Radiation
223	5.2.2 Absorbed Dose
224	5.2.3 Absorbed Dose Rate
225	5.2.4 Exposure (External Radiation Fields)
226	5.2.5 Exposure Rate
227	5.3 Derived Quantities
228	5.3.1 Relative Biological Effectiveness
229	5.3.2 Radiation Weighting Factors
230	5.3.3 Equivalent Dose
231	5.3.4 Tissue Weighting Factors
232	5 3 5 Effective Dose
233	5.3.6 Committed Effective Dose
234	5 3 7 Collective Population Dose
235	5.4 Direct Measurements of Radiation Dose
236	5.4.1 Operational Quantities
237	5.5 Summary
238	o.o Samilary
239	6. Adverse Health Outcomes from Radiation Exposures
240	6.1 Categories of Adverse Health Outcomes
241	6.2 Cancer Incidence and Mortality
241	6.2 1 Site-Specific Risk Estimates
242	6.2.2 Effect of Age at Exposure
243	6.2.2 Effect of Sex
244	6.2.4 Special Exposure Groups
245	6.2.1 Infants and Children
240	6.2.4.2 Embryo and Fetus
247	6.3 Heritable (Genetic) Effects
240	6.4 Effect of Genetic Suscentibility
250	6.5 Cardiovascular Effacts
250	6.6 Central Nervois System Effects
251	6.7 Thyroid (Noncancer Effects)
252	6.7 Thylord (Volteanet) 6.8 Lens of the Eva (Cataract)
255	0.8 Lens of the Lye (Catalact)
/	6.9 Skin Effects
254	6.9 Skin Effects
254 255 256	6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations
254 255 256 257	6.9 Skin Effects6.10 Psycho-Social Effects6.11 Summary and Recommendations
255 256 257	 6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations
254 255 256 257 258 250	 6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations 7. Radiation Risk Estimates, Detriment and Uncertainties
254 255 256 257 258 259 259	 6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations 7. Radiation Risk Estimates, Detriment and Uncertainties
254 255 256 257 258 259 260 261	 6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations 7. Radiation Risk Estimates, Detriment and Uncertainties
255 256 257 258 259 260 261	 6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations 7. Radiation Risk Estimates, Detriment and Uncertainties
255 256 257 258 259 260 261 262	 6.9 Skin Effects 6.10 Psycho-Social Effects 6.11 Summary and Recommendations 7. Radiation Risk Estimates, Detriment and Uncertainties

263	7.1.4 Reduction in Quality of Life
264	7.1.5 Life Shortening
265	7.2 Risk Estimates and Uncertainty: Addressing the Issue
266	7.2.1 Introduction
267	7.2.2 Attributability
268	7.2.3 Dose and Dose-Rate Effectiveness Factor
269	7.2.3.1 Low Dose Effectiveness Factor
270	7.2.3.2 Dose-Rate Effectiveness Factor
271	7.2.4 Radiation Weighting Factors
272	7.2.5 Tissue Weighting Factors
273	7.2.6 Biologically-Based Dose-Response Models
274	
275	8. Recommendations
276	8.1 Introduction
277	8.1.1 Principles of Radiation Protection
278	8.1.2 Ethics Principles
279	8.2 Tissue Reactions
280	8.2.1 Skin, Including Extremities
281	8.2.2 Lens of the Eye
282	8.2.3 Acute Organ Effects
283	8.3 Stochastic Effects
284	8.4 Planned Exposure Situation
285	8.4.1 Occupationally Exposed Individuals
286	8.4.1.1 Special Considerations and Dose Criteria for Medical Staff
287	8.4.1.2 Embryo and Fetus
288	8.4.2 Exposure of the Public
289	8.4.3 Exposure Related to Certain Medical Activities
290	8.4.3.1 Comforters and Caregivers
291	8.4.3.2 Human Studies Research
292	8.5 Emergency Exposure Situation
293	8.5.1 Occupationally Exposed Individuals
294	8.5.2 Members of the Public
295	8.6 Existing Exposure Situation
296	8.6.1 Radon and Naturally Occurring Radioactive Material
297	8.6.2 Occupationally Exposed Individuals
298	8.6.3 Members of the Public
299	
300	9. Protection of the Environment
301	9.1 Philosophical Basis of Environmental Radiation Protection
302	9.2 Scientific Basis for Radiation Protection Guidance
303	9.3 Recommendations
304	
305	10. Communication of NCRP's System of Radiation Protection to Stakeholders
306	10.1 NCRP's Responsibility to Communicate its System of Radiation Protection
307	10.1.1 Standards of Scientific Excellence and Quality Required by NCRP
308	10.1.2 Peer Review Process for NCRP Reports
309	10.1.3 Other Forms of Communication of NCRP Recommendations to Stakeholders
310	10.1.4 Recent New Initiatives of NCRP Related to Communication of its Recommendations
311	10.1.5 Future Initiatives in Communication of NCRP Recommendations

NCRP CC 1
Draft of April 2016

NOT TO BE DISSEMINATED OR REFERENCED

312	10.2 Communication Strategies for Stakeholders
313	10.2.1 Governmental Agencies
314	10.2.2 Lawmakers
315	10.2.3 Scientific and Professional Organizations
316	10.2.4 Radiation Workers
317	10.2.5 The General Public
318	10.2.6 The Media
319	10.3 Challenges of Communicating Concepts of Radiation Protection
320	
321	Glossary
322	·
323	Abbreviations, Acronyms and Symbols154
324	
325	References (currently at the end of each Section
326	

327 1. Introduction

328 329 330

339

1.1 Goals

The primary goal of the NCRP recommendations is to provide a framework for an appropriate 331 level of protection for people and the environment against the detrimental effects of radiation 332 exposure without unnecessarily limiting the beneficial human actions that may result in or from 333 such exposure. Thus, the recommendations are designed to prevent the occurrence of serious 334 radiation-induced injuries (both acute and chronic) in exposed persons and to reduce the 335 probability of stochastic effects in exposed persons to a degree that is ethically appropriate in 336 relation to the benefits to the individual and to society from the activities that generate such 337 338 exposures.

340 This Report updates the bases of the System for Radiation Protection for the United States (these updated recommendations are referred to as The NCRP System in the rest of this Report) and the 341 342 fundamental recommendations to limit exposures and their subsequent consequences. Its purpose is to inform the reader about all sources of ionizing radiation exposure. It adds to previous 343 recommendations by NCRP (1993a) and ICRP (2007a) by including sources and exposures that 344 have not been specifically addressed. These include patients exposed in medical imaging 345 procedures and radiation therapy, caregivers for patients during medical imaging procedures or 346 treated with radioactive materials, voluntary participants who may be exposed to ionizing 347 radiation in medical research, workers and the general public exposed to naturally occurring 348 radiation sources including those enhanced by technology, and exposure of nonhuman species in 349

350 the environment.

351

The National Council on Radiation Protection and Measurements (NCRP) published its last 352 complete set of basic recommendations on exposure to ionizing radiation in 1993 (NCRP, 353 1993a). The International Commission on Radiological Protection (ICRP) published its most 354 355 recent recommendations for a system of radiological protection¹ in 2007 (ICRP, 2007a). It is now almost 10 y since the publication of the ICRP report and biological research continues 356 to reveal information that adds to our understanding of radiation effects. Recent epidemiologic 357 studies have also added to the understanding of the relationship of radiation dose to the risk of 358 harm. This additional information and understanding leads to the need to consider a clear 359 360 rationalization of the concept of detriment and its application in The NCRP System. Moreover, NCRP has identified portions of the previous recommendations that would benefit 361 from further explanation and additional clarity. It is important to emphasize that The NCRP 362 System recommended is prospective and designed for protection of the population of the United 363 States. Because the risk estimates for various health effects are based on averages over a specific 364 population, the calculated detriment values cannot apply to any single individual. Thus, The 365 366 NCRP System is not intended for retrospective risk analysis for individuals, or for diverse or undefined populations (Figure 1.1). 367

Comment [M7]: Fleming

Will they not publish a new report by the time this report is out. If so cite it. I believe Cool sent me an earlier version of an ethics chapter for that report.

Comment [PF8]: Fleming ... Is this true in medical therapy? (We seem to be doing this in SC 4-7)

¹ The term "radiological protection" is used when quoting from or referring specifically to the ICRP or the ICRP system. Otherwise, the term "radiation protection" is used in this Report on NCRP recommendations. The term "radiologic" is used as a general adjective.



368

373

This Report also explains the need for the development of a Safety Culture that engages workers who may be exposed to radiation, as well as members of the public, in the control of their individual exposure.

377

It is important to be clear about the relationship among scientific, advisory and regulatory bodies and their respective responsibilities for radiation protection. Scientific bodies conduct and analyze studies that provide information on the effects of radiation exposure, and test radiation exposure and protection hypotheses. Advisory bodies interpret the scientific data and establish radiation protection guidance. Regulatory bodies use guidance to promulgate rules for programs that help control exposures to radiation. NCRP has evaluated the current status of this information, guidance and rules and has concluded that an updated NCRP report on basic

recommendations for radiation protection for the United States is timely.

This Report updates the basic recommendations of the NCRP that were published in NCRP

(1993a), as applicable to the current needs in the United States. NCRP agrees with ICRP 388 statements in the Preface to Publication 103 (ICRP, 2007a) that while the biological and physical 389 assumptions and concepts underlying the basic recommendations remain robust, some updating 390 is required. The overall estimates of cancer risk attributable to radiation exposure have not 391 changed greatly in the past 25 y. Conversely, the estimated risk of heritable effects is currently 392 lower than that previously determined. The overall estimates of tissue reactions (formerly 393 deterministic effects)² and stochastic risk remain fundamentally the same. Also as ICRP noted, 394 "It has also become apparent that the radiological protection of the environment should receive 395 more emphasis than in the past". 396

The recommendations and concepts provided in ICRP Publication 103 (ICRP, 2007a) have been
carefully reviewed and in the interest of a uniform international approach to radiation protection
have, in general, been incorporated in this Report. The NCRP System remains based on the three
principles of Justification, Optimization of Protection (the ALARA principle), and Application
of Dose Limits (now termed Dose Criteria by NCRP). However, NCRP recommends some
notable additions to the principles. These are:

- 1. Emphasize the need to justify the removal of a radiation source as well as the addition of a source.
- 407
 2. Include in the justification of specific medical procedures that use radiation the
 408
 409
 409
 409
 409
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
- 410 3. Add the concept of engaging the affected individuals (stakeholders) in the process.
- 4. NCRP has also added a section on the ethical considerations that underlie The NCRP
 System, such as the extension of radiation protection of the environment and the ethical
 principles that inform the justification, optimization, and restriction of dose.
- 414

404

405 406 **Comment [PF10]:** Fleming ... This should be communicated to SC 4-7 and other committees who are using dose limits or the principle of dose limitation.

² In the Report, NCRP has adopted the term tissue reaction in place of deterministic effect.

NOT TO BE DISSEMINATED OR REFERENCED

Finally it is important to emphasize that in this Report NCRP makes no recommendations for 415 dose limits. Instead the recommendations are stated as individual dose criteria for optimization 416 during the planning and design process or individual dose criteria for control to restrict dose 417 during operations, to establish values adequate for protection. The approach emphasizes the role 418 of optimization (ALARA) in radiation protection, and the inherent difficulty in specifying an 419 absolute value for a limit that is applicable in all circumstances. It This also allows regulators 420 and other users more flexibility in designing radiation protection programs while still providing 421 protection to workers, medical patients and the public. 422 423 424 In addition to furthering an international harmonization of radiation protection recommendations and standards, this Report aims to: 425 Clearly explain the basis for its recommendations and the reasons for any changes from 426 427 NCRP (1993a) as well as any differences from ICRP (2007a). 428 Clearly state what is known and what is unknown about biological response to radiation rationalized with new epidemiologic information and the significance relative to the 429 recommendations. 430 Clearly explain the limitations of epidemiologic studies of radiation effects. 431 Clearly identify the uncertainties involved in assessing the risks and detriment of 432 radiation injuries. 433 Consider the ease of implementation of the recommendations. 434 Rationalize The NCRP System for all sources and applications of radiation. 435 • 436 • Specify the rationale for the recommended dose criteria. 437 **1.2 Effects of Concern in Radiation Protection** 438 439

Ionizing radiation, like any other toxin, can damage or kill cells and thus harm bodily tissues and 440 organs. The number of cells affected depends on the dose of toxin absorbed by the body and the 441 sensitivity of the cells affected. In the case of ionizing radiation the cells damaged by the 442 443 radiation are those in which some of the energy carried by the radiation is deposited, or for some cases nearby cells. If a large number of cells in a body organ are killed, the function of that organ 444 will be impaired or destroyed. Damaged cells may be repaired by natural body processes and 445 returned to their normal function. In some cases the cell repair process may result in an error, 446 which could change the function of the cell. This could result in the weakening of organ function 447 or growth of new tissue, such as with cancer development. 448 449

The serious radiation-induced adverse health effects of concern in radiation protection fall into
two general categories: tissue reactions and stochastic effects. An adverse tissue reaction is
defined in a general sense as an injury to a tissue or organ that increases in severity with

increasing radiation absorbed dose, presumably above a certain threshold absorbed dose.

Examples of acute or early adverse tissue reactions are erythema and other skin damage. Chronic

or late adverse tissue reactions include fibrosis, organ atrophy and a decrease in the number of

germ cells that may result in sterility or a reduction in fertility.

457

Comment [PF11]: Fleming ... So, the recommendations are individual dose criteria based on averages over specific populations? I can bet the public doesn't understand this. I can not recall if we emphasize this in the chapter on communication.

Comment [M12]: Cool edit

A stochastic effect is one in which the probability of the effect occurring increases continuously 458 with increasing absorbed dose while the severity of the effect, in affected individuals, is 459 independent of the magnitude of the absorbed dose. The probability of a specific effect for a 460 given absorbed dose is dependent on individual factors such as age and sex. The stochastic effect 461 of most concern for radiation protection is the induction of cancer. 462 463 **1.3 Determination of Radiation Effects** 464 465 1.3.1 Introduction 466 467 The amount of cell killing or damage caused by a specific absorbed dose depends on the 468 469 sensitivity of the cells affected. Consequently, some body organs will be more seriously affected than others. For example, blood cells forming in the bone marrow are more sensitive than most 470 other cells in the body while the cells in the central nervous system and brain are less sensitive. 471 Therefore, serious damage to the body's ability to produce new blood cells will result at a lower 472 absorbed dose than is required to seriously affect the brain. 473 474 The immediate and long-term effects of radiation exposure have been determined from 475 fundamental biological studies, epidemiology studies on exposed human populations and by 476 observing the results of exposure of humans to very high absorbed doses. Immediate effects are 477 observed only after an exposure that is 100 to 1,000 times the exposure an individual will receive 478 from the naturally occurring radiation sources in the living environment. The actual effect, which 479 could be skin damage (burns), temporary or permanent sterilization, loss of hair, or in the 480 extreme, death, will depend on the organs exposed and the absorbed dose received. Partial 481 shielding of a sensitive organ such as bone marrow could significantly mitigate the resulting 482 effect. 483 484 Long-term effects are more complex. The most serious of these appears to be cancer, which will 485 486 be detected many years after exposure, if at all. Cellular changes that could lead to cancer have been detected in fundamental biological studies, but many of these cellular changes can be 487 repaired or mitigated and therefore may not be expressed clinically. Other observed cellular 488 changes following radiation exposure can produce an increased transient resistance to subsequent 489 exposures to radiation. However, studies of radiation exposure in animals have shown that the 490 incidence of cancer increases with absorbed dose in almost all cases. These studies expose the 491 animals to radiation doses that are significantly higher than the exposure an individual could 492 receive from the naturally occurring radiation sources in the living environment. 493 494 Studies of radiation effects on human populations at absorbed doses similar to those received 495 from naturally occurring radiation sources ("normal" exposure) are much more difficult to 496 perform and less conclusive. However, epidemiologic studies on human populations that have 497 received exposures ranging from 30 to 1,000 times "normal" exposures reveal an increase in 498 499 cancer mortality with increasing radiation dose. This increase can be described as linear until the 500 dose is very high, but the uncertainty is large and increases as the dose becomes smaller. At the lowest doses the probability for observing excess cancer includes zero (i.e., there may be no 501 observed cancer related to a radiation dose that is as much as 30 times the "normal" exposure). 502

NOT TO BE DISSEMINATED OR REFERENCED

503

504 When excess cancer can be observed and related to radiation exposure, the dependence on 505 absorbed dose depends on the organ in which the cancer appears. Some organs, such as the 506 active (red) bone marrow, colon and lung, are about three times more sensitive than others, such 507 as the bladder, liver and thyroid. Others such as brain, skin and kidneys are even less sensitive. 508

509 Radiation sensitivity also depends on the age of the individual at the time of exposure.

510 Sensitivity to the effects of radiation exposure decreases with age. There is also a dependence on 511 sex with females somewhat more sensitive than males overall. However, the sex dependence 512 differs with the organ affected. Finally, there are also differences in radiation sensitivity among

- 513 individuals and populations.
- 514

524

526

515 For estimation of the risk of radiation-induced cancers, uncertainties arise from dosimetry,

transfer across populations, the effects of low dose and low dose rate, radiation quality,

517 methodology, elimination of bias, and other physical and biological confounding factors. When a

detailed analysis for a specific situation is performed, the 95 % confidence interval (CI) is

generally a factor of about 2 to 3 around a central estimate of risk based on a uniform whole-

520 body exposure. Within this framework, the Committee has used the available scientific

521 information and its judgment to arrive at nominal detriment values and control values to be used

in radiation protection. These are expressed without uncertainty even though there are somewhat
 similar but alternative values which might have been chosen.

525 **1.3.2** Epidemiologic Studies of Radiation Effects

527 The bulk of the scientific evidence used by the Committee in forming its judgments comes from 528 epidemiologic studies supplemented by animal and cellular mechanistic studies. Well-designed 529 epidemiologic studies are the gold standard for risk estimation because they provide direct 530 information about effects on humans, but there are some well-recognized limitations and 531 uncertainties. 532

1.3.2.1 Types of Studies. There are three main types of radiation effect epidemiologic studies. 533 These vary in their strengths and weaknesses. The strongest type of study regarding causality is a 534 "cohort" study in which a defined group of individuals (preferably with a wide range of 535 exposures) is followed over time and their health outcomes analyzed. These studies may be done 536 either prospectively or retrospectively. The Life Span Study of the atomic-bomb survivors is a 537 cohort study. A "correlation" study is a particular type of cohort study that is based on data 538 averaged over groups. A randomized control study is also a type of cohort study in which people 539 are assigned at random to a group prior to a planned radiation exposure. 540 541

The second most common type of epidemiologic study is the "case-control" study. In this type of study, persons with some specified disease (such as cancer) are matched (for example for age and sex) with a set of persons who do not have the disease. The groups are then compared to assess differences in exposure. Compared with cohort studies it is easier in case-control studies to collect detailed radiation exposure history and information on other risk factors which may influence the disease. However, case-control studies are prone to more types of bias (e.g. recall Comment [M13]: Cool edit

Comment [M14]: Miller ... Needs a reference to a recent LSS paper.

Boice

548 549 550	bias and investigation bias). Subtypes of the case-control studies include the "case-cohort" and "case-base" design.	
550 551 552 553 554	The third type of study is the "ecological" study. Disease rates are assessed at the group or population level. Prevalence rates are compared among different geographic areas or time periods. Since this type of study does not measure disease at the individual level it is the weakest type of study for determining causality, but it can be used to formulate hypotheses.	
555 556 557	1.3.2.2 <u>Limitations</u> . All epidemiologic studies have limitations due to a number of factors. Biases result in conclusions that differ from the truth. Some examples are given:	
558 559 560 561 562 563	• Follow-up bias: If not followed long enough, a population may not vet have developed the disease, resulting in the suggestion that the disease does not occur or occurs at a lower than true rate. Follow-up bias also occurs when exposed people move from the area without notifying the investigator. This type of bias can occur in both cohort and case-control studies.	
564 565 566 567 568	• Ascertainment bias: Also known as selection bias this occurs when there is variation in ascertainment of disease with varying exposure levels. An example would be if more medical examinations occur in persons with higher exposures. Unless corrected this can bias the slope of the dose-response curve upwards. This type of bias also can occur in both cohort and case-control studies.	
569 570 571 572 573	• Recall bias: This bias arises when information is collected retrospectively from individuals who have a disease they believe is due to radiation exposure. They may tend to "recall" more radiation exposures than those who do not have the disease. This is more common in case-control studies.	
574 575 576 577	Confounding factors also limit the results and application of epidemiologic studies. As an example, confounding "by indication" can result when a person with early symptoms of a disease has a diagnostic radiation procedure and then later when the disease is actually diagnosed, it is erroneously attributed to the diagnostic exposure. Tobacco use is perhaps the most serious confounding factor as it is associated with significantly increased risk of	
579 580 581 582	cardiovascular disease and many cancers. Other confounding factors include but are not limited to genetic background, population heterogeneity, medications, hormone levels, diet, alcohol use, and chemical and other occupational or environmental exposures.	
583 584 585 586	There are limitations on the statistical power of epidemiologic studies as a result of both dose level and sample size. Land <u>et al. (1980)</u> pointed out that using the assumption of a linear association between radiation dose and the probability of cancer induction, the sample size required to detect an effect with adequate statistical power is approximately proportional to the	
587 588	inverse of the dose squared. Thus, <u>assuming that</u> a sample size of 1,000 is needed to detect an effect at an absorbed dose of 1 Gy, a sample size of 10,000,000 would be needed if the absorbed	

effect at an absorbed dose of 1 Gy, a sample size of 10,000,000 would be needed if the absorbed
dose were 0.01 Gy. Consequently, for epidemiologic studies in the dose range of 0.01 to 0.1 Gy,

a population of about a million persons is needed. It is clear that to demonstrate a radiation effect

for doses in the normal (background) exposure range below 0.02 Gy would require

592 epidemiologic studies involving several million exposed persons with suitable controls and

Comment [M15]: Cool edit

subject to similar risk factors who are followed for decades. This is virtually impossible to 593 accomplish and statistically significant risk estimates in the very low dose range are not likely to 594 be obtainable from epidemiologic studies. If the dose response is linear-quadratic and not linear, 595 even larger population sizes would be needed. 596

597

- 598
- 599

1.4 Developing the System for Radiation Protection

The combination of differing responses in individuals together with the overall uncertainty in the 600 risk of radiation effects in the low-dose range of "normal" exposure makes it difficult to develop 601 a practical system of radiation protection that is applicable and consistent for all populations 602 world-wide. The system for radiation protection that has been in place for almost 50 y was 603 604 developed by ICRP and NCRP to protect people who might be exposed to radiation doses greater than those received from naturally occurring radiation sources ("normal" exposure). That system 605 was designed to "prevent the occurrence of serious radiation-induced conditions (acute and 606 chronic tissue reactions in exposed persons and to reduce stochastic effects in exposed persons to 607 a degree that is appropriate in relation to the benefits to the individual and to society from the 608 activities that generate such exposures" (NCRP, 1993a). From the results of the many 609 epidemiologic studies that have been conducted in the past 50 y, this expectation for the radiation 610 protection system has, in a general sense, been achieved. 611 612

The Committee also realizes that while there may be small changes in estimates of risk from 613 those given in prior NCRP reports, if these new changes fall within a small percentage of total 614 uncertainty, as a precaution, it may be better to continue with current values thereby minimizing 615 disruption of the current radiation protection system. Alternatively, if new significantly changed 616 risks are estimated then new values for radiation risk and detriment should be recommended 617

regardless of the consequence of substantial or disruptive changes in the current system. 618

619 620 As explained by ICRP in its most recent recommendations on radiological protection (ICRP. 621 2007a) the system of protection takes into account the uncertainties and differences in response to radiation exposure as discussed above. In view of the uncertainties in both the absorbed dose 622 response and the estimate of detriment, primarily resulting from cancer induction, it is 623 appropriate for radiation protection purposes to use age- and sex-averaged tissue response factors 624 and numerical risk estimates. In addition, the ICRP and NCRP agree that the linear non-threshold 625 model remains a prudent basis for radiation protection at low doses and low dose rates, an 626 approach supported by the precautionary principle (Section 3.1). However, for NCRP this does 627 not imply that a linear dose response is the correct biological model to describe the induction of 628 all malignant tumors or other stochastic effects. For practical purposes a linear model is the only 629 way to add doses received at different times and using different dose quantities. This is necessary 630 for the prospective system of protection as constructed and allows the system of protection to be 631 632 sufficiently robust to achieve adequate protection for all ages and both sexes.

- 633
- 634
- 635

Because of the variety of radiation exposure situations and of the need to achieve a consistency 636 across a wide range of applications, the Council has now adopted a formal system of radiation 637

Comment [M16]: Fleming edit

Comment [M17]: Fleming edit

1.5 The Basis and Structure of the System for Radiation Protection

protection aimed at encouraging a structured and feasible approach to protection. The NCRP 638 System has to deal with a number of sources of exposure, some that are already in place, and 639 others that may be introduced deliberately as a matter of choice by society or as a result of 640 emergencies. These sources may be linked by a variety of interconnected events and situations 641 leading to exposure of individuals, groups, or entire populations, both in the present and in the 642 future. The NCRP System has been developed to allow this complex network to be treated within 643 a logical structure. 644 645 The NCRP System has been developed from an extensive body of scientific research on the 646 effects of radiation in humans and nonhuman species, acquired over more than a century; it also 647 encompasses our knowledge of advanced biology and mechanistic studies of radiation effects at 648 649 the molecular and cellular levels. As described in Section 1.2 comprehensive studies in the 650 radiation-effects literature describe short-term and late-term adverse tissue reactions as well as late-term stochastic effects (cancer and hereditary changes). For adverse tissue reactions, 651 important information is available from controlled experimental studies in animals. For cancer 652 and heritable effects, the critical information arises from epidemiologic studies, research on 653 animal and human genetics, and current scientific data on fundamental mechanisms of 654 carcinogenesis and heritable effects. 655 656 Risk coefficients have been derived from analysis of dose-response functions. The detailed 657 epidemiology of radiation effects on Hiroshima and Nagasaki atomic-bomb survivors provides 658 the principal risk coefficient data on which current standards for radiation protection are 659 based. The NCRP System accommodates potential exposures from both external sources and 660 internally deposited radionuclides. It accounts for environmental exposures, emergency 661 exposures, workplace exposures, and medically administered radiation. 662 663 Protection against the harmful effects of radiation requires a well-defined, coherent system of 664 665 quantities and units. The fundamental unit for dosimetry is the organ or tissue absorbed 666 dose. Weighting factors applied to absorbed dose yield equivalent dose and effective dose as measures of stochastic risk. In view of uncertainties associated with the assigned values of tissue 667 weighting factors and risk coefficients used to define overall health detriment, The NCRP 668 System has incorporated age- and sex-averaged tissue weighting factors and numerical risk 669 coefficients. The basic protection criteria are sufficiently robust to protect both males and 670 females (Figure 1.1). Further refinements have been applied to protect the developing embryo 671 and fetus. 672 673 The doubly weighted unit of effective dose may be applied for radiation protection purposes 674 (exposure controls, criteria, and secondary criteria for measurable quantities such as setting 675 primary dose criteria and assigning secondary restrictions on radionuclide concentrations in air 676 and water), but, as a caution, is not defined as a reliable measure for estimating future cancer 677 678 risk. 679 680 1.6 Summary

681

Comment [M18]: Cool edit
Comment [M19]: Fleming edit

There are four important points about the design and use of recommended protection values andtheir associated underlying scientific uncertainties.

684

713

717

719

- 1) The power and statistical significance of epidemiologic studies depends upon the size of 685 the studied population, the risk of the radiogenic effect, the background or spontaneous 686 rate of the effect and a range of confounding factors. Cancer incidence has been shown to 687 be clearly increased in a general population at absorbed doses greater than about 100 688 mGy. At lower doses and dose rates the dose response is not clearly defined by 689 epidemiologic studies. Ad ignoratium isf avoided by realizing that at very low doses, At 690 very low doses, absence of a finding of an increase in cancer does not mean that there is 691 no risk, nor does it imply that there is a risk. Radiation protection programs must deal 692 693 with dose levels below which there is no evidence of a statistically significant increase in 694 cancer rates. Consequently, a model is needed to estimate the risk of cancer incidence as the radiation dose approaches the normal natural background dose. A number of radiation 695 dose-response relationships can be supported by the results of studies using selective 696 adverse outcomes. However, together with ICRP, NCRP continues to use the linear non-697 threshold model for the purpose of developing radiation protection recommendations for 698 699 the general population. The recommended radiation protection values provided in this Report do not constitute a 700 2) threshold between "safe" and "unsafe." The risk of stochastic effects is the largest 701 concern for public and occupational exposures. The proper understanding is that the 702 probability of an effect increases with dose, but it does not have any relationship to a 703
- specific dose or control level.
 Even though there are specific recommended values for individual dose criteria for
 optimization and control, a radiation protection system cannot be rigid. It needs to
 provide for some flexibility in application depending upon other factors and the current
 conditions (especially during emergencies).
- 4) The Council recognizes that there are uncertainties in multiplying a very low effective dose by a large number of individuals to estimate the number of radiation-induced adverse health effects in an exposed population. As a result, NCRP recommends against this practice.
- However, for the purposes of retrospective evaluation of radiation related risks, such as in
 epidemiologic studies and retrospective risk analysis, it is appropriate to use sex- and age specific data and calculate sex- and age-specific risks.
- 718 The following portions of the Report attempt to build on the above constructs.
- For purposes of radiation protection it is useful to organize the exposures into various exposure
 situations, and among categories of individuals who receive the exposures. Section 2 explains the
 three exposure situations and three categories of exposure to which The NCRP System applies.
- Section 3 discusses the ethical foundations (i.e., theories and principles) and philosophical
 considerations of moral significance that impact on The NCRP System. This discussion
 Understanding the athical foundation of The NCRP System halves to ground enceifing about
- 726 Understanding the ethical foundation of The NCRP System helps to ground specific claims about

Comment [PF20]: Fleming ... Define this fallacy in the glossary

NOT TO BE DISSEMINATED OR REFERENCED

727	radiation protection in a widely adopted system of values that, in fact, are believed to be held	
728	universally by members of disparate cultures. This Report considers the ethical foundation for a	
729	system of radiation protection and identifies ethical theories and principles in which these values	
730	are embedded.	 Comment [M21]: Fleming revisions
731		
732	The NCRP System has been developed based upon scientific information on the effects of	
733	radiation, ethics, and expert opinion derived from experience with radiation sources and events.	
734	Ethicists have specified the theoretical underpinnings of the system of radiation protection	
735	(Gonzalez, 2011; Hansson, 2007). This Report provides a finer-grade approach in specifying the	
736	ethical principles which underlie justification, optimization (the ALARA principle) and dose	
737	limits (criteria). The national and international aspects of The NCRP System itself are specified in	
738	Section 4.	 Comment [M22]: Fleming revisions
739		
740	Protection against the harmful effects of radiation requires a well-defined, coherent system of	
741	quantities and units. Radiation protection quantities and units must be generally applicable to	
742	occupational, environmental, and medical exposure to ionizing radiation. In Section 5 the	
743	quantities and units used in The NCRP System are defined and briefly discussed.	
744		
745	Section 6 describes the potential adverse health outcomes from ionizing radiation. These include	
746	adverse tissue reactions, cancer and noncancer effects and adverse psycho-social effects.	
747		
748	The means for assessing the risk of radiation exposure and its health detriment are discussed in	
749	Section 7. ICRP has utilized the concept of health detriment as an expansion of the overall	
750	adverse health impact of radiation beyond cancer and noncancer risks. The calculation of	
751	detriment is complex and has a number of associated uncertainties and assumptions. Section 7	
752	provides an overview of this concept and discusses NCRP's recommendations for its application	
753	in the recommended dose criteria.	
754		
755	Section 8 provides the NCRP's recommendations for controlling radiation exposure in the	
756	United States for specific situations.	
757		
758	Section 9 introduces and proposes an approach for screening dose criteria for nonhuman species	
759	below which no consideration is needed, and the protection of the environment for the United	
760	States. The principal aim is to provide both a factual basis and coherent ethic from which to	
761	establish a framework for an appropriate level of protection of the environment against the	
762	detrimental effects of radiation exposure. These recommendations are consistent with NCRP's	
763	other radiation protection recommendations in that they are intended to prevent the occurrence of	
764	adverse radiation-induced effects while still enabling those activities which provide benefit to	
765	society from such exposures. <u>NCRP adopts an anthropocentric extensionism</u>	
766	(Section 3.1) in its approach to protection of the environment, while supporting protection of the	
767	environment when the needs humans are not in conflict with those of the environment.	 Comment [M23]: Fleming addition
768		MR needs to be edited currently is somewhat
769	Finally, Section 10 provides guidance for effective communication of the NCRP	garbled
//0	recommendations in this Report to all stakeholders. Stakeholders in this context are defined as all	

parties that would have an interest in the recommendations. Suggestions for communication of

	NCRP CC 1 NOT TO BE DIS Draft of April 2016	SEMINATED OR REFERENCED	
772	these recommendations to professionals, stakeholders, media, and the	public are presented.	
773	Underlying this guidance these suggestions is the importance of enhan	icing a stakeholder's	Comment [M24]: Cool edit
774	autonomy. The Council believes this topic is critical to the understand	ing, acceptance, and	
775	implementation of these recommendations.		
776			
777	References (Section 1)		
778			
779	ICRP, 2007a		
780	Land et.al. (1980) (Science 1980. 209 (4462):1197-1203)		
781	NCRP 1993a		
782	Hansson, S, 2007		
783	Gonzalez, A.J. (2011). The Argentine Approach to Radiation Safety: Its Eth	ical Basis, in Science and	
784	Technology of Nuclear Installations, Volume 2011, Article ID 910718,	15 pages	
785	http://dx.doi.org/10.1155/2011/910718, Review Article.		Comment [M25]: Fleming additions
786			

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

787 **2. Exposure Situations and Categories of Exposure**

For purposes of radiation protection it is useful to organize exposures into various exposure situations, and categories based on the individuals who are receiving the exposures.

Recommendation: Three exposure situations, Planned, Emergency and Existing, be used as
a general approach for applying The NCRP System.

Recommendation: Three categories of exposure, Occupational, Public, and Medical, be
used as a method for identifying the individuals receiving exposures and the protection
criteria to be applied.

2.1 Exposure Situations

801 An exposure situation is a circumstance by which a source of radiation, through various

pathways, causes the exposure of an individual. Sources may be either radioactive materials, or

803 machines which emit radiation, and may be of natural origin, or man-made. Protection of the 804 individual can be achieved by taking action at the source, or at points in the exposure pathways,

and occasionally by modifying the location or characteristics of the exposed individuals. The

- specific opportunities for protection depend upon the prevailing circumstances that exist for that
- 807 situation. 808

788

791

794

798

799 800

As described in Sections 2.1.1, 2.1.2 and 2.1.3, three exposure situations can be used to describe

- radiation exposures, and are useful in organizing The NCRP System. This NCRP
- recommendation follows the recommendations of ICRP in Publication 103 (ICRP, 2007a).

812 However, NCRP does not regard the boundaries defining these situations to be rigid

813 demarcations. There may be occasions when the situation is not well defined and the application

of The NCRP System must allow some flexibility for informed judgment.

816 2.1.1 Planned Exposure Situations

817818 Planned Exposure Situations encompass all those instances in which the source of exposure is

deliberately introduced into an individual's environment for some purpose, thereby causing

exposure. Such situations are characterized by the fact that protection decisions can be made, at

least in principle, before the introduction of the source, and protection accisions can be made, a
 the source as well as the pathways leading to the exposure of the individual.

823

Planned Exposure Situations include all of the man-made uses of radioactive material and

radiation, ranging from applications in power generation to industrial, academic, and medical

uses. Naturally occurring radioactive materials may present a planned exposure situation, when

the material is obtained, processed, and used with forethought to accomplish some particular

purpose. In this case, the process and disposition of the materials would be planned in advance,

just as with any other radioactive material.

830

842

864

865 866

831 2.1.2 Emergency Exposure Situations

832 Emergency Exposure Situations are those in which a source of exposure is suddenly present in 833 an individual's environment, and the levels of exposure warrant urgent actions to achieve the 834 objectives of radiation protection. This is the case in an accident or malicious event, and is often 835 characterized by the fact that the source is not well understood, may be rapidly changing, and is 836 not under any controls. In an emergency, there may be only limited means to take any protective 837 actions based on modifying the source, and protection is based upon controls that may be placed 838 on individuals. 839 840

841 **2.1.3** Existing Exposure Situations

Existing Exposure Situations are so named because the source of exposure, often of natural
origin, but occasionally as a result of previous human activities or events, exists in the
individual's environment, and through various pathways causes exposure. Such situations are
characterized by the fact that the source was not intentionally introduced for some purpose, that
there may be limited means to take any protective actions based on modifying the source itself,
and that the levels of exposure do not warrant urgent actions to achieve the objectives of
radiation protection (otherwise the situation would be considered an emergency).

Existing Exposure Situations include, in general terms, both natural background in the human 851 environment, and residual contamination that may be present in the environment due to past 852 activities, including those from accidents or previously controlled activities that were not 853 properly remediated. From a radiation protection standpoint, once the situation is recognized 854 and characterized, actions can be undertaken to reduce exposures. Depending on the 855 circumstances, actions make take a short or a very long period of time. An example of a short 856 time period would be the recognition of excessive radon in a home, which can often be 857 858 significantly reduced by various abatement technologies. Long time periods may be needed for 859 remediation of large areas of contamination, and radiation protection may be heavily dependent upon development of awareness and actions on the part of the individuals themselves. Further, 860 the level of individual exposures may be highly variable, and some levels may be greater than 861 the nominal expectation for individual dose restriction when radiation protection actions are first 862 considered. 863

- 2.2 Categories of Exposure
- 867 **2.2.1** <u>Occupational Exposure</u>

868
869 Occupational exposure involves the exposure of individuals in the course of their work.
870 Occupational exposure does not include exposure to medical procedures as a patient, research
871 subject, or comforter or caregiver, nor exposure to naturally occurring radioactive materials
872 outside of the work environment. Because radiation is ubiquitous in the environment, from a
873 practical standpoint occupational exposure is limited to exposures for which it is reasonable and
874 feasible for the workers' employer to have responsibility for exercising controls. Occupational
875 exposure can occur in any of the exposure situations, and needs to be treated appropriately in

each circumstance. In some cases, for example in the early phases of an emergency exposure
situation, responders, whether or not normally occupationally exposed, are likely to be faced
with radiation and other hazards that are much different from those usually expected in their
usual work environment. The radiation protection criteria for occupational exposure are
described in Section 8.

881882 2.2.2 Public Exposure

Public exposure comprises any exposure of individuals outside of the described occupational and
medical categories. Public exposure can occur in all three of the exposure situations. Further,
individuals who would be considered as occupationally exposed at their work place, would be
considered to be publically exposed at other times. The radiation protection criteria for various
aspects of public exposure are described in Section 8.

890 **2.2.3** <u>Medical Exposure</u>

892 Medical exposures of patients are dealt with separately in The NCRP System because the

planned exposure for purposes of diagnosis or therapy of disease provides a direct benefit to the

individual exposed. NCRP also uses the category of medical exposure to cover those individuals
 who may voluntarily be participating in research that results in their exposure to radiation, and to

895 who may voluntarily be participating in research that results in their exposure to radiation, 896 individuals who may be engaged in the comfort and care of a patient who has received

radioactive material. The latter group is limited to those individuals who are not occupationally

involved in medical treatment, and are usually close friends, family members or parents of the

patient. The radiation protection criteria for medical exposure are described in Section 8.

900 901

883

889

891

902 **Reference** (Section 2)

903

ICRP (2007a). International Commission on Radiological Protection. Recommendations of the
 ICRP, ICRP Publication 103, Ann. ICRP 37(2–4) (Elsevier, New York).

906
3. The Ethical Foundations of the System for Radiation Protection (as of 2-28-16) (Additional comments received from CC 1 members since 2-28-16 are under review)

909

Understanding the ethical foundation of The NCRP System helps to ground specific claims about
radiation protection in a widely adopted system of values, ones that, in fact, are believed to be
held universally by members of disparate cultures. Like ICRP (1959), NCRP mentioned early on
the need for an ethical approach to radiation protection (Taylor, 1957). More recently, we see
this commitment to ethicals considerations in such matters as radiation risk for astronauts (NCRP
Report No. 167), spaceflights to Mars (NCRP Commentary 23), treatment of human subjects of
research using radiation (SC 4-7), and protection of the environment (XXX).

917

927 928

944

Section 3 considers the ethical foundation for a system of radiation protection. Such
considerations provide transparency about the values which underlie such a system, they identify
ethical theories and principles in which these values are embedded and they clarify the ethical
duties associated with such protection.

The ethical components of The NCRP System included a set of interrelated components
comprised of moral significance, ethical theory and specific renditions of those theories, and key
ethical principles and the principles.

3.1 Moral Significance

While much of this Report deals with how and whether radiation protection is possible, questions 929 about who and what should be protected are paramount, particularly as more attention is being 930 paid to repercussions of human activity on the environment. Radiation protection is normally 931 thought to apply to humans and, by extension, to the environment in which humans reside. Is 932 this approach adequate? Does it include fetuses and future generations or only those humans 933 presently living? If inadequate in protecting the environment, should it be revised to do so, 934 thereby extending to nonhuman but sentient species, such as mammals, birds, insects and fish? 935 936 Or, should it also include non-sentient entities such as rock bodies, forests, deserts, and bodies of 937 water? Does any direct ethical relationship exist between humans and the natural environment? Answers have been given to these questions based on certain assumption about whom to accord 938 moral significance, paralleling the concept of legal standing which answers the question, "to 939 whom or what does the law apply?" To whom or what does a system of radiation protection 940 941 apply? 942

943 **3.1.1** <u>Anthropocentrism</u>

The claim that only humans have moral significance is based on their capability to think and to
choose. This view does not ignore the environment, including sentient species and non-sentient
entities, in considering the effects of radiation. However, the justification of any concerns is
rooted in human needs and interests. Ethical concern for deleterious effects to the environment
and the biota therein, is based on the value that currently-living humans place on them. Humans
are viewed as stewards of nature.

952 3.1.2 Anthropomorphic Extensionism

Comment [M26]: Andersen – At this point, I don't have any specific comments on this section as written –which is very informative. My suggestion is that it be moved to an appendix in the report and/or captured in a separate NCRP document to serve as background and a reference for a more succinct statement of NCRP's view on the appropriate ethical foundations or principles for radiation protection.

MR ... see also Adelstein comments at 3.1.1 to .3.1.3, and at 3.2 to 3.2.2.

Fleming/Kase

Comment [M27]: Shows a number of Fleming edits (4-10-16) throughout Section 3

Comment [M28]: Fleming ... K. Higley would know if something exists in NCRP publications that appeals to environmental ethics

Higley

953

Arguments are offered to extend the reach of moral significance backward to unborn fetuses and 954 forward to future generations based on either the needs and interests of currently-living humans 955 956 (e.g., their desire to bond, to care for their lineage) or on the fact that they are already human (fetuses) or will likely be human (future generations). This is an anthropocentric extensionism. 957 Whether extended beyond existing humans or not, the anthropocentric view claims that humans 958 have ethical duties *regarding* the natural world but not directly to the natural world (Desjardins, 959 XXXX). 960 961 Non anthropomorphic extensions of ethics emerged in the last century although some will date it 962 back to the Stoics. Ethicists differ as to whether moral significance should be aligned so 963 964 narrowly with humans. Some reason that other sentient beings should be taken into consideration 965 because those beings can experience pleasure and pain. This viewed has informed the belief that nonhuman animals have rights which need protection by humans (Reagan, XXXX). Another 966 view is based in interests. Being sentient, nonhuman animals are capable of having interests. To 967 only protect human interests and not the interest of these creatures to avoid pain is described as 968 speciesism (Singer, XXXX). 969 970 971 3.1.2 Biocentrism 972 Non-anthropomorphic extensions of ethics emerged in the last century although some will date 973 them back to the Stoics. Some ethicists point to the limits of anthropocentric extensionism (e.g., 974 that it favors beings that are like humans, that it fails to consider the concerns that are beyond 975 individuals, such as systems and their interconnectedness, and it is not a comprehensive ethic). 976 While biocentricism extends moral standing beyond animals to all living beings it does so 977 through a systematic environmental philosophy, that accounts for more than ethical 978 considerations and considers what has value. The value of living beings is not only instrumental 979 980 but also intrinsic. The biocentrist asserts that all living entities has intrinsic value. Unexplored 981 landscapes and living beings hidden to human view are valued whether or not they are useful to

humans. This biocentricism values not only any living being's needs and interests but also the 982 fact the living beings have an objective good of their own or, in Paul Taylor's words "are 983 teleological centers of life (Taylor, 1986). This gives living beings inherent worth. Unexplored 984 landscapes and living beings hidden to human view are valued whether or not they are useful to 985 humans. On this view, radiation protection should extend to all living beings; humans have 986 duties to them not just regarding them (Desjardins, XXXX). Also, on this view, the protection of 987 certain biota may trump the interest of humans. 988

3.1.3 Ecocentrism 990

989

991

992 Still others argue that holding the capacity to reason, and the ability to experience pain and pleasure is too anthropocentricantrhropocentric. In addition, having an objective good of one's 993 994 own is limited to living beings. There are aspects of natural world which may not have a good of 995 their own but are interconnected to an ecology that must be protected. Ecocentrists argue that It 996 is the ecological whole that should be the basis of value and concomitantly the basis of our 997 ethical duties. Both anthropocentrism and biocentrism needs to be replaced with an ecocentrism

Comment [AA(29]: Ansari ... Do we need this qualifier? Fleming ... No, it is removed

NOT TO BE DISSEMINATED OR REFERENCED

that values the interconnectedness of the whole. We have duties, on this view, not only to living 998 beings but also to nonliving natural objects and ecological systems. Biocentrists often, according 999 to this view, literally fail to see the forest for the trees. Wetlands, prairies, and rivers_isare 1000 1001 valuable in its their own right and should be accorded desires moral consideration (Desjardins, XXXX). The Wilderness Act of 1964 to an extent represents ecocentrism. This view raises 1002 1003 interesting challenges regarding radiation protection. This is a view that is increasingly common among stakeholders in the public. including the very existence of background radiation. Using 1004 background radiation as a norm for radiation protection limits, borrows to some extent on 1005 1006 ecocentrism. 1007 It's fair to say that the The NCRP System has been primarily constructed from has implicitly 1008 1009 adopted an anthropocentric extensionism. view. It is prospective and considers fetuses among 1010 the populations it protects. The radiation community has long believed that standards for protection of humans often provide an adequate level of protection for nonhuman biota. Section 1011 1012 9 points outnotes that this view has been challenged, noting that there are circumstances where 1013 this is not the case. 1014 1015 However, rRectifying the gap that exists because of the inadequacy of human-only based radiation standards need not necessarily commit one to biocentrism or ecocentrism. In fact, 1016 similar sets of duties may be deduced from all of themanthropocentrism, biocentrism, and 1017 ecocentrism. In other words, some consensus can be found among these views on moral 1018 1019 standing. 1020 At times All of these positions on moral significance one may consistently apply all these views 1021 to the protection of the environment. As individuals, we might sometimes act as moral pluralists 1022 using all these views in the attempt to fulfill our duties of radiation protection. Prudence may 1023 recommend that we do so. 1024 1025 1026 However, among these differing views on moral significance, there are important differenceswill 1027 be a variety of discriminations. For example, the extent of protection may differ. Stronger duties to all biota or the ecological whole than those required of anthropocentrcism extensionism will 1028 exist. Resolution of conflicts created by competing needs for protection among humans, all biota, 1029 and the ecological whole may differ as well, resulting in human needs receiving higher or lower 1030 1031 priority over other needs. 1032 **3.2 Ethical Theories**Foundations and Ethical TheoriesPrinciples 1033 1034 Specific ethical theories about right and wrong generally can be categorized by one of three 1035 foundations: teleological, deontological, or virtue-based. 1036 1037 3.2.1 Ethical Theories 1038 1039 Teleological foundations refer to ends or purposes. For those that adopt this approach, 1040 consequences matter, hence the name "consequentialism." Utilitarianism (Bentham (XXX) Mill 1041

1042 (XXX)) is grounded in the claim that the consequences of an action determine its ethical

Comment [M30]: Adelstein ... One thing about the current version. I believe the emphasis on the moral dimension of radiation protection is important, But I am concerned with sections 3.1 and 3.2, which contain standard presentations on medical ethics. For those who are familiar with ethical principles, the sections are a bit text-book. Just as we do not present the principles of health physics to readers of this report, we might assume readers (at least some of them) do not have to be instructed in medical ethics. On the other hand, I appreciate that others will not be familiar with the material. So, my recommendation is to put the text noted here into an appendix or, at least, put the terms such as anthropocentric, biocentric, ecocentric etc. into a glossary.

Fleming ... This should primarily be a Council decision. In almost every committee I have served on for the NCRP this same issue arises, i.e. where to put the ethics. at the beginning, at the end, or in an appendix. In all cases it has remained in the body of the text. These views of moral significance are generally not known. They are not treated in medical ethics.

Comment [DLM31]: Miller We should state explicitly what view we have adopted, without qualification ("It's fair to say...").

<mark>Fleming</mark>

Comment [M32]: Cool edit Comment [M33]: MR ... something was missing here, should "one" or some other word be added?

Comment [AA(34]:

Ansari ... Should this word be "Principles"? Below discussion is about ethical foundations and ethical principles

Fleming.

1043	permissibility The principle of utility, ("Actions are right in proportion as they tend to promote	
1044	happiness," Mill, p. 55) when applied to a situation (or rule) will help us know what is right or	
1045	wrong. Natural Law is another teleological view that uses ends or purpose to establish right from	
1046	wrong (Aquinas, XXXX).	
1047		
1048	Deontology (root deon , meaning duty) emphasizes the determination of one's duties without	
1049	referring to consequences. Immanuel Kant, anticipating the use of consequences as the	
1050	determiner of right and wrong, argued that ethical duties should not be based in hypothetical	
1051	imperatives. Rather, a categorical imperative determines our duties. "Respect persons as an end	
1052	only, never as a means" is one accessible formulation of the categorical imperative. Kant relied	
1053	on logic to help sort out the foundation for ethics. He claimed that one would never will for	
1054	another what one would not will for oneself (e.g., one would not be willing to impose extreme	
1055	harm on another since he or she would not be willing to have extreme harm imposed on	_
1056	themselves).	Co
1057	2 2 1 Wirtug	thi
1058	9.2.1 <u>viitue</u>	Fle
1060	A virtue-based approach to the ethics, found prominently in the work of Aristotle (Aristotle,	Co
1061	Nicomachean Ethics, XXXX) and given a rebirth in modern times, is less inclined to create rules	ne
1062	and instead emphasizes a way of being or living. Virtuous behavior involves living in the mean	tel
1063	and not at the extremes. As noted below, the virtue of prudence leads to precautionary actions.	int
1064		Flo
1065	3.2.2 Ethical Principles	
1066	Falical main sinter attended to a station of and differences and an and the station of the	
1067	identifying athies above us to note important differences among values and they also and in	
1068	identifying etitical duties. Principles are not merely descriptive of value differences. They are	
1069	prescriptive statements about which values we should or <i>should</i> or <i>ought</i> to hold. Curlously, both	
1070	deontological (Kant, 1785) and teleological (Mill, 1879) foundations may support the same	
10/1	etnical principles. When they are applied, nowever, they will sometimes support differ duties	
1072	regarding the same event.	Co
1073	One helpful approach focuses on four ethical principles (Beauchamp and Childress 2012)	
1075		Fle
1076	1. Provide good (beneficence): The value expressed is that of well-being.	
1077	2. Prevent harm (non-maleficence): This value expressed is protection and the duty to	
1078	refrain from causing a loss.	
1079	3. Respect an individual's autonomy (autonomy): the value expressed is freedom or liberty	
1080	of action and our duty to not interfere in another's self-determination.	
1081	4. Act fairly (justice): The value expressed is fairness and the duty to ensure equity (not	
1082	merely equality).	
1083		
1084	Three of these principles were used in the Belmont Report (DHHS, 1979) in addressing ethical	
1085	issues in research on human subjects. Non-maleficence, a fourth principle, was subsumed under	
1086	beneficence in that document.	
1088	A fifth principle, the precautionary principle, has been introduced into the parlance of radiation	
1089	protection notably by the European Union and internal law and is taken up by the ICRP (i.e.	
1009	protection, notably by the European officin and internal law and is taken up by the ICKL.	
1000		

omment [DLM35]: Miller ... I have to say that is is not at all clear to me.

Heming ... Does the e.g. help?

Comment [AA(36]: Ansari ... We probably don't need to make this a separate subsection. For the other two ethical foundations discussed above, neleogical and deontological, we didn' break the text nto subsections.

leming

Comment [M37]: Fleming ... need an example here Fleming

NOT TO BE DISSEMINATED OR REFERENCED

The principle states that, in the face of significant uncertainty or ignorance about the extent of a 1091 harm, one should act in just a way that the public should be afforded greater protection from 1092 exposure to the harm. Sound evidence can ameliorate this duty but in the meantime, precaution 1093 should be taken and protections should not be relaxed. 1094 1095 1096 In ethical thought, precaution is a form of prudence in the exercise of practical wisdom (Aristotle Nicomachean Ethics XX). It has been abstracted into a principle by those who invoke it as a 1097 guide. Being practically wise comes from the experience of making difficult decisions on 1098 practical matters. It is often described as more art than science. 1099 1100 These principles are normally thought to be non-reducible. Autonomy is not merely a form of 1101 1102 non-maleficence, since a consequence of respecting autonomy could result in harming self or 1103 others. Non-maleficence involves preventing harm, whereas beneficence emphasizes providing 1104 a good. In order to provide good, one might, indeed, need to allow harm to occur, whether or not 1105 they are balanced against each other. Those who collapse the differences among these principles 1106 run into difficulty when their distinction makes the difference in realizing right and wrong in a particular situation. 1107 1108 Furthermore, these four five principles may sometimes conflict. In those cases, a ranking needs 1109 1110 to be established. Individuals and groups may differ on which principle or duty outweighs 1111 another (NCRP, 2010a). Ethical disagreements are resolved between parties when they realize they share the same values. Nevertheless, individuals and groups may differ on fundamental 1112 values or on the weight to be placed on the ethical duties these values represent. They may 1113 1114 disagree not only with respect to how to fulfill ones duties but also to whom and what, depending on moral significance as noted above, those duties apply. Resolving these differences can be 1115 1116 difficult because it is often the case that the *weight* one puts on a principle's role in relation to another can be relative to the values of the culture with which one associates. In the United 1117 States, for example, autonomy as expressed in self-determination often holds sway over other 1118 principles. Yet, in its subcultures, non-maleficence may outweigh autonomy (employers are 1119 1120 required to protect workersversus workers). The precautionary principle has taken hold in the 1121 European community. Determining which ethical principle properly guides the choice of 1122 alternative courses of action can be quite challenging. 1123 1124 A fifth principle has been introduced into the parlance of radiation protection, notably by the 1125 ICRP (i.e., the precautionary principle). "The precautionary principle or precautionary approach to risk management states that if an action or policy has a suspected risk of causing harm to the 1126 public or to the environment, in the absence of scientific consensus that the action or policy is 1127 1128 not harmful, the burden of proof that it is not harmful falls on those taking an action." (Wikipedia, https://en.wikipedia.org/wiki/Precautionary-principle) 1129 1130 1131 The principle states that, in the face of significant uncertainty or ignorance about the extent of a 1132 harm, one should act in just a way that the public should be afforded greater protection from exposure to the harm. Sound evidence can ameliorate this duty but in the meantime, precaution 1133 should be taken and protections should not be relaxed. 1134 1135

Comment [DLM38]: Miller ... In whose subcultures? The nation's?

Fleming

Comment [M39]: Cool edit

Comment [M40]: Miller ... The precautionary principle needs to be stated and explained. Also, it is in international and EU law, not just ICRP recommendations, and applies to much besides radiation protection.

COMMUNICATION FROM THE COMMISSION on the precautionary principle. COMMISSION OF THE EUROPEAN COMMUNITIES. Brussels, 2.2.2000 COM(2000) 1 final.

(I have a PDF.)

Fleming

NOT TO BE DISSEMINATED OR REFERENCED

In ethical thought, precaution may be a form of prudence or state of practical wisdom, in this 1136 case, between the extremes (Aristotle Nicomachean Ethics XX). It has been abstracted into a 1137 principle by those who invoke it as a guide. Prudence is abstracted from prudential judgment or 1138 1139 phronesis. Being prudent comes with the experience of making difficult decisions on practical matters. It is described as more art than science. 1140 1141 3.2.3 Ethics and the Fundamental Principles of Radiation Protection 1142 1143 Not all principles to which members of the radiation community appeal are principles of ethics. 1144 1145 The international and U.S. radiation protection communities have established three principles of 1146 radiation protection. Kase notes that historically "...the fundamental principles of justification, 1147 optimization, and dose limitation as initially stated in ICRP Publication 26 have been adopted and applied by the NCRP in its recommendations (NCRP, 1993a). ICRP and NCRP 1148 1149 recommendations on dose limitation for the general public and for occupationally exposed 1150 individuals are based on the same analyses of radiation risk, and, while similar, there are 1151 differences reflecting the aspects of radiation application and exposure circumstances unique to 1152 the United States" (Kase, 2004). 1153 1154 These radiation protection principles function as norms of practice. They do express commitments to certain values and to the relationship among the values. As norms of practice 1155 they clarify for the radiation protection community the weight to be placed on some values over 1156 others. While not identical to norms of practice, the ethical principles mentioned above ean be 1157 1158 detected as underlyingunderlie these norms of practiceradiation protection principles. Ethicists have explored the relationship between the major ethical theories mentioned above and 1159 1160 justification, optimization (the ALARA principle), and dose limitation (criteria) (Gonzalez, 2011; Hansson, 2007). In Section 4 a different analysis is offered, one that closely examines 1161 these norms of practice, demonstrating at the same time-their ties to the ethical principles 1162 1163 mentioned in this section.

Comment [M41]: Adelstein ... One thing about the current version. I believe the emphasis on the moral dimension of radiation protection is important, But I am concerned with sections 3.1 and 3.2. which contain standard presentations on medical ethics. For those who are familiar with ethical principles, the sections are a bit text-book. Just as we do not present the principles of health physics to readers of this report, we might assume readers (at least some of them) do not have to be instructed in medical ethics. On the other hand, I appreciate that others will not be familiar with the material. So, my recommendation is to put the text noted here into an appendix or, at least, put the terms such as anthropocentric, biocentric, ecocentric etc. into a glossary.

Fleming

Comment [KK42]: Cool This is confusing. What do we mean by "detected" Fleming

Comment [M43]: Cool edit

Formatted: Highlight

1164

NOT TO BE DISSEMINATED OR REFERENCED

1165	References (Section 3)	 Comment [M44]: MR Need to check and
1166		complete the references
1167	NCRP Report No. 167	Fleming
1168	NCRP Commentary 23	
1169	SC 4-7	
1170	(XXX)) an NCRP report on the environment/??	 Comment [M45]: Fleming K. Higley would
1171	Desjardins, Joseph. 2012 Environmental Ethics	know if something exists in NCRP publications that
1172	Regan, Tom. (2004) The Case for Animal Rights	appeals to environmental ethics
1173	Singer, Peter (2009) Animal Liberation	Higley
1174	Taylor, Paul (2011) Respect for Nature	
1175	Desjardins, Joseph (2012)	
1176	Desjardins, Joseph (2012)	
1177	The Wilderness Act of 1964 Public Law 88-577 (16 U.S. C. 1131-1136) 88thCongress, Second Session	
1178	September 3, 1964	
1179	Bentham, Introduction to the Principles of Morals and Legislation	
1180	Mill (1879) Utilitarianism	
1181	Mill (1879) Utilitarianism	
1182	Kant (1785) Groundwork or the Metaphysics of Morals	
1183	Aristotle. Nicomachean Ethics (XXXX) use SC 22	
1184	Beauchamp, Tom and Childress, John (2012) Principles of Biomedical Ethics	
1185	DHHS 179	
1186	NCRP 2010a	
1187	Communication from the Commission on the Precautionary Principle, Commission of the European	
1188	Communities, Brussels, 2.2.2000 COM (2000) 1 finalWikipedia	 Comment [M46]: Not yet cited in the text
1189	ICRP 26	
1190	Kase 2004	
1191	Hansson, S, 2007	
1192	Gonzalez, A.J. (2011). The Argentine Approach to Radiation Safety: Its Ethical Basis, in Science and	
1193	Technology of Nuclear Installations, Volume 2011, Article ID 910718, 15 pages	
1194	http://dx.doi.org/10.1155/2011/910718, Review Article.	 Comment [M47]: Fleming additions
1195		
1196		
1197		

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

1226

1227

1198
11994. The NCRP System for Radiation Protection1200Recommendation: Use a system of protection to control exposure to radiation and1201radioactive materials to ensure adequate protection of people and the environment while1202allowing for activities that are beneficial for human development.

The NCRP System has been developed based upon scientific information on the effects of
radiation, ethics, and expert opinion derived from experience with radiation sources and events.
The NCRP System is composed of a set of interrelated components comprising the principles of
protection (Sections 4.1, 4.2 and 4.3), exposure situations (Section 2), categories of exposures
(Section 2), and key requisites for implementation (Section 8).

1210Recommendation: Apply the principles of justification, optimization (the ALARA1211principle), and restriction of individual dose in all exposure situations.1212

The three principles of protection, namely justification, optimization (the ALARA principle), and 1213 1214 restriction of individual dose, provide a coherent and systematic approach to addressing exposure. The principles of radiation protection are applicable in each of the exposure situations, 1215 and can be applied in essentially the same manner in any situation, except for exposure to 1216 1217 patients during imaging and radiation therapy procedures. Specifically, it must first be 1218 determined that taking action(s) is justified, and then protection should be optimized within appropriate dose criteria for individual exposure. Decisions in a particular circumstance will 1219 1220 involve decisions that may need to weigh the ethical principles described in Section 3, and are 1221 best taken with the involvement of stakeholders. Implementation then relies upon the use of a set of requisites, including assessment of the exposure, accountability for protection, 1222 1223 transparency in communications regarding the exposure, and inclusiveness of all relevant stakeholders. Each radiation protection principle is described in the following sections. 1224 1225

4.1 Justification

1228Recommendation: Any action to add, increase, reduce, or remove a source of exposure to1229people or the environment be justified.1230

1231 Recommendation: All factors, both radiologic and nonradiologic, and particularly the 1232 economic, social and psychological implications, be included in the justification and 1233 understanding of the implications of an action. 1234

The principle of justification of radiation exposure requires benefits of taking action to outweigh the harm that may result from the action. This means taking an informed decision, at an appropriate decision-making level, that the benefit gained by the introduction or removal of the source, action on exposure pathways, and action on individuals is, overall, beneficial [i.e., whether the benefits to individuals and to society outweigh the resulting harm (including radiation detriment)].

Two ethical principles discussed in Section 3 are key in decisions on justification. It is supported by the principle of non-maleficence and the principle of beneficence, with the latter

1244 outweighing the former, insofar as the benefit created must exceed any harms that may result.

Comment [M48]: Fleming ... I suggest we keep the focus on justification

Comment [M49]: Fleming edits

NOT TO BE DISSEMINATED OR REFERENCED

The principle of justice also comes into play, in that there should be a commitment to ensuring that benefits be fairly distributed or, minimally, that harms be equitably shared. However, the principle of justification does not guarantee justice plays the primary role. When considering benefits and harm, consideration must be given to the wide range of possibilities, not just the radiation benefit or harm. Thus, radiation protection may be, and usually is, only one input in a much broader consideration of benefits and harm, which include social and economic considerations.

1252 Experience has shown that many of the most important factors in dealing with radiation are not 1253 directly related to hazards caused by radiation exposure, but are rather related to nonradiological 1254 impacts. Except in medical patient exposure, the radiation exposure to an individual would be 1255 considered a potential harm; however, there may be other nonradiological hazards that would 1256 cause harm that significantly outweigh the radiation exposure. Benefits may accrue in various 1257 1258 ways, such as economic benefits of working at a particular job, assurance that a piece of 1259 equipment will function as intended by verifying integrity through nondestructive testing, or receiving safe and reliable supply of goods such as energy or sterilized medical products. 1260 Another important consideration is the social and psychological implications of exposure, such 1261 as stress, disruption, and stigma directed as those exposed. While difficult to consider, these 1262 factors must be included in deciding what the appropriate course of action might be. Thus it is 1263 particularly important to involve relevant stakeholders and interested parties in the process of 1264 justification. Doing so as to respects the autonomy of individuals, and provide the most complete 1265 insights into the implications of taking an action. 1266

1268 **4.1.1** Addition or Removal of a Source

1267

In a Planned Exposure Situation, the introduction of a new source of exposure can be considered 1270 before any exposures occur, and a determination made as to whether such an introduction is 1271 justified. For Emergency and Existing Exposure Situations, the decision is not whether to 1272 1273 introduce the source, but rather to decide what should be done with a source that is causing 1274 exposure. Both occupational and public exposure to humans must be considered, as well as exposures in the environment that are in keeping with human interests. In each case, the decision 1275 is whether actions to reduce or eliminate the exposure have an overall beneficial effect, 1276 particularly in prevailing circumstances in which the actions may be hazardous to those 1277 performing them or significantly intrusive to individuals, society, or the environment. It is these 1278 types of decisions where the social and psychological factors play a particularly important role. 1279 1280 The range of options that are possible, particularly the degree to which action can be taken to 1281 control the source of exposure, will be broad when considering introduction of a new source. 1282

Further, decisions can be taken before the source is introduced, and can be fully implemented before any exposure occurs. All of these factors should be taken into account in deciding if the introduction of the source is justified. When the source of exposure is already existing and a decision is needed on radiation protection, there may be more limited options for control, and it may not be possible to exercise all controls on the source. When the source exists, and poses significant implications for individuals or the environment (an emergency), then decisions and actions must be taken urgently to ensure adequate radiation protection. Thus, it is important to Comment [M50]: Fleming edits

Comment [CD51]: Cool ... Phrasing here will have to be aligned with Section on Environmental Exposure, and whatever term we use.

Comment [M52]: Fleming edits

MR

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

consider, and justify, when actions would be taken before emergencies occur in order to facilitate
 rapid actions to provide radiation protection.

1293 **4.1.2** <u>Medical Exposure</u> 1294

1305

The application of radiation or radioactive materials in medicine is unique because individuals are being deliberately exposed for the purpose of diagnosis and treatment of disease. The process of justification in the context of medical exposure thus requires additional considerations. Note that occupational and public exposure that may result from medical use of radiation are considered as if they were the addition of another source of exposure for individuals other than the patient.

The benefit-to-harm considerations in medical exposures are different from those used for
occupational and public protection. For patients, the benefit is direct and personal, and the result
of the medical exposure should be preservation or improvement in the patient's health.

1306 There are three levels of justification of a radiologic practice in medicine (ICRP, 2007a): 1307

- At the first and most general level, the proper use of radiation in medicine is accepted as doing more good than harm to society. This general level of justification is now taken for granted, and is not discussed here further.
- At the second level, a specified procedure with a specified objective is defined and justified (e.g., chest x rays for patients showing relevant symptoms, or a group of individuals at risk for a condition that can be detected and treated). The aim of the second level of justification is to judge whether the radiologic procedure will improve the diagnosis or treatment, or will provide necessary information about the exposed individuals.
- At the third level, the application of the procedure to an individual patient should be justified (<u>i.e.</u>, the particular application should be judged to do more good than harm to the individual patient). Hence all individual medical exposures should be justified in advance, taking into account the specific objectives of the exposure and the characteristics of the individual involved.

1322 While a medical exposure may be properly justified on each level for a particular patient, 1323 individual patients may refuse treatment, thereby exercising their autonomy. In this case, the 1324 principle of autonomy takes precedence over the principles of beneficence and non-maleficence. 1325 1326 Refusal may represent a conscious choice based on individual values and preferences, but it could also be based on an incomplete or incorrect appreciation of the relative benefits and harms, 1327 so emphasis should be placed on a full and complete interaction between the medical personnel 1328 1329 and the patient to provide information and facilitate understanding of the implications of having, 1330 or not having, the examination or treatment. ICRP Publication 105 (paragraph 57) (ICRP, 2007b) notes that "The harm, more strictly the detriment, to be considered is not confined to that 1331 1332 associated with the radiation; it includes other detriments and the economic and societal costs of the practice. Often, the radiation detriment will be only a small part of the total." NCRP 1333 recommends that justification, as practiced by the referring practitioner and the practitioner 1334 responsible for the performance of the diagnostic or therapeutic procedure, include a 1335

determination of the most appropriate medical imaging procedure. This determination will 1336 depend on the patient, the indication for the examination, and other factors (e.g., availability, 1337 local expertise, cost). These determinants should be considered separately. While the medical 1338 determination should be based on the strength of available clinical evidence, socio-economic 1339 factors will vary by location and circumstance, and may be more important to the patient than 1340 radiation considerations. Clinical decision support, in the form of professional society 1341 recommendations is available to guide the selection of the most appropriate medical imaging 1342 procedure and should be used when applicable. Clinical decision support should ideally include 1343 an indication of the relative radiation exposure from the available imaging procedures. 1344 1345 Recommendation: Justification, as practiced by the referring practitioner and the 1346 practitioner responsible for the performance of the diagnostic or therapeutic procedure, 1347 include a determination of the most appropriate medical imaging procedure. 1348 1349 Justification of screening examinations is a separate issue. There are situations where it is 1350 reasonable to protect patients from themselves with regard to patient-initiated screening 1351 examinations (also called individual health assessments), but that protection is principally 1352 medical (the consequences of false-positive, true-negative and false-negative examinations can 1353 1354 be a deterioration in health) and economic (screening examinations cost money). Certain screening programs have been demonstrated to have significant clinical value. Criteria for 1355 selection of screening programs have been suggested in Europe by the Heads of the European 1356 Radiological Protection Competent Authorities (HERCA, 2012). Protecting individuals from 1357 excessive screening is supported by the primary exercise of the principle of non-maleficence and, 1358 1359 depending on a patient's knowledge, may not really involve the secondary interference in the 1360 patient's autonomy. 1361 4.2 Optimization (the ALARA Principle) 1362 1363 1364 Recommendation: The likelihood of incurring exposures, the number of people exposed, 1365 and the magnitude of their individual doses should all be kept as low as reasonably achievable, taking into account economic and societal factors. 1366 1367 1368 Optimization of protection is the process of determining what level of protection and safety makes exposures, and the probability and magnitude of potential exposures, as low as reasonably 1369 achievable (ALARA), economic and societal factors being taken into account (the ALARA 1370 1371 principle). This means that the level of protection should be the best under the prevailing circumstances, maximizing the margin of benefit over harm. In order to avoid severely 1372 inequitable outcomes from this optimization process, there should be restrictions on the doses or 1373 risks to the individuals from a particular source. The term optimization is used internationally, 1374 and is adopted in these NCRP recommendations for the purposes of fostering a common 1375 framework and approach throughout the world. In all cases it refers to the application of the 1376 ALARA principle. 1377

1378

Optimization is clearly supported by the principle of non-maleficence. The expectation thatradiation exposure should meet the ALARA principle is a direct appeal to prevent harm or the

1385

risk of harm. Optimization is contextualized, however, by economic and societal concerns.
Hence, what constitutes 'reasonably achievable' is related to costs associated with radiation
protection (including those resulting from negative health or environmental outcomes) as well as
societal goods that are achievable.

1386Recommendation: Optimization be applied in all exposure situations when the potential1387dose to an individual exceeds the NID.

1388 Optimization of protection is the key component of radiation protection in any exposure 1389 1390 situation. Optimization should be applied in all exposure situations consistent with the 1391 individual dose criteria for optimization as stated in Section 8. In circumstances such as an Emergency or Existing Exposure Situation where individual exposure levels may be greater than 1392 the an appropriate individual dose criterion for control, optimization, actions would first seek to 1393 reduce these exposures, but then continue to reduce exposures using the ALARA principle. This 1394 is in contrast to previous paradigms where efforts were simply focused on reducing exposures 1395 below some intervention level. Thus the NCRP recommendation goes beyond previous 1396 recommendations, requiring optimization in all situations and circumstances. 1397 1398 **4.2.1** Public 1399 1400 Optimization for public exposure is intended to reduce the exposure from a source to various 1401 members of the public. NCRP recognizes that optimization can only effectively be undertaken 1402 for a particular source that has an accountable party responsible for radiation protection. 1403 1404 Account should be taken for other sources which may expose particular individuals in the 1405 selection of the relevant individual dose criteria (Section 4.3). 1406 Exposures may take place via any pathway, including direct radiation, inhalation and ingestion. 1407

Sources in Planned Exposure Situations should be controlled at the source, reducing direct radiation and the release of effluents, and not be <u>directly</u> dependent upon actions of the individuals. For Emergency and Existing Exposure Situations, it may not be possible to take actions directly on the source, such as the wide distribution of deposited radionuclides on the ground. Actions may, however, be possible on some of the pathways, such as food and water,

ground. Actions may, however, be possible on some of the pathways, such as food and
and upon the location and habits of individuals.
For many Existing Exposure Situations, the responsible individuals may be the exposed

rot many Existing Exposure Situations, the responsible individuals may be the exposed
 individuals themselves, such as in the case of radon exposure in the home. In this case, the
 individuals would be responsible for obtaining an assessment of radon in their home, and if
 necessary, for enlisting a qualified remediation contractor to consider the best options for
 effectively reducing the radon concentration.

1421 **4.2.2** <u>Occupational</u>

1420

1422

Optimization of protection for occupational exposure focuses upon workers in the particular
 circumstance, be it in Planned, Existing, or Emergency Exposure Situations. In theory, any
 individual at work will be receiving some exposure from natural background. To avoid

Comment [M53]: Cool edit

Comment [M54]: Cool edit

1426

1443

1448

1452

1454

control of the individual's employer or the specific user of the source. 1427 1428 Optimization is to include all the contributions to the occupational exposure of the individual. 1429 Individuals are specifically identified, monitored as appropriate, and records of exposure can be 1430 maintained and made available if the individual works for other entities. In some cases, a 1431 balancing of the exposure pathways, such as external exposure and inhalation, may be needed to 1432 reduce the effective dose to the lowest achievable level. 1433 1434 1435 In many ongoing applications, optimization is simply the continuation of good radiation protection programs and practices which traditionally have been effective in keeping the average 1436 and individual exposures for monitored workers well below the limits (NCRP, 2009. 1437

confusion, NCRP focuses its attention upon exposures from sources that are reasonably under the

Approaches employing quantitative estimates of total radiation detriment and costs of protection have been developed by the ICRP (1983; 1990). ICRP has broadened the optimization concept to a multi-attribute consideration (ICRP, 2006). Application of these and other quantitative approaches to the making of decisions for meeting the ALARA principle have been presented in various NCRP reports.

The ALARA principle is also qualitative, and is fueled by a fundamental mindset of always
asking the question about whether there are ways to improve protection. NCRP recognizes that
there is a strong connection between a robust radiation protection program and effective use of
the ALARA principle with concepts of safety culture which have emerged in recent years.

In Emergency and Existing Exposure Situations the ability to monitor and control exposure may
be reduced. Nevertheless, every attempt should be made to characterize the working
circumstances, and provide protection that meets the ALARA principle.

1453 4.2.3 Medical

1455 Optimization in a medical exposure of a patient has an entirely different purpose from

optimization of occupational or public exposure. In medical exposure, the intention is to achieve the necessary diagnostic or therapeutic outcome, and thus the ALARA principle means as low as reasonably achievable to achieve the intended outcome, and is best described as management of the radiation dose to the patient to be commensurate with the medical purpose.

1460 1461 The

1461 The medical purpose is to provide benefit to the patient, not merely to prevent harm, so 1462 beneficence may outweigh non-maleficence even though the exposure necessary in the medical 1463 context in order to achieve the benefit may be significantly greater than exposures in the 1464 nonmedical arena. Commensurability is sought, not with harms but with the medical purpose or 1465 the benefit.

1466
1467 Optimization is a multidisciplinary task involving the technologist, medical and health physicist,
1468 medical or dental practitioner, quality assurance and quality control committees and, to some
1469 extent, the equipment manufacturer and the professional radiologic societies. The objective is to
1470 design and use the equipment in such a way that an appropriate dose to obtain the desired image

Comment [PF55]: Fleming ... Do we need to make it clear that this is not necessarily the cumulative dose an individual may have gotten but only the occupational exposure

Comment [M56]: MR ... probably should give the references to the NCRP reports

Coo

1471 1472 1473 1474 1475 1476	or desired therapy is consistently achieved. NCRP Report No. 172 (NCRP, 2012a) provides specific recommendations for optimization of protection in imaging, and the use of diagnostic reference levels (DRLs) and achievable doses as a tool to optimize image quality and the radiation delivered to patients for imaging examinations. DRLs and achievable doses do not apply to radiation therapy. NCRP confirms the recommendations in NCRP (2012a):	
1477	Recommendation:	
1478	DRLs not be viewed as absolute determinants of appropriate use of medical radiation.	
1479	Optimization must take into account both patient dose and clinical utility, based on image	
1480	quality.	
1481	DRLs not be used for regulatory or commercial purposes or to establish legal standards of	
1482	care.	
1483		
1484	DRLs and achievable doses are tools used to help reduce the risk of stochastic effects.	
1485	Optimization of protection with respect to the risk of adverse tissue reactions, in particular from	
1486	interventional medical procedures, was addressed in NCRP Report No. 168 (NCRP, 2010b) and	
1487	Statement No. 11 (NCRP, 2014a). NCRP (2010b) emphasizes that the safe performance of	
1488	fluoroscopically-guided interventional (FGI) procedures requires controlling radiation dose in	
1489	order to prevent unexpected or avoidable adverse tissue reactions and to minimize the severity of	
1490	medically unavoidable injuries. NCRP (2010b) also provides guidance for controlling dose and	
1491	for patient post-procedure follow-up. NCRP (2014a) provides an administrative approach to	
1492	managing radiation dose for FGI procedures. It provides a process for evaluating procedures that	
1493	result in a clinically important tissue reaction, and states that the quality assurance and peer	
1494	review process "shall include a careful assessment of procedure justification, patient-specific	
1495	factors, radiation dose optimization, the time course over which radiation doses were	
1496	administered, disease severity, and procedure complexity."	
1497		
1498	4.3 Restriction of Individual Dose	
1499		
1500	Recommendation: The dose to individuals be restricted by both dose criteria for	
1501	optimization and dose criteria for control in specific exposure situations.	
1502		
1503	The radiation protection principle of restricting an individual's dose is fundamental and is	
1504	intended to ensure adequate protection. It also is intended to ensure that optimization does not	
1505	result in individuals or groups of individuals receiving an exposure that is inappropriate under	
1506	the prevailing circumstances. Although historically the principle of limitation has been focused	
1507	upon the definition of dose limits, the principle is, in fact, broader, and encompasses all	
1508	individual dose criteria. This principle receives its support from the ethical principle of non-	
1509	maleficence, placing a boundary on harm for a particular individual irrespective of the balancing	
1510	of benefit, and from the principle of justice, to ensure that the distribution of doses in an	
1511	optimized situation is equitable.	
1512		
1513	Although many factors may set restrictions on the range of options in an optimization process,	
1514	from a radiation protection standpoint the most significant is the selection of an individual dose	
1515	criterion for optimization that adequately protects the individual and which, from a protection	

Comment [PF57]: Fleming ... I find this connection of the second and third principle of radiation protection interesting. Is there ever the case that one might appeal to the third principle independently of the second. Another way of putting this is, "Is this third principle always subservient to optimization. What is there is a conflict between ALARA and individual dose limits?

NOT TO BE DISSEMINATED OR REFERENCED

standpoint, ought not to be exceeded in planning the protection strategy. In the United States,
and internationally, a plethora of terms have been used to describe individual dose criteria,
creating much discussion and confusion. NCRP believes it is better to focus on the specific use
of individual dose criteria for optimization and individual dose criteria for control when
specifying adequate protection in the exposure situation and prevailing circumstance, rather than
the different terms that have been used or are being used in other recommendations, and by
various users of radiation.

1523

Restrictions take two general forms in these recommendations. First is the application of 1524 1525 individual dose criteria in the optimization process to ensure an equitable outcome and to focus resources on individuals who are receiving the highest exposure. These will be referred to as the 1526 1527 individual dose criteria for optimization, recognizing that ICRP has termed them constraints or reference levels depending on the exposure situation, that in the United States the Federal 1528 Guidance for Occupational Exposure uses the term Administrative Control Level, and that 1529 1530 radiation source users employ a variety of terms such as "planning value". These individual dose 1531 criteria for optimization are established by the user or entity responsible for the source in the planning for protection. (NCRP recommendations for dose criteria are given in Section 8.) They 1532 1533 are a guide to the process, and the numeric value should be set to challenge the system to improve safety. If the resultant doses are found to approach or be greater than the previously 1534 established individual dose criteria for optimization, this would be an indication that the 1535 protection strategies need to be examined, and changes considered. Exceeding the numerical 1536 1537 value of the individual dose criteria for optimization should not be considered a violation. However, a regulatory authority may choose to require that the responsible entity establish such 1538 1539 values, and to take certain actions, such as review of the program, as a part of the radiation control program. A regulatory authority may also choose to require that individual dose criteria 1540 for optimization be reviewed as part of the regulatory review process, to ensure that the broader 1541 goals of adequate protection are achieved. 1542 1543 1544 Second is the application of individual dose criteria in the control process to restrict the dose to

1545 individuals living or working in a radiation environment that exceeds the normal ubiquitous radiation background. NCRP recommendations for individual dose criteria for control are given 1546 in Section 8 and define adequate protection for an individual in a specified exposure situation 1547 and prevailing circumstance. This form of restriction on individual dose has often been referred 1548 to as the dose limit. The term "dose limit" denotes a specific and absolute value of individual 1549 dose from all sources of exposure to that individual. Regulatory authorities establish dose limits 1550 1551 as the basis for judging the adequacy of radiation protection for an individual and appropriate functioning of the radiation protection program to ensure adequate protection. From the 1552 standpoint of accountability and responsibility, exceeding the numerical value of a dose limit is 1553 automatically a violation. The NCRP leaves to regulatory authorities the prerogative to establish 1554 such values in regulations when appropriate. 1555 1556

NCRP believes that great care is needed in deciding what type of individual dose restriction is appropriate for a particular exposure situation and prevailing circumstance. The term dose limit has in too many cases been used in contexts when an individual dose criterion for optimization is the preferred approach to achieving protection. Likewise, various other terms have been used on Comment [M58]: Ansari ... We state (lines 1468 and 1490 of the PDF version) that our individual dose criteria for optimization is similar to "dose constraint" and criteria for control is somewhat analogous to "dose limit". One would expect then that criterion for optimization be less than criterion for control, and we would use the latter to restrict individual dose not the former.

Comment [PF59]: Fleming ... Why is this not a violation of the third principle? See my earlier remarks.

Comment [M60]: Ansari ... We state (lines 1468 and 1490 of the PDF version) that our individual dose criteria for optimization is similar to "dose constraint" and criteria for control is somewhat analogous to "dose limit". One would expect then that criterion for optimization be less than criterion for control, and we would use the latter to restrict individual dose not the former.

Comment [M61]: Cool edit

42

1603

1604

1561	occasion when, in actuality, a dose limit is being imposed because exceeding the absolute value
1562	of dose constitutes a violation. This has caused confusion on the part of both regulatory agencies
1563	and entities using radiation, sometimes to the detriment of establishing a robust radiation
1564	protection program.
1565	
1566	Recommendation: The phrase "individual dose criteria for optimization" be used in
1567	planning and design of a radiation protection program as a restriction in the process of
1568	optimization of protection.
1569	
1570	Recommendation: The phrase "individual dose criteria for control" be used to establish a
1571	value for adequate protection in a particular exposure situation and prevailing
1572	circumstance.
1573	
1574	4.3.1 Occupational
1575	. —
1576	Individual dose criteria for optimization for occupationally exposed individuals are applied to
1577	specific identified individuals, and may be of the form of an annual value, or shorter time frames
1578	(including specific tasks or events) as may be appropriate for effective planning of radiation
1579	protection. It is often better to pursue optimization around certain tasks, in addition to looking at
1580	the overall optimization of protection for an individual.
1581	
1582	Individual dose criteria for control for occupationally exposed individuals are applied to the
1583	doses received by specific identified individuals in their work environment. Comparison of doses
1584	received with the individual dose criteria for control provides an assessment of the effectiveness
1585	of the radiation protection program as well as providing a means for restricting individual doses.
1586	It is incumbent upon licensees, employers, and other responsible entities to provide proper
1587	monitoring, to maintain dose records, and to exchange information so that an accurate record for
1588	a year is produced, irrespective of the number of different entities for whom an individual may
1589	work during the year.
1590	
1591	Occupational exposure may occur in any exposure situation. As such, the use of dose criteria
1592	will dependent upon whether it is possible to have sound, ongoing controls, assessment, and
1593	after he the ease in Evisting Evisions. Elitetians, Hervery and program for the the ease in Evisting Evision Situations, and may
1594	onen be the case in Existing Exposure Situations. However, such prospective controls are offen
1595	Final available in Emergency Exposure Situations, and may not be available in some Existing
1202	individual dose criteria that are appropriate for the prevailing circumstances
1200	mervieuai dose eriteria mai are appropriate for me prevaining encumistances.
1590	4 3 2 Public
1600	T.0.2 <u>1 done</u>
1601	In a Planned Exposure Situation, a dose limit for a member of the public can only be established
1602	in the context of the contribution from particular licensee or other responsible entity because it is

Comment [PF62]: Fleming ... Without any consideration of cumulative doses, particularly for those members of the public whose occupation or natural environment or medical status suggests the other sources should be considered... is there another alternative, e.g the licensee and, if it is the case, the specific features of a environment, occupation, or medical status of the member of the public.

single individual may be exposed. For Emergency and Existing Exposure Situations, the concept

not possible to accurately account for all of the possible contributors of exposure to which any

of a limit cannot be effectively applied in public exposure, and reliance should be placed upon 1605 the ALARA principle guided by individual dose criteria for optimization. 1606 1607 Individual dose criteria for optimization for members of the public are established by entities 1608 responsible for a source to ensure that the dose contributed from their activities meets the 1609 ALARA principle. In Planned Exposure Situations, the criteria should be established in advance 1610 and used in the planning and design of the radiation source control. Appropriate monitoring 1611 should be conducted to assure adequate protection within the individual dose criteria for control. 1612 1613 1614 In an Emergency Exposure Situation, actions will need to be taken urgently to protect public health and safety, usually based on facility conditions or limited information. As such, the 1615 1616 individual dose criteria for optimization must be established in advance, and can be later refined when assessments of dose can be made for the circumstances. Meanwhile, individual dose 1617 criteria for control should be applied to assure adequate radiation protection for the exposed 1618 1619 individuals. 1620 In Existing Exposure Situations, an assessment is needed of the potential exposures that may be 1621 received, or are being received by individuals. The individual dose criteria for optimization are 1622 used to guide application of the ALARA principle in planning and designing any remedial 1623 action. Individual dose criteria for control would be used to control access and to assure 1624 adequate protection for individuals accessing or residing in the affected area. Adjustment of 1625 these criteria during a remediation activity may be a rather long and continuous process, 1626 depending on the circumstances, as described in NCRP Report No. 175 (NCRP, 2014b). 1627 1628 In Emergency and Existing Exposure Situations, the numeric values of the individual dose 1629 criteria may be selected from within a relatively broad band of dose, as described in Section 8. 1630 Optimization to achieve the ALARA principle is to be pursued irrespective of whether the 1631 assessed individual doses are greater than or less than the established individual dose criteria for 1632 1633 optimization, with priority being given to reducing exposures of any individuals that may be 1634 receiving doses greater than the individual dose criteria for control. 1635 In public exposure, the individual dose criteria for optimization are generally not specific to any 1636 particular individual, and instead are applied to a representative individual, defined to be 1637 representative of the more highly-exposed individuals in the population (ICRP Publication 101) 1638 (ICRP, 2006). This term is the equivalent of, and replaces, -average member of the critical 1639 group², described in previous ICRP and NCRP recommendations. 1640 1641 4.3.3 Medical 1642 1643 Individual dose criteria for optimization take an entirely different form in the context of medical 1644 patient exposures. This is because the goal of optimization in medical exposure is to achieve the 1645 necessary diagnostic or therapeutic outcome while avoiding unnecessary radiation, and thus the 1646

1646 necessary diagnostic of therapeutic outcome while avoiding unnecessary radiation, and thus to 1647 ALARA principle means as low as reasonably achievable to achieve the intended clinical

purpose. Medical exposures include exposures of patients in the course of their medicalexamination and treatment, exposure of individuals who may voluntarily take part in medical

Comment [PF63]: Fleming ... Optimization trumps the dose limit principle?

Comment [M64]: MR ... probably should give the references to the previous ICRP and NCRP reports

Comment [M65]: Cool edit

Coo

44

NOT TO BE DISSEMINATED OR REFERENCED

research, and exposure of individuals (other than those who are occupationally exposed) who are
specifically engaged in the comfort or care of a patient (refer to SC 4-7 report when it is
completed). The concept of a dose limit does not apply to medical exposures for patients
undergoing diagnostic or therapeutic procedures. From an ethical perspective, in medical
exposure beneficence is seen to outweigh non-maleficence, but is unlikely to outweigh
autonomy.
Public and occupational exposure that may be concurrent with medical treatment is handled in

1657 accordance with the provisions described in Sections 4.3.1 and 4.3.2, respectively. For 1658 occupational exposure, NCRP Report 168 (NCRP, 2010a) provides recommendations for certain 1659 cohorts, such as those involved in certain interventional procedures, where on rare occasions, in 1660 1661 order to save a patient's life or to prevent severe and irreparable injury to a patient, it may be necessary for the individual to be exposed to a radiation dose (from that specific procedure) that 1662 when added to the cumulative dose received thus far in the year would exceed an occupational 1663 1664 dose limit. The recommendations in this Report reaffirm the recommendations in NCRP 1665 (2010a).

4.3.3.1 <u>Imaging Procedures</u>. An appropriate process for management of the risk of stochastic
effects is the use of diagnostic reference levels (DRLs) and achievable doses NCRP supports the
use of diagnostic reference levels (DRLs) and achievable doses as tools for optimization of
protection and as guides to promoting safe practices (Brink and Miller, 2015; NCRP, 2012a;
ICRP, 2007b). This Report reaffirms the recommendations in NCRP (2012a).

Screening imaging procedures are performed on asymptomatic patients and may be performed on multiple occasions. Against the benefit of early detection are the risk of radiation exposure, the adverse effects of true negative, false-negative and false-positive examinations, and the economic cost. A discussion of the nonradiation adverse effects of screening for breast cancer can be found in Lauby-Secretan <u>et al.</u> (2015). In order to optimize radiation exposure, particular care should be taken to monitor the output of radiologic devices used for screening, especially computed tomography (CT) scanners.

4.3.3.2 Radiation Oncology. Localized high absorbed doses of radiation are employed in treating 1681 some cancers and other diseases. Adverse tissue reactions and carcinogenic effects are expected 1682 and considered in the risk/benefit calculation. For radionuclide therapy, there is a concomitant 1683 whole or partial-body exposure. The resulting toxicity, generally to active bone marrow, often 1684 limits the administered activity. In addition, the exposure of caregivers and comforters needs to 1685 be taken into account when significant gamma rays escape from the body (NCRP, 1995; 2006a). 1686 As noted in Section 4.3.3, dose limits do not apply to radiation therapy treatments, and DRLs are 1687 not an appropriate means for optimization, since the intent is to deliver a tumoricidal dose to 1688 cancerous tissues. 1689

1690

1666

1672

Comment [JTB66]: Bushberg Insert reference to SC 4-7 NCRP Report when completed

MR

Comment [KK67]: Bushberg Define.

MR ... check Report No. 172

1691 **References** (Section 4)

- 1692
- Beatrice Lauby-Secretan, Chiara Scoccianti, Dana Loomis, Lamia Benbrahim-Tallaa, Véronique
 Bouvard, Franca Bianchini and Kurt Straif for the International Agency for Research on
 Cancer Handbook Working Group (2015). "Breast-Cancer Screening Viewpoint of the
 IARC Working Group," N Engl J Med 372(24):2353-2358.
- Brink, J.A. and Miller, D.L. (2015). "U.S. National Diagnostic Reference Levels: Closing the
 Gap," [Editorial] Radiology 277(1):3-6.
- 1699 HERCA (2012)
- http://www.herca.org/documents/HERCA%20Position%20Paper%20on%20screening.pdf.
 ICRP (1983). Cost-Benefit Analysis in the Optimization of Radiation Protection. ICRP
- Publication 37. Ann. ICRP 10 (2-3).
- ICRP (1990). Optimization and Decision Making in Radiological Protection. ICRP Publication
 55. Ann. ICRP 20 (1).
- 1705 ICRP (2006), ICRP Publication 101
- ICRP (2007a). International Commission on Radiological Protection. Recommendations of the
 ICRP, ICRP Publication 103, Ann. ICRP 37(2–4) (Elsevier, New York).
- ICRP (2007b). International Commission on Radiological Protection. Radiological Protection in
 Medicine, ICRP Publication 105, Ann. ICRP 37(6) (Elsevier, New York).
- 1710 NCRP reports.... that give approaches to the making decisions for meeting the ALARA principle
- NCRP (1993). National Council on Radiation Protection and Measurements. Limitation of
 Exposure to Ionizing Radiation, NCRP Report No. 116 (National Council on Radiation
 Protection and Measurements, Bethesda, Maryland).
- 1714 NCRP (1995). NCRP Commentary 11
- 1715 NCRP (2006a). NCRP Report No. 155
- 1716 NCRP (2009). NCRP Report No. 160
- 1717 NCRP (2010a). NCRP Report No. 168
- 1718 NCRP (2014a). Statement No. 11
- 1719 NCRP (2014b). Report No. 175
- 1720 NCRP (2012a). Report No. 172
- 1721

1722 1723	5. Quantities, Units, and Measurements (This section is currently under further review)		Comment [M68]: MR I think this section needs to be replaced by a simpler version (like the
1724			section in Report No. 160) that simply states and defines only the quantities and units used in this
1725	5.1 Introduction		Report. For now, I have just retained Darrell's text
1726			and the members comments.
1727	Radiation protection is a physical science. When a living organism is irradiated by external or	1	The standard ICRP or other technical definitions
1728	internal radiation sources, discrete amounts of energy are imparted to organs and tissues of the	i I	would appear in the usual style NCRP Glossary.
1729	body. The absorbed dose, or quantity of energy imparted per unit mass of an absorbing medium,	i	Fisher I disagree that this section should be
1730	may be measured or calculated. Radiation dose and dose rate are thus expressed using well-	i -	deleted in favor of a simple glossary, because
1731	defined quantities and units.	j.	a complete section; it corrects errors and
1732		i.	misperceptions, and provides updated clarification
1733	Radiation dosimetry accounts for all relevant contributions to energy imparted to matter by	1	terminology, philosophy, notations and symbols
1734	radiation of different types and qualities, including x-rays, gamma-rays, alpha particles, beta	- i	used by ICRP. The issues are generally confusing
1735	particles, neutrons, fragments from spontaneous fission, and charged-particle recoil ions. Each	1	(myself included!). THEREFORE, to sort things out, I
1736	radiation type differs spatially in localized energy deposition patterns produced and density of	1	have put in a substantial effort after many
1737	localized chemistry changes, such as formation of highly reactive free radicals. The resulting		that this NCRP Report is fully up-to-date. In
1/38	ionization patterns influence the type and frequency of cellular-level biological effects that may	1	radiation protection, there is considerable
1739	historial affactiveness (PPE) per unit of absorbed dose	1	reflected in your collective comments on the
1740	biological effectiveness (RDE) per unit of absorbed dose.	1	current draft.
1741	Biological systems may also vary widely in their response to a constant radiation absorbed dose	i i	MR There should be a Section 5 (not deleted, but
1743	Tissue radiosensitivity differs among the organs in the hody. Biological response may be	1	its content to be discussed), and there usually is a
1744	expressed as whole-organ effects or cellular-level effects as near-term adverse tissue reactions	1	definitions of guantities and units are only one set
1745	or as long-term late effects. The interpretation of dose and dose rate in terms of consequences or		of entries.
1746	effects on living systems is a radiobiological science that takes localized energy depositions into		Comment [M69]: Fisher I have found a few
1747	account. The study of biological response to ionizing radiation requires rational systems for		key sentences from NCRP Report 155, especially well written, that I would like to borrow and
1748	relating absorbed dose and absorbed dose rate to observed changes after radiation exposure.		incorporate into the current draft of Section 5. In
1749	Thus, the foundational systems for expressing dose and dose-response relationships, dose-rate		revision, these would represent only minor changes to the current draft.
1750	effects, and radiobiological responses must accommodate many different radiation types and		
1751	qualities within a complex biological environment for general application to radiation protection.		
1752			
1753	Protection against the harmful effects of radiation requires a well-defined, coherent system of		
1754	quantities and units. Radiation protection quantities and units must be generally applicable to		
1755	occupational, environmental, and medical exposure to ionizing radiation. The radiation dose		
1756	quantities and units appropriate for use in radiation protection are discussed in this Section.		
1/5/	5 2 Prove Consulting		
1758	5.2 Base Quantities		is the place for recommendations. I think that we
1759	The concept of radiation dose incorporates the integral of all energy deposition events within a		must be clear that the quantities and units we
1761	defined volume over a specified period of time for a well-defined source-target geometry		for radiation protection.
1762	Conditional parameters defining the radiation source include the source activity emissions		
1763	spatial distribution, and material density. Biological target conditional parameters include target		Cool Do we have any recommendations?
1764	mass and geometry, material density, tissue type and radiation sensitivity for a defined endpoint		
1765	The ability to determine, quantify, and express dose and dose rate for radiation exposure is		

1767

1789

1802

1806 1807 1808

1810

1768 **5.2.1** Energy Imparted by Ionizing Radiation

1770 Quanta of energy ($\underline{\epsilon}$) in definable amounts (joule) are deposited in matter by ionizing radiation

when charged and uncharged ionizing particles interact with atoms and molecules in the

absorbing medium. These energy depositions represent discrete ionization events.

1774 **5.2.2** <u>Absorbed Dose</u>

1775 1776 The basic unit of radiation energy deposition by ionizing radiation is <u>absorbed dose $D(r_T)$ to an</u> 1777 absorbing tissue or target region (<u>T</u>) due to radiation of type R.(r_T). Absorbed dose is the 1778 fundamental physical quantity applicable to all radiation exposures, for all types of ionizing 1779 radiation, for any absorbing medium, and for all biological targets and geometries. Absorbed 1780 dose is a measurable quantity. The concept of absorbed dose applies to individual subjects 1781 (humans or animals) workers medical patients, and members of the public of any age

(humans or animals), workers, medical patients, and members of the public of any age.

1783 Since the actual amount of radiation energy imparted at the microscopic scale may be highly 1784 variable, due either to non-uniform distribution of radionuclides in tissues, or due to densely 1785 ionizing particle tracks, the definition of the absorbed dose is given as a point function, which 1786 allows for specification of dose in terms of spatial distributions and linear energy transfer. Thus, 1787 absorbed dose is the mean of all energy deposition events (ε/m) in specified microscopic target

volumes (cells and cell nuclei).

1790 In its simplest constitution, the absorbed dose $D(r_T) = \varepsilon/m$, where ε is the energy imparted to a 1791 specified target region and *m* is the mass of the absorbing medium. The units of absorbed dose 1792 are joule per kilogram (J kg⁻¹) in the International System of Units (SI), where the special name 1793 for the unit of absorbed dose is gray (Gy), and 1 Gy equals exactly 1.0 J kg⁻¹.

Absorbed dose is proportional to the number of ionization events in the target region, which is proportional to the amount of physical damage produced. Therefore, absorbed dose is directly relevant to observed organ, tissue, and tumor cell killing (immediate) effects. Absorbed dose may also be related to delayed effects, cumulative effects, and stochastic effects such as the probability of cancer induction as a function of dose.

1801 5.2.3 <u>Absorbed Dose Rate</u>

The absorbed dose rate $\dot{D}(r_T, t)$ expresses the amount of energy imparted to an absorbing tissue or region r_T per unit time *t*. The time-integral of the absorbed dose rate is the total absorbed dose. For a defined dose-integration period <u> τ </u>, the absorbed dose is therefore:

$$D(r_T, \tau) = \int_0^{\tau} \dot{\mathrm{D}}(r_T, t) dt$$
(5.1)

1809 5.2.4 Exposure (External Radiation Fields)

Radiation detectors in air serve as surrogate measures of radiation exposure to persons or objects
 in the same radiation field; that is, the kerma or kerma rate for an absorbing material in free

Comment [AA(71]:

Ansaral ... In NCRP 116 and ICRP 103, the notation D(T,R) is used. We should use the same notation to avoid confusion.

Kasel believe that Darrell is using the ICRU notation.

1813 space (such as a radiation detector) may be directly related to the kerma or kerma rate for another 1814 material (such as a living organism) for which it may not be convenient or possible to measure 1815 the radiation field directly. The concept of exposure has been used as a measure of the ability of 1816 photon (x-ray or gamma-ray) fields to ionize air molecules. <u>Exposure</u> is the term given to 1817 irradiation of matter <u>in air</u> by x rays or gamma rays, where exposure is the quotient of (the 1818 absolute value) of the total charge of the ions of one sign (+ or -) produced in air (<u>Q</u>, when all of 1819 the electrons liberated by photons in a defined volume of dry air are completely stopped in air, in

coulombs, C) and the mass of the volume of air; thus $\underline{X} = \underline{Q}/\underline{m}_{air}$ in units of C kg⁻¹.

The traditional unit of exposure is the roentgen (R), and of exposure rate is roentgen per hour (R h⁻¹), where 1 R = 2.58 x 10⁻⁴ C kg⁻¹ (exactly). The SI unit is gray, where 1 R = 8.69 x 10⁻³ J kg⁻¹ = 8.69 x 10⁻³ Gy (kerma in air).

1826 **5.2.5** <u>Exposure Rate</u> 1827

1825

1834

1835 1836

1842

1850

1828 <u>Exposure rate</u> is exposure per unit time, or $\underline{\dot{X}} = \underline{\dot{Q}}/m_{air} \underline{t}$ (C kg⁻¹ s⁻¹), for \underline{t} in seconds or hours. 1829 Exposure rate meters used in radiation protection measure and display the exposure rate per unit 1830 time (commonly μ R h⁻¹, mR h-1), or in units of a derived operational quantity based on an organ, 1831 tissue, or whole-body dose equivalent (μ Sv h⁻¹, mSv h⁻¹; see Section 5.4). The terms <u>exposure</u> 1832 and <u>exposure rate</u> do not apply to irradiation by charged particles or to radiation from internally 1833 deposited radionuclides.

5.3 Derived Quantities

For a constant value of absorbed dose, the biological effects observed may be different for each
radiation type and quality, pattern of energy deposition, and dose rate. Organs and tissues also
differ in radiosensitivity per unit absorbed dose. The biological effectiveness of an absorbed
dose depends also on biological end point, cellular-level repair mechanisms, and other modifying
factors. Therefore, The NCRP System takes many such factors into account.

Derived quantities are multiples of the absorbed dose that account for observed differences in biological effect for a single target tissue when radiations of different ionization qualities are compared, or when the radiosensitivities of different tissues are compared for a single radiation type. Derived quantities account for the relative biological effectiveness (RBE) of radiation per unit absorbed dose for radiations of different qualities or ionization density, and for biological targets having different responses per unit absorbed dose. Derived quantities may also account for age and gender determinants of radiation effectiveness for a given absorbed dose.

1851 **5.3.1** <u>Relative Biological Effectiveness</u>

The relative biological effectiveness (RBE) of any given radiation may be compared to a
reference radiation that produces the same level of response (by tissue and end point) per unit
absorbed dose. By definition, the RBE is the ratio of the absorbed dose of a reference radiation
to the absorbed dose of a test radiation that produces the same level of biological effect, all other
conditions being equal: RBE = *D*reference/*D*test. Typical reference radiations are ⁶⁰Co gamma

rays and 200 or 250 x rays. If the reference and the test radiations produce different types of
biological effects, the radiations cannot be compared and an RBE cannot be specified for the test
radiation. The RBE is commonly used in radiobiology research for comparing the effects from
radiation of different qualities or energies. The RBE may also be used for radiation protection
purposes when it is necessary to infer a radiation-weighted absorbed dose to an organ or tissue
(Section 8.2.1).

1865 5.3.2 <u>Radiation Weighting Factors</u>

1866 In radiation protection, dimensionless weighting factors (w_R) may be assigned to radiations of 1867 different qualities and energies (such as x-rays and gamma rays, beta particles, alpha particles, 1868 1869 neutrons, and heavy charged particles) to represent an approximate value of relative biological 1870 damage or risk of detriment produced by each for a constant radiation absorbed dose. Radiation weighting factors are used to derive the equivalent dose from the absorbed dose (averaged over 1871 1872 an organ or tissue). Values of radiation weighting factor for charged particles and neutrons allow 1873 for differences in energy deposition among various radiations; the factors are set by committee relative to baseline for x- or gamma radiation ($w_R = 1.0$), apply only to stochastic effects, and 1874 usually represent conservative or upper limits on experimentally observed values. Radiation 1875 weighting factors should not be used to predict short-term tissue reactions, and should not be 1876 applied to individual subjects. Currently accepted radiation weighting factors for radiation 1877 protection were established by ICRP Publication 103 (ICRP, 2007a), and recommended values 1878 1879 of w_R are given in Table 7.1. 1880

1881 5.3.3 Equivalent Dose

The equivalent dose $H(r_T, \tau)$ to an organ or tissue r_T is a derived radiation protection quantity for relating absorbed dose to the probability of a future stochastic radiation effect (cancer induction and hereditary changes, if any) in that organ or tissue. The equivalent dose represents the sum of all the contributions from radiations of different types $D_R(r_T, \tau)$ multiplied by their respective radiation qualities w_R :

1888 1889 1890

1882

 $H(r_T, \tau) = \sum_R W_R D_R(r_T, \tau)$ $H_T = \sum_R w_R D_{T,R}$

1891 1892

The units of equivalent dose are also joule per kilogram (J kg⁻¹), where the special name for the 1893 unit of equivalent dose is sievert (Sv), and 1 Sv equals exactly 1.0 J kg⁻¹. However, equivalent 1894 dose is not purely a physical quantity, but rather a surrogate of dose representing a numerical 1895 entity of radiation damage *risk*-based on the physical quantity absorbed dose. In practice, the 1896 unit of equivalent dose should not be used to predict individual risk of cancer or hereditary 1897 effects in workers or medical patients. The concept of equivalent dose applies only to population 1898 group averages (reference models) for radiation protection planning, and not to individual 1899 subjects for risk assessment. 1900

Comment [AA(72]: Ansari ... I think we should only list 250 kVp x rays here.

Fisher ... I agree that 200 kVp may be deleted as a reference radiation for RBE calculations.

Comment [M73]: Ansari ...This notation looks unnecessarily complicated. We should use the same notation used in other NCRP reports and by ICRP.

Fisher ... Armin, please note that the symbols and nomenclature given are completely current with ICRP (ICRP has been evolving). ICRP has adopted these new symbols. The use of equations and notation has been reduced to the simplest forms (minimalism).

MR ... whatever we decide to use, the symbols need to be defined (i.e., r_{T} , and τ are not yet explained], and the source of this equation needs to be referenced, since this is not what is in ICRP Publications 103 or 110. Are these in later ICRP publications or in ICRP works-in-progress and not yet published? [see also Equation (5.3)]

Comment [M74]: MR ... this is the basic equation for equivalent dose given in ICRP Publications 103 and 110.

Comment [M75]: Cool edit

1901

1906

Since the radiation-weighting factors were developed only for stochastic effects, the equivalent dose is not applicable to tissue reactions, and equivalent dose should not be used for evaluating organ or tissue toxicity from radiation. Instead, the absorbed dose $D(r_T)$ is the quantity relevant for evaluating biological effects in tissue.

1907 5.3.4 <u>Tissue Weighting Factors</u>

1908 1909 Organs and tissues vary in radiation sensitivity and propensity to undergo radiation-induced 1910 changes that could lead to cancer induction and hereditary effects. Tissue weighting factors (w_T) 1911 have been selected by committee (ICRP, 2007a) for organs and tissues (r_T) of the body to 1912 represent the approximate relative contribution of tissue radiosensitivity to total risk of radiation 1913 detriment from <u>stochastic effects</u> after exposure to radiation, subject to the limiting condition that 1914 the sum of all the tissue weighting factors is equal to 1.0 in a reference model (Table 7.2).

1915 1916 The tissue weighting factors (\underline{w}_T) are independent of radiation quality, and apply only to 1917 population groups and not to individuals. The choice of tissue weighting factors as measures of 1918 relative detriment representing all population groups implies and acknowledges a high degree of 1919 uncertainty in the individual values for each organ or tissue.

1920 1921 The scientific basis for selecting tissue weighting factors is the observed cancer incidence among 1922 Japanese atomic-bomb survivors; thus, the organ and tissue weighting factors are stipulated only 1923 as a measure of relative cancer risk, and do not apply to short-term tissue reactions. The tissue 1924 weighting factors (\underline{w}_T) consider the mortality and morbidity risks of cancer, the risk of severe 1925 hereditary effects for all generations, and the length of life lost due to these effects (Section 7), 1926 apportioned by organ or tissue.

1926 1927

1933

1935

1928 The tissue weighting factors are used for calculating effective dose for radiation protection 1929 purposes and comparing an individual worker's dose against applicable protection criteria. The 1930 weighting factors apply to both external sources and internal emitters. The current practice is to 1931 apply age- and gender-averaged tissue weighting factors specified by the ICRP (2007a) that 1932 represent mean values for humans averaged over both sexes and all ages.

1934 **5.3.5** Effective Dose

1936 Effective dose *E* is the quantity used in radiation protection for establishing individual dose 1937 criteria for workers and members of the general public exposed to radiation and radionuclide 1938 intakes. The units of effective dose *E* are joule per kilogram (J kg⁻¹), and the special named unit 1939 for effective dose is the sievert (Sv), where $1 \text{ Sv} = 1.0 \text{ J kg}^{-1}$. However, the effective dose is 1940 merely a construct or surrogate of risk and not a purely physical quantity. Instead, effective dose 1941 represents an overall risk of observed detriment attributable to stochastic effects of radiation.

By definition, effective dose is a hypothetical, population-average construct, based on absorbed dose that is associated with biological response to organ equivalent dose weighted according to estimates of detriment from exposure to radiation or intake of radionuclides. The concept of Comment [AA(76]: Ansari ... This should be just T not rt? The R is for type of radiation.

(5.3)

effective dose applies to groups of subjects (reference models) only, and does not apply 1946 1947 specifically to any one individual. 1948

 $E = \sum_{T} W_{T} \left[\frac{H(r_{T}, \tau)^{male} + H(r_{T}, \tau)^{female}}{2} \right]$

 $E = \sum_{\mathrm{T}} w_{\mathrm{T}} H_{\mathrm{T}}$

Numerically, the effective dose is the sum of all the weighted equivalent doses for all irradiated 1949 organs and tissues of the body of a reference model, whether the body is irradiated uniformly or 1950 1951 non-uniformly. This reference model was averaged to represent a hybrid reference (50th percentile) male and female representing all ages and sizes in a standard population: 1952 1953

1954

1955

1956

1957

1958 1959 Since effective dose is not directly predictive of cancer incidence in a particular individual, values of effective dose should not be used to estimate future cancer risk from specific sources of 1960 radiation exposure. Individual assessments of potential detriment should only be based on organ 1961 1962 or tissue radiation absorbed dose $D(r_T)$.

1963

1966

1972

1974

1964 In occupational radiation safety, effective dose should be determined for comparing exposure 1965 scenarios to the individual dose criteria.

Calculated values of effective dose may be useful for radiation protection planning to compare 1967 exposures that could result from different work activities. For example, the relative exposures 1968 associated with different diagnostic or fluoroscopically-guided interventional procedures may be 1969 nominally compared using effective dose. In this context, effective dose might be appropriate 1970 1971 for use by institutional review boards and radiation safety committees.

5.3.6 Committed Effective Dose 1973

1975 The committed effective dose represents an estimated future equivalent dose or a future effective 1976 dose that could be received from an intake of a long-lived, long-retained radionuclide that will 1977 continue to irradiate the body for a time period greater than one year after intake. The committed 1978 equivalent dose is the time integral of the equivalent dose rate in an organ or tissue that will be 1979 received by an individual, represented as a standard anthropomorphic reference person. The time 1980 integral for calculating a committed equivalent dose is 50 years for adults, and to age 70 years for children. The committed effective dose represents the sum of the products of the committed 1981 equivalent doses and the appropriate tissue weighting factors (w_T) , where the integration time is 1982 50 y (adults) or to age 70 y (for children) following the radionuclide intake. 1983 1984

By definition, the committed effective dose is a quantity used in radiation protection for 1985 establishing individual dose criteria for workers from exposure to internally deposited 1986 1987 radionuclides. Use of the committed internal effective dose infers substantial uncertainties. The committed effective dose is not purely a physical or measureable quantity, but rather a surrogate 1988

of potential future effective dose representing a numerical entity of risk based on the physical 1989

Comment [M77]: Ansari ... This notation looks unnecessarily complicated. We should use the same notation used in other NCRP reports and by ICRP.

Fisher ... Armin, please note that the symbols and nomenclature given are completely current with ICRP (ICRP has been evolving). ICRP has adopted these new symbols. The use of equations and notation has been reduced to the simplest forms (minimalism).

MR ... whatever we decide to use, the symbols need to be defined (i.e., r_T , and τ are not yet explained], and the source of this equation needs to be referenced, since this is not what is in ICRP Publications 103 or 110. Are these in later ICRP publications or in ICRP works-in-progress and not yet published? [see also Equation (5.2)]

Comment [M78]: MR ... this is the basic equation for effective dose given in ICRP Publications 103 and 110.

Comment [M79]: MR ... need to be very careful how this is worded. There is more precise wording for this point in ICRP Publications 103 and 105 that should replace the current wording if this point is retained. I have reworded this sentence.

Comment [M80]: MR ... This quantity is not mentioned anywhere in the main text of the document.

Fisher ... The section includes committed effective dose, collective population dose, and operational quantities because they need to be included (keeping 5.0 as a main section) for completeness. If you think their mention is missing elsewhere in the report, we might ask ourselves why, and what needs to be done for the other sections. These are significant concept in national radiation protection

MR ... NCRP reports usually only discuss quantities and units used in the particular report. I can see a couple of outcomes:

- •Delete the terms since they do not appear in the body of the report ... although committed effective dose is part of effective dose (i.e., for intakes of radionuclides)
- Alter the content of the body of the report such that the terms are needed and thus are included ... that would likely require saying more in the
- text about implementation of the recommendations and the role of these
- quantities in implementation.

2000

2012

2023 2024

2025

NOT TO BE DISSEMINATED OR REFERENCED

quantity absorbed dose. In common practice, the committed equivalent dose to an organ or 1990 tissue represents an appropriate quantity for recording and tracking the potential future 1991 cumulative internal equivalent dose to radiation workers from internally deposited, long-lived 1992 1993 radionuclides. Calculated values of committed effective dose may be used for radiation protection planning to compare exposures that could result from different work activities 1994 1995 involving long-lived, long-retained internally deposited radionuclides. In practice, the committed effective dose should not be used for predicting adverse tissue reactions, for 1996 1997 epidemiologic studies, or for predicting individual risk of cancer or hereditary effects. 1998

1999 **5.3.7** Collective Population Dose

Collective population dose, <u>S</u>, or collective effective dose, refers to the product of the average effective dose for a population subgroup *i* and the number of persons in the subgroup over a specified period of time; $S = \sum_i E_i N_i$, where E_i is the average effective dose and N_i is the number of persons in the subgroup. The unit of the collective effective dose is joule per kilogram (J kg⁻¹), and its special name is person-sievert (ICRP, 2007a).

Collective dose represents a measure of the total dose impact on a community affected by a radiation-generating activity. Collective dose applies only to populations with individual effective dose values that are substantially greater than environmental background levels plus contributions from beneficial medical exposures. This is useful for comparing the radiological impact of competing plans for introducing or removing a source of radiation exposure.

Sometimes collective dose is used in epidemiologic studies. Since there are significant
 dosimetry uncertainties in epidemiologic studies, and since individual responses to radiation are
 highly variable, the collective dose is not intended as a tool for epidemiologic research.

Computation of collective dose to prospectively predict future risk to an exposed population by
 multiplying small risk coefficients by large population numbers is biologically and statistically
 uncertain and leads inevitably to unsupportable claims of adverse health effects from ionizing
 radiation (NCRP 1997; 2012). Therefore, calculation of the number of adverse health effects
 expected, based on collective effective doses representing trivial individual doses, should be
 avoided (ICRP 2007).

5.4 Direct Measurements of Radiation Dose

Radiation doses from external sources are estimated using measurements from area-monitoring
instruments and personal dosimeters. It is not possible to directly measure radiation doses to
internal organs of the body from external gamma-ray, beta-particle, or neutron radiation sources.
Therefore, the information obtained from personal dosimeters and area-monitoring instruments
must be converted to operational quantities that may be used to compare an individual's radiation
exposure against established dose criteria.

The measurement of radiation quantities corresponding to an estimate of whole-body effective dose requires calibration and correction factors unique to each dosimeter, device, and instrument to account for and record an individual's exposure. Radiation survey instruments are calibrated **Comment [KK81]:** Kase ... Except for this sentence the paragraph discusses committed effective dose. The purpose of this sentence is not clear to me.

Comment [M82]: MR ... This quantity is not mentioned anywhere in the main text of the document.

Fisher ... The section includes committed effective dose, collective population dose, and operational quantities because they need to be included (keeping 5.0 as a main section) for completeness. If you think their mention is missing elsewhere in the report, we might ask ourselves why, and what needs to be done for the other sections. These are significant concept in national radiation protection.

MR ... NCRP reports usually only discuss quantities and units used in the particular report. I can see a couple of outcomes:

- •Delete the terms since they do not appear in the body of the report ... although committed effective dose is part of effective dose (i.e., for intakes of radionuclides)
- •Alter the content of the body of the report such that the terms are needed and thus are included ... that would likely require saying more in the text about implementation of the

recommendations and the role of these quantities in implementation.

2051

2059

2071

2073

NOT TO BE DISSEMINATED OR REFERENCED

by exposing the detector to a well-characterized radiation field (traceable to a national standards
laboratory). Instruments used under different field conditions may exhibit energy dependence,
temperature and pressure dependence, directional dependence, source distance and geometry
effects, and contributions from radiation scatter. Therefore, appropriate correction factors are
needed to relate field instrument readings to laboratory-controlled calibration conditions.

Modern radiation detectors, personal dosimeters, and associated electronic instrumentation 2042 provide direct measurements of external penetrating (gamma, x-ray, or neutron) radiation fields 2043 to which people may be exposed. Passive dosimeters (condenser-type pocket dosimeters, film 2044 2045 badges, thermoluminescent dosimeters, optically stimulated luminescent dosimeters, chemical dosimeters, track-etch films) record an integrated exposure over time. The absorbed dose related 2046 to this exposure can be determined by manual or systematic electronic read-out. Active 2047 2048 electronic dosimeters (ion current chambers, personnel dose-rate meters, and survey instruments) 2049 record absorbed dose and absorbed dose-rate. Radiation instruments do not measure equivalent 2050 dose $H(r_T, T_D)$ or effective dose E.

2052 Conversion from a radiation measurement in air to absorbed dose in the body requires an 2053 anatomical model to represent the human body and the location of various organs within that 2054 body. The absorbed dose in a given organ can vary substantially depending on the incident 2055 photon energy, angle of entry, organ size, shape and position, and body size. In practice, without 2056 detailed knowledge of the photon energies and irradiation geometries, the organ absorbed dose 2057 may only be estimated, and the overall uncertainties in translating the air-measurement to organ 2058 dose may be great (NCRP, 2015a).

2060 Neutron fields are detected by measuring nuclear reactions that produce energetic charged recoil nuclei, protons, alpha particles, and fission fragments. Since neutron interactions with matter 2061 depend on neutron energy, a number of different methods are needed to detect and measure the 2062 neutron field over a broad energy spectrum (10^{-2} to 10^7 eV). Several different materials are 2063 2064 appropriate for neutron detection. For slow neutrons, the most common neutron detector 2065 measures the conversion of boron-10 to lithium-7, or conversion of lithium-6 to hydrogen-3 2066 (tritium) with release of a detectable alpha particle. For medium energy neutrons, the detection 2067 medium helium-3 is converted to hydrogen-3 with release of a detectable proton. For fast neutron detection, a moderator rich in hydrogen, such as polypropylene, is used to thermalize 2068 fast neutrons by elastic neutron scattering. These instruments provide estimates of dose 2069 2070 equivalent to the worker.

2072 **5.4.1** Operational Quantities

Radiation protection guidelines, standards and limits are nominally specified in units of
equivalent dose and effective dose, which cannot be measured directly. Thus, operational
quantities have been developed for radiation protection purposes to relate measured quantities to
applicable dose criteria. "Operational quantities" represent derived quantities based on
measurements using personal dosimeters or area radiation field instruments for assigning worker
doses and for demonstrating compliance with radiation exposure guidelines, standards, and
limits.

Comment [AA(83]: Ansari ... It may be better to cite a reference for this and not include the details here.

Comment [M84]: Kase ... Is the specification of dose equivalent here necessary because these instruments do not use the radiation weighting factors appropriate for equivalent dose? If so, this needs to be explained.

Fisher ... I agree with your comment on dose equivalent and equivalent dose...yes, further explanation is needed because measuring instruments do not incorporate radiation weighting factors and most people don't know the difference.

Comment [M85]: MR ... This quantity is not mentioned anywhere in the main text of the document.

Fisher ... The section includes committed effective dose, collective population dose, and operational quantities because they need to be included (keeping 5.0 as a main section) for completeness. If you think their mention is missing elsewhere in the report, we might ask ourselves why, and what needs to be done for the other sections. These are significant concept in national radiation protection.

MR ... NCRP reports usually only discuss quantities and units used in the particular report. I can see a couple of outcomes:

- Delete the terms since they do not appear in the body of the report ... although committed effective dose is part of effective dose (i.e., for intakes of radionuclides)
- •Alter the content of the body of the report such that the terms are needed and thus are included ... that would likely require saying more in the
- text about implementation of the recommendations and the role of these
- quantities in implementation.

2081

2087

2095

2096

2097

The operational quantities are based on the concept of radiation absorbed dose $D(r_T)$ at a specific point in an organ or tissue (or tissue equivalent material). The absorbed dose $D(r_T)$ to an organ or tissue in a radiation worker from external radiation sources cannot be measured directly, but can be related to the operational quantities by comparing radiation fields with dosimeters measured in tissue-equivalent phantoms.

Three operational dose-equivalent quantities have been defined: <u>ambient dose equivalent</u>, <u>directional dose equivalent</u>, and <u>personal dose equivalent</u>. Each of these quantities is derived from the product of the absorbed dose $D(r_T)$ at a specific point in an organ or tissue-equivalent phantom and a radiation quality factor Q, based on the linear energy transfer (LET) value assigned to the incident radiation, where the dose equivalent $H = D(r_T) Q$. Further, it is assumed that the operational value H (in Sv) may be compared for radiation protection purposes to the time-integrated equivalent dose $H(r_T, \tau)$.

5.5 Summary

The basic radiation dose quantities and units, and their applications in radiation protection are summarized in Table 5.1.

- Absorbed dose is the basic physical dose quantity that is applicable to all radiation
 exposures, for all types of ionizing radiation, for any absorbing medium, and for all
 biological targets and geometries. Absorbed dose is the quantity relevant to adverse tissue
 reactions and future stochastic effects.
- Equivalent dose to an organ or tissue is a radiation protection quantity derived from absorbed dose related to the probability of a future stochastic radiation effect (cancer induction and hereditary changes, if any) in that organ or tissue. Equivalent dose is not purely a physical quantity, but rather a surrogate of dose that expresses a measure of future cancer risk. Equivalent dose is used in the calculation of effective dose.
- Effective dose to the whole body is the quantity used in radiation protection for
 establishing dose criteria for workers and members of the general public exposed to
 radiation and radionuclide intakes. Effective dose represents an overall risk of detriment
 attributable to stochastic effects of radiation. Estimates of effective dose may be used to
 evaluate the relative radiological impact of exposure to a work activity but should not be
 used for predicting future cancer risk for individuals or population groups.
- Collective effective dose represents the product of the average effective dose for a population subgroup and the number of persons in the subgroup over a specified period of time. Collective effective dose applies only to effective doses that are substantially greater than background. Collective effective dose is not an appropriate quantity for epidemiologic studies or to project future cancer risk in an exposed population, particularly at low doses.

Comment [M86]: MR ... This statement (last sentence) is incorrect. For example, the personal dose equivalent $H_p(10)$] is the surrogate for effective dose when comparing recorded doses to an effective dose criteria.

Fisher ... Your comment on the operational value H (Sv) and equivalent dose is interesting.... The new text is verbatim, as recommended and written by Wes Bolch for consistency with ICRP. Remember your goal for consistency with ICRP (not the out-ofdate ICRP of years past).

MR ... This whole paragraph is confusing ... is ICRU completely revising its definitions of these three operational quantities? And has it published a new report on this yet? ICRU is the body that defines the operational quantities, and ICRP jointly with ICRU have done the Monte Carlo calculations to relate these operational quantities to quantities like air kerma, fluence and specific organ/tissue doses, and the radiation protection quantity effective dose. Equivalent dose is only relevant as an intermediate step to get to effective dose.

Dose equivalent is a separately quantity (defined at a point); the one defined as H = D Q.

Comment [M87]: Kase ... Here we are again using dose equivalent. The implication in the last sentence is that there is no difference between dose equivalent and equivalent dose. I think that this paragraph needs to be rewritten.

Comment [M88]: MR ... This quantity is not mentioned anywhere in the main text of the document.

2122

Table 5.1 --- Summary of basic radiation dose quantities and units.

Quantity	Symbol	Applicable To	Special Name	 Comment [M89]: Miller I think th 'Not Applicable to" will confuse many p
Absorbed dose	<u>D</u> (r _T)	Individual organ and tissue dosimetry, whole-body dose, and tumor dosimetry Organ or tissue sub-regions and multi-cellular dosimetry Cellular and nucleus dosimetry Derived risk coefficients for stochastic effects and adverse tissue reactions Individual patients for medically administered radionuclides	Gray (Gy)	Kase/MR agree, that column was dele Fisher I think Table 5.1 has lost some revision. MR Darrell is referring to the deletion Applicable to" column.
Equivalent dose	$\underline{\mathrm{H}}(r_{T},\tau)$	Population organ and tissue dosimetry	Sievert (Sv)	
		Stochastic effects Calculating effective dose		
Effective dose	<u>E</u>	Age and sex-averaged population groups	Sievert (Sv)	
		Stochastic effects		
		Establishing primary radiation limits		
		Establishing secondary limits for		

2125 **References** (Section 5)

2126

- ICRP (2007a). International Commission on Radiological Protection. Recommendations of the ICRP,
 ICRP Publication 103, Ann. ICRP 37(2–4) (Elsevier, New York).
- NCRP (1997). Uncertainties in fatal cancer risk estimates used in radiation protection. Bethesda, MD:
 National Council on Radiation Protection and Measurements; NCRP Report No. 126.
- 2131 NCRP (2012). Uncertainties in the estimation of radiation risks and probability of disease causation.
- Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 171.
 NCRP (2015a). National Council on Radiation Protection and Measurements. Uncertainties in the
- Measurement and Dosimetry of External Radiation, NCRP Report No. 158 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).

2136

2137 6. Adverse Health Outcomes from Radiation Exposures 2138 2139

2140

2145

6.1 Categories of Adverse Health Outcomes

For many years, it has been the common practice in the development of radiation protection 2141 standards to categorize radiation-induced adverse health effects into stochastic effects and tissue 2142 reactions. This was based on the accepted general mechanism of formation of these types of 2143 adverse outcomes. 2144

2146 Stochastic effects are cancer and heritable (genetic) effects that occur by chance, can occur at any absorbed dose and have no observable threshold. (Note that in Section 6 the term dose will 2147 2148 refer to absorbed dose unless otherwise specified.) The effects are initiated in single cells. Cancer and heritable mutation frequencies increase with dose but the severity of the effect is not dose-2149 dependent. Stochastic effects generally have a very long latency period, being observed in mice 2150 to occur in the next generation for heritable effects and, in humans, after 20+ y for solid cancers 2151

2152 following radiation exposure.

2153

2154 The other major class of adverse health outcomes is tissue reactions. The classification stems from the assumption that these were determined directly by the radiation exposure. In addition, 2155 the severity of the disease increases with increasing dose. These outcomes were renamed as 2156 tissue reactions in the ICRP 2007 Recommendations (ICRP, 2007a) because of the enhanced 2157 2158 evidence that such responses could be modified after irradiation rather than being determined at the time of radiation. Tissue reactions can occur at early or late times after irradiation. In 2159 addition, they typically exhibit a threshold response that has been the basis historically for 2160 establishing recommended dose limits. The underlying mechanism for the early effects involves 2161 cell killing whereas the later effects involve modifications of the tissue involved. Such tissue 2162 reactions include cataracts, circulatory disease, respiratory disease and neurocognitive damage. 2163 Threshold doses have been set by ICRP at a 1 % incidence of an effect (ICRP, 2007a). Recent 2164 2165 studies have indicated that for circulatory disease and lens cataracts the threshold dose is lower than previously observed and differences between acute and protracted exposures are not entirely 2166 clear. The conflicting recent human evidence of effects at low doses tempers the conclusions that 2167 can be drawn and their applicability to radiation protection guidance at this time (Little et al., 2168 2015; NCRP, 2016a). 2169

2170

Given that there is not necessarily a clear distinction between the two major classes of adverse 2171 health outcomes and that this will lead to some confusion as to what might be included in the 2172 calculation of detriment, it is appropriate at this time to consider all radiation-induced diseases 2173 under the single category of "adverse health outcomes." 2174

2175 2176 When a clear threshold is apparent for a particular outcome, this threshold dose can be used in protection practice to establish an appropriate dose criterion. This dose criterion will be 2177 significantly higher than that for any adverse health outcome that is characterized as stochastic. 2178 However, a decision might need to be made as to whether some specific tissue reactions (e.g., 2179 circulatory diseases or cataracts) should be considered for inclusion in a detriment calculation, 2180 bearing in mind what impact this can have on the overall development and use of detriment. 2181

2182	
2183	Recommendation: The term "tissue reactions" be used instead of deterministic effects.
2184	
2185	Recommendation: The review of the mechanism of formation and dose-response
2186	characteristics of the major classes of tissue reactions continue with a view to considering if
2187	they should be incorporated into the detriment calculation, and if so, how they should be
2188	incorporated.
2189	
2190	Reference (Section 6.1)
2191	
2192	ICRP (2007a). The 2007 Recommendations of the International Commission on Radiological
2193	Protection. ICRP publication 103 Annals of the ICRP, 37, 1-332
2194	Little MP, Zablotska LB, Brenner AV, Lipshultz SE (2015). Circulatory disease mortality in the
2195	Massachusetts tuberculosis fluoroscopy cohort study. Eur J Epidemiol. 2015 Aug 9. Epub
2196	ahead of print]
2197	NCRP (2016a). National Council for Radiation Protection and Measurements. Guidance on
2198	Radiation Dose Limits for the Lens of the Eye. NCRP Commentary No. 2x (National
2199	Council on Radiation Protection and Measurements, Bethesda, Maryland).
2200	
2201	
2202	6.2 Cancer Incidence and Mortality
2203	
2204	Human epidemiologic studies of radiation-induced cancers form the basis for radiation
2205	protection guidance (ICRP, 2007a; INCRP, 1993a). Nominal fisk coefficients are derived by
2206	averaging sex and age-at-exposure metime fisk estimates obtained from studies with adequate
2207	dose-response data. The Japanese Life Span Study (LSS) has been relied upon for these
2208	given radiation for medical nurnoses, workers exposed to radiation, survivors of radiation
2209	given radiation for incurcal purposes, workers exposed to radiation, survivors of radiation
2210	acclucitis, and populations exposed to elevated levels of natural background radiation. Fooled
2211	informative Incidence data tend to have less diagnostic misclassification than mortality data and
2212	provide better estimates for cancers that have relatively low lethality such as the thyroid
2213	provide better estimates for earliers that have relatively low retuancy such as the thyroid.
2215	Estimates of radiation risk can be influenced by the following
2216	• quality of the exposure data available (measured or reconstructed)
2217	 dose rate (acute or chronic) the type of exposure (external or internal)
2217	 quality of the radiation (low or high linear energy transfer)
2210	• organ or tissue exposed
2213	 nonulation characteristics (such as age-at-exposure time-since-exposure sex genetic
2220	nredisposition and period of observation)
2221	 presence of co-factors or lifestyle factors (such as tobacco use and viral infections) and
	\bullet - DECAURA VERAPIONES OF THE SEVEN TO AND STATE OF CONTRACT ON A DECEMBER OF CONTRACT OF CONTRACT.

2223 2224

A comprehensive review of radiation epidemiology is beyond the scope of this Report. The 2225 Committee considered the comprehensive reviews of radiation studies published by UNSCEAR 2226 (2008), the BEIR VII Committee (NA/NRC, 2006) and EPA (2011), recent data from the LSS 2227 2228 (Ozasa et al., 2012) and other worker, patient and environmental data (Dauer et al., 2010; Gilbert, 2009; Shore, 2014). In addition, NCRP published a recent review of epidemiologic 2229 2230 investigations and their associated uncertainties in NCRP Report No. 171 (NCRP, 2012), and the 2013 NCRP Annual Meeting reviewed exposed populations that have contributed to our 2231 understanding of radiation effects (Boice, 2014). As of 2016, Scientific Committee 1-25 is 2232 preparing a Commentary on recent epidemiologic studies conducted over the past 10 or so years 2233 2234 to provide guidance on the dose-response relationships that might be considered for radiation 2235 protection. 2236

A brief review of selected site-specific radiation effects (Section 6.2.1) is followed by a more in depth look at age-specific (Section 6.2.2) and sex-specific (Section 6.2.3) differences in cancer risks.

2241 6.2.1 Site-Specific Risk Estimates

2240

2242

2251

Cancers not convincingly linked to radiation. Not every cancer has been consistently seen to be 2243 increased following radiation exposure. For example, there is little evidence for an association 2244 with radiation for induction of chronic lymphocytic leukemia (CLL), pancreatic cancer, prostate 2245 2246 cancer, cervical cancer, testicular cancer, non-Hodgkin's lymphoma, Hodgkin's disease or multiple myeloma (UNSCEAR, 2008). For some cancers, an excess risk has only been seen 2247 following very high (radiotherapeutic) doses (e.g., cancers of the small intestine, rectum, uterus 2248 and kidney) (NCRP, 2011). Thus, for a number of cancers the risk following low doses of 2249 2250 radiation either do not exist or are highly uncertain.

Leukemia. Radiation-induced leukemia is the most prominent stochastic radiation effect. It is 2252 2253 seen most frequently in radiation-exposed populations, has one of the highest risk coefficients, has a short minimum latency of about 2 y, and shows a wave-like pattern of risk over time 2254 (peaking about 10 y after exposure and decreasing in risk thereafter). The dose-response 2255 2256 relationship is most consistent with a linear-quadratic model. Children are at highest risk; the embryo-fetus is not considered more vulnerable than young infants. Risk varies by cell type with 2257 acute myelogenous leukemia (AML) predominating in most studies. CLL is not considered a 2258 radiation effect. Myelodysplastic syndrome (MDS) has recently been reported to be increased 2259 2260 among Nagasaki survivors of the atomic bomb and an association has been reported following multiple CT exposures in childhood. However, MDS is biologically and clinically different from 2261 AML and should not be considered an early phase of AML (Albitar et al., 2002). MDS should be 2262 considered a discrete entity and not combined with leukemia for risk estimation. 2263 2264

Breast cancer. Radiation-induced breast cancer has been observed in many cohorts of exposed
 women. Excess risk is seen to decrease with increasing age at exposure and there is little
 evidence for a risk following exposures around the menopausal ages, over age 45 y. Exposures
 to young girls around the age of menarche and breast budding carry a high risk. The dose response relationship is consistent with linearity and fractionation does not diminish risk

2286

appreciably. The latency is long and inversely related to age at exposure (<u>i.e.</u>, it takes a young girl many years for a radiogenic cancer to develop and a shorter time for an older woman).
Excess absolute risks are more similar than excess relative risks across different populations.
Despite comprehensive genetic studies, there is little evidence to date that inherited genetic mutations in breast cancer genes (<u>e.g.</u>, <u>BRCA1</u> enhance the risk of radiogenic breast cancer developing.
Thyroid cancer. Radiation-induced thyroid cancer was the first solid tumor reported to be

2277 Invroid cancer, Radiation-induced thyroid cancer was the first solid tumor reported to be 2278 increased among Japanese atomic-bomb survivors. Numerous studies of children irradiated for 2279 benign and malignant conditions report very high relative risks. The age-at-exposure effect is 2280 remarkable with the highest risk among those exposed under age 5 y, including newborns, and 2281 very little risk is observed among those exposed after age 15 y. Incidence studies of adults 2282 administered diagnostic levels of radioactive ¹³¹I find no evidence of an effect. Radioactive 2283 iodine exposures following the Chernobyl accident are linked to excess thyroid cancer among 2284 children who drank contaminated milk. Several other comprehensive studies, however, find 2285 little evidence for an increase in thyroid cancer or disease following intakes of radioactive ¹³¹I.

2287 Lung cancer. Radiation-induced lung cancer is a major consequence of exposure to the atomic bombs among Japanese survivors. Excesses are clearly linked to radon progeny exposure among 2288 underground miners and following high and prolonged exposure to residential levels. Patients 2289 given radiation therapy for malignant conditions are at high risk of subsequent lung cancer and 2290 2291 smoking appears to interact in a more than additive fashion. However, there is little evidence for lung cancer risk following low dose exposures to low-LET radiations. Most notable is the 2292 absence of increased lung cancer risks among tuberculosis patients who received up to several 2293 hundred chest fluoroscopic examinations and among patients with severe scoliosis who received 2294 up to 160 spinal x-ray examinations. These patient populations are notable because significant 2295 increases in breast cancer were clearly evident. Occupational studies are difficult to interpret 2296 2297 because of the inability to adequately control for the effect of cigarette smoking on lung cancer 2298 risk. 2299

2300 Stomach cancer. Similar to lung cancer, radiation-induced stomach cancer is a major effect among Japanese atomic-bomb survivors. There is clear evidence for excess risks among patients 2301 treated with radiation for malignant and benign conditions. There is little evidence for a 2302 2303 demonstrable effect in other populations exposed to low doses of low-LET radiation. The ongoing large-scale worker studies in Europe and the United States should be able to provide 2304 2305 quantitate estimates of risk following exposures received gradually over time that cumulate to a level where excesses should be observed. Until recently, the dose ranges were too narrow and the 2306 number of excess cancers too small to be informative. 2307 2308

<u>Other cancers.</u> The other cancers that are reported to be significantly elevated among Japanese
atomic-bomb survivors include cancers of the esophagus, colon, liver, gallbladder, ovary,
bladder, non-melanoma skin cancer, renal pelvis and ureters. The most recent cancer incidence
data confirm these increases as well as the previously mentioned cancers that were not
significantly elevated: there was no indication of a statistically significant dose response for
cancers of the pancreas, prostate, kidney, cancers of the rectum, gallbladder and uterus.

Comment [KK90]: From Irwin

Irwin It would be useful to put the residential level into perspective. Could the residential level be "in excess of EPA guidelines" or "an order of magnitude greater than average outdoor air levels"?

Boice

2315

2321

2327

Mortality from radiation-induced brain cancer is not significantly elevated and the incidence data
are not clearly interpretable since benign conditions were included in the analysis: there was a
clear increase in brain and central nervous system (CNS) conditions but this appeared to be due
to an unusually high risk of schwannoma; glioma and meningioma were not significantly
increased.

<u>Combined solid cancers.</u> The brief descriptions above of site-specific cancers indicate that a
 single dose-response model does not fit all individual cancers: rates of some cancers are not
 significantly or consistently elevated (e.g., pancreas), some are elevated only after large doses
 (e.g., rectum), some depend entirely on a young age at exposure (e.g., thyroid), and some are
 sex-specific (e.g., breast).

Combining all cancers mingles heterogeneous data with different dose-response shapes, 2328 2329 latencies, and age modifications of risk. Thus, although a common practice for radiation 2330 protection purposes, combining all cancers to make inferences of risks at low doses is a somewhat tenuous approach. The results are specific to the population studied and reflect age 2331 2332 and sex characteristics as well as the exposure patterns (acute or chronic). For example, the mix of cancers that were markedly elevated in a recent U.K. male worker study (i.e., pleural cancer 2333 and cancers of the rectum, and testes) were not the types expected following low-dose radiation 2334 exposure. Combining all cancers together increases statistical precision but lacks biological 2335 2336 plausibility, so interpretation and application to radiation protection circumstances should be done cautiously. 2337

2338

Studies that have combined all cancers together with an aim to investigate the shape of the dose-2339 response relationship include the Japanese atomic-bomb survivor studies, the U.K. worker study, 2340 the 15-country study, U.S. worker studies, and the recent INWORKS study (Ozasa et al., 2012; 2341 Preston et al., 2007; Muirhead et al., 2009; Cardis et al., 2005; Schubauer-Berigan et al., 2015; 2342 2343 Richardson et al., 2015). The data are not entirely consistent. While linearity is consistent with 2344 the Japanese atomic-bomb survivor data, a linear-quadratic shape shows a statistically significant fit for the first time. The 15-country study is difficult to interpret because of acknowledged 2345 biases in the Canadian dosimetry data and the likely confounding by cigarette smoking (i.e., lung 2346 cancer was the only significantly elevated site). The U.K. and INWORKS results were 2347 influenced by likely confounding due to asbestos exposure since pleural cancer was significantly 2348 elevated. The U.S. study is not independent of the INWORKS study, but results were not 2349 significantly elevated. It is envisioned that the U.S. Million Person Study will be sufficiently 2350 advanced that preliminary results will be available for consideration (Bouville et al., 2015). 2351 2352

2353 <u>INOTE:</u> CC-1 AWAITS THE NCRP SC 1-25 COMMENTARY ON EPIDEMIOLOGIC
2354 STUDIES AND IMPLICATIONS ON THE LNT MODEL AS USED IN RADIATION
2355 PROTECTION. THUS A SECTION IS ENVISIONED ON THE LATEST ESTIMATES
2356 OF LIFETIME RISK AND DOSE-RESPONSE MODELS WILL BE FORTHCOMING.]
2357

Comment [KK91]: Kase ... Incidence rates?

Comment [KK92]: Kase ... References?

oice

Comment [DLM93]: Miller What results? The paragraph starts of talking about the shape of the dose-response curve, but by the end of the paragraph you are talking about specific organs and cancers.

Boice

Comment [DLM94]: Miller I don't understand. By when? Who will be doing the considering, and when will that happen? Perhaps it would be better to say that, when completed and published, data from the million worker study will likely provide additional valuable data.

Kase

This will be revised when the SC 1-25 Commentary is incorporated.

Comment [KK95]: Kase New text pending SC 1-25 Commentary.

Boice

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

2358 6.2.2 Effect of Age at Exposure

2359

Radiation protection of a population typically uses recommended dose criteria that are the same
for all persons. It is clear however that there are differences in the risk of radiation-induced
cancers that depend upon the sex and age of an individual.

2363

In general, persons exposed at younger ages are at increased risk. One obvious reason for this is that those exposed at young ages are likely to live longer and have more time to express risk and detriment. At the other end of the scale persons exposed at very old ages are at lower risk since they generally die from other causes before radiogenic cancer can develop. In addition, tissue sensitivity for a given absorbed dose may vary with age. An additional complication is that depending upon the model used (age-at-exposure versus attained age) differing conclusions are reached regarding the effect of age (Figure 6.1 from Ozasa et al., 2012).

2371 2372 For solid cancers there is a large body of evidence that excess relative risks (ERRs) diminish with increasing age at exposure (UNSCEAR, 2008). This pattern of risk is observed in the 2373 Japanese atomic-bomb survivor data for both solid cancer incidence and mortality, related to 2374 absorbed dose, (Figure 6.1, left-hand panel), and in several other exposed groups (e.g., radiation 2375 therapy patients). For leukemia, ERRs also generally diminish with increasing age at exposure. 2376 The pattern of variation of excess absolute risks (EARs) with age at exposure is generally the 2377 reverse. For constant attained age the EAR for solid cancers increases with increasing age at 2378 2379 exposure, as seen in the LSS (Figure 6.1, right-hand panel). While these differences in models that describe excess cancer risks over time may seem academic, they can lead to substantially 2380 different risk projections, especially if applied to populations with different baseline rates of 2381 cancer. In attempting to estimate lifetime population cancer risks, it is important to predict how 2382 risks might vary as a function of time after radiation exposure, and in particular for individuals 2383 for whom the uncertainties in projecting risk to the end of life are most uncertain, (i.e., persons 2384 2385 who were exposed in childhood). 2386

Lifetime risk projection models therefore must account for the modifying effects of sex, age-atexposure and attained age. In general, the parameters in these ERR and EAR risk models have been estimated using incidence data from the studies of the Japanese atomic-bomb survivors with follow-up from 1958 through to 1998 for solid cancers (Preston <u>et al.</u>, 2007).

2391 [Note: New incidence data is forthcoming; should be available before Report is complete.]

Another example of age-dependence comes from the U.K. Health Protection Agency Report
HPA-CRCE-028, "Radiation Risks from Medical X-ray Examinations as a Function of the Age
and Sex of the Patient" (Wall <u>et al.</u>, 2011). Table 6.1 indicates that children have a higher

absolute risk than adults, that the risk, related to effective dose, for a general population is 5.5 %

2397 per sievert, including children and that for an adult population it is 4.0 % per sievert.
NOT TO BE DISSEMINATED OR REFERENCED





FIG. 2. Modification of the excess relative risk (ERR) for all solid cancer by age at exposure and attained age.

FIG. 3. Modification of the excess absolute risk (EAR) for all solid cancer by age at exposure and attained age.

2400 2401

2402 Fig. 6.1. Modification of excess relative risk (ERR) (left-hand panel) and excess absolute risk

- 2403 (EAR) (right-hand panel) for all solid cancer by age-at-exposure and attained age.
- 2404 (Captions on the original "Figs. 2 and 3" will be removed)

NOT TO BE DISSEMINATED OR REFERENCED

2406

Table 6.1 --- Comparison between age and sex-specific risk coefficients for cancer incidence for x-ray examinations (Wall et al., 2011) and ICRP nominal risk coefficients for detriment-adjusted cancer (ICRP, 2007a). (Table 23 title on the original will be removed)

TABLE 23 Comparison between age and sex specific risk coefficients for cancer incidence for x-ray examinations (present work) and ICRP nominal risk coefficients for detriment-adjusted cancer (ICRP, 2007)

Source of dataScope of dataPopulationRisk/EPresent work (Table 22)Range in risk/E for both sexes and all examinations0 - 9 y7.8 - 20 % per Sv30 - 39 y2.8 - 9.2 % per Sv60 - 69 y0.8 - 6.8 % per SvICRP Publication 103 (ICRP, 2007)Nominal risk coefficient for detriment-adjusted cancerWhole5.5 % per SvAdult4.0 % per Sv				
Present work (Table 22) Range in risk/E for both sexes and all examinations 0 - 9 y 7.8 - 20 % per Sv 30 - 39 y 2.8 - 9.2 % per Sv 60 - 69 y 0.8 - 6.8 % per Sv ICRP Publication 103 (ICRP, 2007) Nominal risk coefficient for detriment-adjusted cancer Whole 5.5 % per Sv Adult 4.0 % per Sv	Source of data	Scope of data	Population	Risk/E
(Table 22) and all examinations 30 - 39 y 2.8 - 9.2 % per Sv 60 - 69 y 0.8 - 6.8 % per Sv 60 - 69 y 0.8 - 6.8 % per Sv ICRP Publication 103 (ICRP, 2007) Nominal risk coefficient for detriment-adjusted cancer Whole 5.5 % per Sv Adult 4.0 % per Sv 4.0 % per Sv 4.0 % per Sv	Present work (Table 22)	Range in risk/E for both sexes and all examinations	0 – 9 y	7.8 – 20 % per Sv
ICRP Publication 103 (ICRP, 2007) Nominal risk coefficient for detriment-adjusted cancer Whole 5.5 % per Sv Adult 4.0 % per Sv			30 - 39 y	2.8 – 9.2 % per Sv
ICRP Publication 103 (ICRP, 2007) Nominal risk coefficient for detriment-adjusted cancer Whole 5.5 % per Sv Adult 4.0 % per Sv			60 – 69 y	0.8 – 6.8 % per Sv
(ICRP, 2007) detriment-adjusted cancer Adult 4.0 % per Sv	ICRP Publication 103 (ICRP, 2007)	Nominal risk coefficient for detriment-adjusted cancer	Whole	5.5 % per Sv
			Adult	4.0 % per Sv

2414 **6.2.3** Effect of Sex

2415

Females are at a greater risk for radiation induced cancer than are males for a given absorbed 2416 dose (NCRP, 1989; 2000; EPA, 2011). The largest and most recent pool of data in this regard 2417 comes from the atomic-bomb survivors (Ozasa et. al., 2012). The difference in risk is primarily 2418 related to the cancer induction in organs unique to each sex (Table 6.2); also noted in NCRP 2419 Commentary No. 23 (NCRP, 2014). For example, breast and ovary are relatively high in 2420 radiation sensitivity whereas the testis and prostate are very low in terms of radiation-induced 2421 cancer. There are however additional differences in other organs with females being more 2422 2423 sensitive than males for cancer of the esophagus, stomach and lung. Using an ERR model for cancer incidence at age 70 y with exposure at age 30 y the ERR is 0.66 per gray for females and 2424 0.31 per gray for males (Ozasa et al., 2012). The female/male ratio for all solid cancers is 1.65 2425 2426 (95 % CI: 1.4, 3.1). The difference is less using an EAR model with the female/male ratio being 1.1 (95 % CI: 0.80, 1.74). The cancer incidence data are similar with the ERR per gray 2427 2428 female/male ratio for all solid cancers being 1.6 and the EAR per gray 1.4 (Preston et al., 2007). 2429 Thus females are at about 20 to 30 % higher risk than the sex-averaged risk and males are at about 20 to 30 % lower risk than the sex-averaged values. These differences are comparable with 2430 2431 the range of other uncertainties that occur in the process of risk estimation. The recommended dose criteria of ICRP (and NCRP) are based upon sex-averaged nominal risks and detriment 2432 (ICRP, 2007a). 2433 2434 Recommendation: We'll wait until the new RERF cancer incidence data is published. It 2435 2436 will include age, sex and site-specific risk estimates. It has been submitted for publication and should be forthcoming. 2437 2438 [Specifically and FYI: The Life Span Study (LSS) of 120,321 atomic-bomb survivors is a 2439

2440 prospective cohort study with continuous cancer incidence surveillance since 1958. There have been two comprehensive reports (1994 and 2007) on the risks of solid cancer incidence following 2441 2442 radiation exposure. A new report is now ready for publication. The current data have been updated 2443 through 2009 representing 11 additional years of follow-up since the 2007 report. In addition to the 2444 longer follow-up period, a number of comprehensive changes have been incorporated. They are, the 2445 inclusion of lifestyle data (smoking, drinking, and reproductive factors) collected from mail surveys and clinical interviews, updated doses, and updated migration coefficients to account for migration 2446 2447 of cohort members into and out of the cancer registries' catchment areas. The 2009 update contains 2448 a total of 3.3 million person-years of follow-up and 24,096 incident cases, which represent roughly an additional 0.5 million person-years and 7,000 additional cancers since the 2007 report. Nearly 2449 2450 38 % of the LSS cohort was alive at the end of 2009. The Dosimetry System 2002 has not been 2451 altered, however, survivor input data used to calculate doses have been reviewed and updated. 2452 Changes include restoration of map coordinate precision that was lost due to memory constraints in 2453 early computer systems; corrections for distortion in WWII-era maps, use of geographical 2454 information systems to accurately determine ground distance for those with detailed shielding 2455 drawings; accounting for terrain shielding using digital terrain elevation data now available for all survivors, at their re-estimated locations. Results include the shape of the dose response, risks at 2456 2457 low doses, and the effect of adjusting for smoking, and modification of the dose response by sex, 2458 attained age and age at exposure. (Grant et al., RRS, 2012 abstract)]

Comment [KK96]: Kase ... Assuming that the first ratio given, 1.65, is for ERR, what is the difference between the first of these statements and the second? Both seem to be referring to cancer incidence.

Boice

2459Table 6.2 --- Sex-specific differences in the excess relative risk (ERR) per gray for major cancers2460(adapted from Ozasa et al., 2012).

2461

2462 [Note: The table might be improved by including the individual sex-specific ERRs in2463 addition to the sex-averaged ERRs.]

2464

_

Cancer Type	${\rm ERR}~{\rm Gy}^{-1} \\ ({\rm averaged~over~both~sexes})^a$	Female to Male Ratio (sex-specific ERR Gy ⁻¹ estimates)
All solid cancers	0.42	2.1^{b}
Esophagus	0.60	4.3
Stomach	0.33	3.7
Colon	0.34	1.4
Liver	0.38	1.6
Gallbladder	0.48	0.43
Lung	0.75	2.7
Bladder	1.19	1.7
Cancer Type (sex-specific organs)	ERR Gy ⁻¹ (age averaged)	Not Applicable
Female breast	1.5	
Ovary	0.79	
Prostate	Little evidence for an association with radiation (UNSCEAR, 2008)	
Testicular	Little evidence for an association with radiation (UNSCEAR, 2008)	

^aThe sex-averaged ERR Gy⁻¹ is shown for subjects at the attained age of 70 y after exposure at age 30 y. ^bA ratio of 2.1 can be interpreted as females having a risk of radiation-induced cancer death that is 2.1 times that of males. These patterns generally hold when estimates are based on excess absolute risk per gray and for cancer incidence data as well (Preston *et al.*, 2007).

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

2468

2467 **References** (Section 6.2, 6.2.1, 6.2.2, and 6.2.3)

- DAUER, L.T., BROOKS, A.L., HOEL, D.G., MORGAN, W.F., STRAM, D. and TRAN, P.
 (2010). "Review and evaluation of updated research on the health effects associated with
 low-dose ionising radiation," Radiat. Prot. Dosim. 140(2), 103–136.
- GILBERT, E. (2009a). "Ionising radiation and cancer risks: What have we learned from
 epidemiology?" Int. J. Radiat. Biol. 85(6), 467–482.
- SHORE, R.E. (2014). "Radiation impacts on human health: certain, fuzzy, and unknown,"
 Health Phys. 106(2), 196-205.
- Boice JD Jr (2014). Implications of radiation dose and exposed populations on radiation
 protection in the 21st century. Health Phys. 106(2):313-328; 2014
- NCRP (2011). Second primary cancers and cardiovascular disease after radiation therapy.
 Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report
 No. 170; 2011.
- NCRP (2012). Uncertainties in the estimation of radiation risks and probability of disease
 causation. Bethesda, MD: National Council on Radiation Protection and Measurements;
 NCRP Report No. 171; 2012.
- Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW,
 Pierce S, Freireich EJ, Estey EH. Myelodysplastic syndrome is not merely "preleukemia".
 Blood. 2002 Aug 1;100(3):791-8.
- PRESTON, D.L., RON, E., TOKUOKA, S., FUNAMOTO, S., NISHI, N., SODA, M.,
 MABUCHI, K. and KODAMA, K. (2007). "Solid cancer incidence in atomic bomb survivors: 1958–1998," Radiat. Res. 168(1), 1–64.
- BOICE, J.D., JR. (2006). "Ionizing radiation," pages 269 to 293 in Cancer Epidemiology and
 Prevention, 3rd ed., Schottenfeld, D. and Fraumeni, J.F., Jr., Eds. (Oxford University Press,
 New York).
- BOICE, J.D., JR. (2010a). "Uncertainties in studies of low statistical power," J. Radiol. Prot. 30(2), 115–120.
- BOICE, J.D., JR. (2010b). "Editorial: Models, models everywhere—is there a fit for lifetime risks?" J. Natl. Cancer Inst. 102(21), 1606–1609.
- BOICE, J.D., JR. (2011). "Lauriston S. Taylor Lecture: Radiation epidemiology— the golden age and future challenges," Health Phys. 100(1), 59–76.
- Boice JD Jr (2014).. The importance of radiation worker studies. J Radiol Prot. 2014
 Sep;34(3):E7-12.
- Muirhead CR, O'Hagan JA, Haylock RG, Phillipson MA, Willcock T, Berridge GL, Zhang W. (2009) Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers. Br J Cancer. 2009 Jan 13;100(1):206-12.
- NCRP (2015). National Council for Radiation Protection and Measurements. *Health Effects of Low Doses of Radiation: Perspectives on Integrating Radiation Biology and Epidemiology*.
 NCRP Commentary No. 24 (National Council on Radiation Protection and Measurements,
 Bethesda, Maryland).
- Richardson DB, Cardis E, Daniels RD, Gillies M, O'Hagan JA, Hamra GB, Haylock R, Laurier
 D, Leuraud K, Moissonnier M, Schubauer-Berigan MK, Thierry-Chef I, Kesminiene
- 2511 A.(2015). Risk of cancer from occupational exposure to ionising radiation: retrospective

- cohort study of workers in France, the United Kingdom, and the United States (INWORKS).
 BMJ. 2015 Oct 20;351:h5359
- 2514 CARDIS, E., VRIJHEID, M., BLETTNER, M., GILBERT, E., HAKAMA, M., HILL, C.,
- 2515 HOWE, G., KALDOR, J., MUIRHEAD, C.R., SCHUBAUER-BERIGAN, M.,
- 2516 YOSHIMURA, T., BERMANN, F., COWPER, G., FIX, J., HACKER, C., HEINMILLER,
- 2517 B., MARSHALL, M., THIERRY-CHEF, I., UTTERBACK, D., AHN, Y.O., AMOROS, E.,
- 2518 ASHMORE, P., AUVINEN, A., BAE, J.M., SOLANO, J.B., BIAU, A., COMBALOT, E.,
- 2519 DEBOODT, P., DIEZ SACRISTAN, A., EKLOF, M., ENGELS, H., ENGHOLM, G.,
- 2520 GULIS, G., HABIB, R., HOLAN, K., HYVONEN, H., KEREKES, A., KURTINAITIS, J.,
- 2521 MALKER, H., MARTUZZI, M., MASTAUSKAS, A., MONNET, A., MOSER, M.,
- PEARCE, M.S., RICHARDSON, D.B., RODRIGUEZ-ARTALEJO, F., ROGEL, A.,
 TARDY, H., TELLE-LAMBERTON, M., TURAI, I., USEL, M. and VERESS, K. (2005).
- 2524 "Risk of cancer after low doses of ionising radiation: Retrospective cohort study in 15
 2525 countries," Br. Med. J. 331(7508), 77.
- Schubauer-Berigan MK, Daniels RD, Bertke SJ, Tseng CY, Richardson DB. (2015). Cancer
 Mortality through 2005 among a Pooled Cohort of U.S. Nuclear Workers Exposed to
 External Ionizing Radiation. Radiat Res. 2015 Jun;183(6):620-31. Epub 2015 May 26.
- NCRP (1989). National Council on Radiation Protection and Measurements. *Guidance on*
- *Radiation Received in Space Activities*, NCRP Report No. 98 (National Council on Radiation
 Protection and Measurements, Bethesda, Maryland).
- NCRP (2000). National Council for Radiation Protection and Measurements. *Radiation Protection Guidance for Activities in Low-Earth Orbit*, NCRP Report No. 132 (National
 Council on Radiation Protection and Measurements, Bethesda, Maryland).
- NCRP (2014d). National Council for Radiation Protection and Measurements. *RADIATION PROTECTION FOR SPACE ACTIVITIES: SUPPLEMENT TO PREVIOUS*. NCRP
 Commentary No. 23 (National Council on Radiation Protection and Measurements,
 Bethesda, Maryland).
- OZASA, K., SHIMIZU, Y., SUYAMA, A., KASAGI, F., SODA, M., GRANT, E.J., SAKATA,
 R., SUGIYAMA, H. and KODAMA, K. (2012). "Studies of the mortality of atomic bomb
 survivors, Report 14, 1950–2003: An overview of cancer and noncancer diseases," Radiat.
 Res. 177(3), 229–243.
- PRESTON, D.L., RON, E., TOKUOKA, S., FUNAMOTO, S., NISHI, N., SODA, M.,
 MABUCHI, K., and KODAMA, K. (2007). "Solid cancer incidence in atomic bomb survivors: 1958–1998," Radiat. Res. 168(1), 1–64. (in footnote b of Table 6.2)
- Howe GR. Lung cancer mortality between 1950 and 1987 after exposure to fractionated
 moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a
 comparison with lung cancer mortality in the Atomic Bomb survivors study. Radiat Res.
 1995 Jun;142(3):295-304.
- Ronckers CM, Land CE, Miller JS, Stovall M, Lonstein JE, Doody MM. Cancer mortality
 among women frequently exposed to radiographic examinations for spinal disorders. Radiat
 Res. 2010 Jul;174(1):83-90.
- 2553 Grant <u>et al.</u> (2012). RRS, 2012 abstract

2554 6.2.4 Special Exposure Groups

2555

2560

2567

There are several exposure groups that require special attention: infants, children, the embryo and fetus, and the pregnant woman. This is because of radiation sensitivity, vulnerability and ethical considerations. Justice, and equity particular, would have us treat these populations in such a way that they are protected because of their differences with adults.

6.2.4.1 Infants and Children. Radiation exposure of infants and children is of fundamental
concern. This is true whether the exposure is accidental, natural background, or due to medical or
industrial sources. Children represent the largest group of what are often considered to be
populations most at risk for radiation induced adverse health effects. They represent a substantial
percentage of persons exposed as members of the public. In 2014, 23 % of the U.S. population
was age 0 to 17 y.

There are significant anatomical and physiological differences between infants, children and 2568 adults that result in differing absorbed doses and potential effects based upon age at exposure. 2569 Specific differences in age at exposure risk estimates are discussed elsewhere in this Report. It is 2570 commonly assumed that children might be 2 to 3 fold more sensitive to cancer than are adults. 2571 This generality is not strictly applicable for all tumor types. UNSCEAR (2013) has conducted a 2572 rigorous scientific review of the literature regarding 23 specific tumor types and concluded that 2573 for about 25 % of these cancer types (including leukemia, thyroid, breast, skin and brain cancer), 2574 children were clearly more radiosensitive. For about 15 % of the cancer types (e.g., colon cancer) 2575 children appear to have the same radiosensitivity as adults. For about 10 % of the cancer types 2576 2577 (e.g., lung cancer) children appear to be less sensitive to external radiation cancer induction than 2578 are adults. For about 20 % of cancer types (e.g., cancer of the esophagus) the data are too weak to draw a conclusion. Finally, for about 30 % of cancer types (e.g., Hodgkin's disease, prostate, 2579 rectum and uterine cancer) there is only very weak or no relationship between radiation exposure 2580 and risk of cancer. 2581

It should be noted that effective dose and associated risk estimates are based upon an ageaveraged population and do not take into account the issues discussed above. Currently the
public exposure dose criteria for infants and children are the same as for the general public. At
present, projections of lifetime risk for specific cancer types following exposure at young ages
are statistically insufficient.

2588

2582

The annual dose limit for the public recommended in ICRP (1977) was 5 mSv. This was reduced 2589 five-fold to 1 mSv in the 1990 recommendations of the ICRP (ICRP, 1991b), essentially driven 2590 by the new Japanese data on exposure at young age and the realization that young age at 2591 2592 exposure was associated with approximately a 2 to 3 fold higher risk of radiation-induced cancer. 2593 (See paras 64, 191 and B84 of ICRP, 1991b). In addition, the detriment model used was based 2594 upon annual conditional death probability of fatal radiation-induced cancer, and the observation 2595 that exposure at young ages confers a risk over a much longer time than exposure at older ages. A very complex and detailed analysis is contained in Annex C and table C5 of ICRP (1991b). 2596 The ICRP (1991b) reduction in public dose limits from 5 to 1 mSv was proportionally greater 2597

Comment [M97]: Fleming addition

than that recommended for occupational exposure (from 50 to 20 mSv) because the risk to children was the driving factor in risk when public exposure was considered.

2600

2611

2614

2620

2622

2625

2631

The data regarding potential radiation effects on children has become clearer over the last 2601 decade, especially with regard to specific tumor types and the temporal pattern of risk expression 2602 for different tumors. However, the overall risk coefficient has not changed significantly since the 2603 Council's prior recommendation (NCRP, 1993a). The greater sensitivity of children was already 2604 factored into that recommendation which followed the ICRP (1991b) 1 mSv public dose limit. 2605 While cancer risk estimates for an age-averaged population are used for broad radiation 2606 2607 protection purposes, when infants and children are involved, attention should be directed, if possible, to the specifics of exposure, age-at-exposure, absorbed doses to certain tissues and the 2608 2609 particular effects of interest. This is supported by both the principle of non-malificience as well as the principle of justice which requires unequal treatment to achieve an equitable situation. 2610

Recommendation: The public dose criteria should continue to incorporate the sensitivity of
 infants and children.

6.2.4.2 Embryo and Fetus. Insofar as the the embryo and fetus are considered morally significant
(Section 3.2), NCRP extends radiation protection to them. The embryo and fetus They are highly
sensitive to radiation. The nature and severity of effects depend upon absorbed dose and the
stage of development. Recent extensive reviews of the effects of in utero exposure have been
published by both NCRP (2013) and ICRP (2003).

2621 There are a number of potential radiation induced-effects on the embryo/fetus.

Embryonic loss. Doses above about 0.15 to 0.2 Gy may cause pre-implantation and pre-somite embryonic loss but there does not appear to be a significant risk to health expressed after birth.

Malformations. The background rate for major congenital malformations in the absence of
ionizing radiation exposure is about 3 %. Minor malformations occur in an additional 4 % of
births (NCRP, 2013). There appears to be greater sensitivity to radiation-induced malformations
during major organogenesis (3 to 7 weeks post conception). There appears to be a true dose
threshold at about 0.2 Gy absorbed dose to the fetus.

CNS effects include potential severe mental retardation and/or reduction in intelligence quotient 2632 (IQ). CNS effects are greatest at 8 to 16 weeks post-conception and to a lesser extent at 16 to 25 2633 weeks post conception. Atomic-bomb survivor data for severe mental retardation indicate a 2634 lower confidence bound on the threshold of about 0.3 Gy. A radiation dose of 1 Gy would 2635 increase the risk of severe mental retardation by about 40 %. There does not appear to be a risk 2636 2637 of radiation-induced severe mental retardation at low doses such as those typically associated 2638 with radiation protection. A linear dose-response model fit the Japanese data for IO loss during the sensitive period (8 to 15 weeks post conception and with an IO loss of around 25 points per 2639 gray. A threshold dose was not apparent, however at doses of <0.10 Gy effects were essentially 2640 undetectable and considered negligible. 2641

2642

Comment [PF98]: Fleming ... This can probably said more elegantly and perhaps early on when looking at special populations.

NOT TO BE DISSEMINATED OR REFERENCED

Data on induction of neoplasms following in utero exposure is somewhat contradictory and has 2643 been debated for years. The case-control Oxford study following diagnostic radiology pelvimetry 2644 examination indicated an increased risk of childhood neoplasms but with the same risk for all 2645 2646 types of neoplasms. On the other hand, data from all cohort studies following in utero medical or occupational exposures have failed to observe statistically significant increases in childhood 2647 leukemia or cancer (e.g., Court Brown and Doll, 1960; Schonfeld et al., 2012). The range of 2648 composite increase ranged from 0 to 30 %. The children of Japanese women who were pregnant 2649 at the time of the atomic bombings also did not show a significantly increased risk of childhood 2650 cancer. Overall, doses to the embryo/fetus above 0.5 Gy will increase the risk of cancer but the 2651 risk of cancer at doses <0.1 Gy has not been fully resolved. A detailed discussion and analysis of 2652 the epidemiologic studies is contained in NCRP (2013). 2653 2654

Recent publications and analyses of the Japanese atomic-bomb survivor data indicate that the
lifetime risk may be lower for the irradiated embryo/fetus than for the irradiated child (Preston <u>et</u>
al., 2008). Overall, it is prudent to assume there is a risk of cancer following prenatal exposure
and that the risk of developing cancer later in life is similar to the risk following childhood
irradiation which is, at most, about 3 times that of a general population of all ages (Section
6.2.4.1).

In summary, the sensitivity of the embryo/fetus for both mental retardation and cancer should be considered when making protective guidance.

2665 References (Section 6.2.4)

- 2667 COURT BROWN WM, DOLL R, HILL RB. Incidence of leukaemia after exposure to diagnostic
 2668 radiation in utero. Br Med J. 1960 Nov 26;2(5212):1539-45.
- NCRP (2013). Report No. 174 Preconception and prenatal radiation exposure health effects and
 protective guidance.
- ICRP (1977). Recommendations of the International Commission on Radiological Protection, ICRP
 Publication 26. Annals of the ICRP, 1.
- ICRP (1991b). ICRP Publication 60: 1990 Recommendations of the International Commission on Radiological Protection, Elsevier Health Sciences.
- ICRP (2003). Biological effects after prenatal irradiation (Embryo and fetus), Publication 90 Annals ofthe ICRP.
- 2677 NCRP (1993a). NCRP Report No. 116, Limitation of exposure to ionizing radiation.
- 2678 NCRP (2013). Report No. 174 Preconception and prenatal radiation exposure health effects and
 2679 protective guidance.
- PRESTON, D.L., CULLINGS, H., SUYAMA, A., FUNAMOTO, S., NISHI, N., SODA, M., MABUCHI,
 K., KODAMA, K., KASAGI, F. and SHORE, R.E. (2008). "Solid cancer incidence in atomic bomb
 survivors exposed in utero or as young children," J. Natl. Cancer Inst. 100(6), 428–436.
- Schonfeld SJ, Tsareva YV, Preston DL, Okatenko PV, Gilbert ES, Ron E, Sokolnikov ME, Koshurnikova
 NA. Cancer mortality following in utero exposure among offspring of female Mayak Worker Cohort
 members. Radiat Res 178: 160-165; 2012.
- UNSCEAR (2013). Sources Effects and Risks of Ionizing Radiation, UNSCEAR 2013 Report, Annex B:
 Effects of Radiation Exposure of Children, United Nations New York, 2013

2688

2664

2666

Comment [M99]: Miller ... Is all this material necessary? The reader could just be referred to NCRP Report No. 174, which treats it exhaustively.

2689

6.3 Heritable (Genetic) Effects 2690 Over the past 60 or so years, there have been a range of studies conducted to establish whether or 2691 2692 not there are risks of heritable disease to offspring of parents exposed to ionizing radiation as a result of accidents or medical exposures. Studies of atomic-bomb survivors and to a lesser extent 2693 of those exposed as a result of the Chernobyl accident are quite comprehensive. The overall 2694 conclusion is that there is no direct evidence that parental exposure results in excess heritable 2695 disease in offspring. In addition, there have been a number of studies on genetic disease in the 2696 offspring of long-term survivors of childhood cancer. Two such studies were reviewed by 2697 UNSCEAR (UNSCEAR, 2001) and as with adults, there is no evidence that radiation exposure 2698 in childhood confers any measurable risk of heritable effects in offspring. Over the past decade, 2699 2700 there have been additional studies that have focused on survivors of childhood and adolescent 2701 cancer (UNSCEAR, 2013). Gonadal doses from radiation therapy often range from tenths of a gray up to 20 Gy. There has been no consistent evidence of chromosomal instability, 2702 2703 minisatellite mutations, transgenerational genomic instability, change in sex ratio of offspring or 2704 congenital anomalies after these childhood exposures, This conclusion is supported by a number of national and international organizations (e.g., ICRP, 2007a; NAS/NRC, 2006; NCRP; 2005; 2705 2706 UNSCEAR, 2001). 2707 However, because there are clearly heritable effects observable in the offspring of mice and other 2708 mammalian and non-mammalian species (UNSCEAR, 2001), it has long been deemed necessary 2709 to develop a risk estimate for human exposures based on mouse data. The most recent approach 2710 has taken advantage of recent data on the genetics of human genetic diseases by basing the 2711 heritable risk on human background mutation data and mouse radiation-induced mutation data 2712 (ICRP 2007a; UNSCEAR 2001). For the purposes of incorporating heritable risk into the overall 2713 risk from ionizing radiation, heritable risk is calculated for continuous low dose-rate exposures 2714 over two generations. In this way, the present heritable risk estimates developed by UNSCEAR 2715 (2001) and ICRP (2007a) essentially using the same methods, is about 0.2 % per gray. This value 2716 2717 is more than 20-fold less than the nominal risk estimate for cancer (5 % per sievert), and for radiation protection purposes this value for heritable risk is included with cancer in the overall 2718 risk for gonads (ICRP, 2007a). 2719 2720 2721 Recommendation: The heritable risk estimate of 0.2 % per gray developed for UNSCEAR and ICRP be accepted in health detriment evaluations. 2722

2724 **References** (Section 6.3)

2725

2723

ICRP (2007a). International Commission on Radiological Protection. Recommendations of the 2726 ICRP, ICRP Publication 103, Ann. ICRP 37(2-4) (Elsevier, New York). 2727

2728 NAS/NRC (2006). BEIR VII

2729 NCRP (2005). NCRP Report No. 150

UNSCEAR (2001). United Nations Scientific Committee on the Effects of Atomic Radiation. 2730

Hereditary Effects of radiation. UNSCEAR 2001 Report to the general Assembly, with 2731

Scientific Annex, No. E.01.IX.2 (United Nations Publications, New York). 2732

2733

Effects of radiation exposure of children, 2013 Report, Volume 2, United Nations, Vienna. 2734 2735 6.4 Effect of Genetic Susceptibility 2736 2737 Over the past decade or so, there has been an extensive increase in knowledge of the genetic 2738 basis of diseases, especially cancers of many different types (Weinberg, 2013). For example, for 2739 so-called high penetrance genes, excess spontaneous cancers are expressed in a large proportion 2740 of carriers. In addition, there are gene-gene and gene-environment interactions that can lead to 2741 variations in the likelihood of cancer across the population. How such information might convert 2742 into inter-individual differences in susceptibility to radiation-induced cancer has been quite 2743 extensively discussed by ICRP (1998), NAS/NRC (2006), and UNSCEAR (2001; 2006). 2744 However, it remains unclear as to the magnitude of the effect of any such sensitivities even at the 2745 2746 individual level, let alone a population level. 2747 Sankaranarayanan and Chakraborty (2001) conducted an extensive analysis of potential impacts 2748 at the individual and population levels. They used a Mendelian one-locus, two allele autosomal 2749 dominant model for predicting the impact of cancer predisposition and increased radiosensitivity 2750 on the risk of radiation-induced cancers in the population and in relatives of affected individuals 2751 using breast cancer due to <u>BRCA1³</u> mutations. The general conclusions from their study were 2752 that, when the proportion of cancers due to the susceptible genotype is small (<10 %), the 2753 attributable risks are small. On the other hand, when the proportion of cancers resulting from the 2754 susceptible genotypes is large (10 %), there can be significant increases in attributable risk for 2755 relatively small increases in cancer susceptibility (>10-fold) and radiosensitivity (>100-fold) in 2756 the susceptible populations. This means that the increase in cancer risk to a heterogeneous 2757 population of susceptible and nonsusceptible genotypes will generally be quite small if the 2758 proportion of susceptible individuals is small and the radiation sensitivity relatively small. On the 2759 2760 other hand cancer risks assessed on the basis of an individual (in radiation therapy situations, for 2761 example) might be greatly influenced by genotype. For the purposes of radiation protection, dose criteria for the public will not be significantly influenced by genetic radiosensitivity whereas 2762 they certainly could be influenced in some occupational settings and for individual assessments 2763 for defined medical exposures. 2764 2765 2766 In this context, progress is being made in demonstrating experimentally that there are complex interactions that underlie the expression of cancer-predisposing genes of lower penetrance 2767 (NAS/NRC, 2006). This knowledge highlights the difficulty that will be encountered in trying to 2768 incorporate facets of genetic radiosensitivity into the radiation risk assessment process, 2769 especially at low doses and doses rates. 2770 2771

UNSCEAR (2013). United Nations Scientific Committee on the Effects of Atomic Radiation

2772 Recommendation: That specific genetic sensitivities not be incorporated into radiation risk 2773 estimates for populations.

³ A gene on chromosome 17 that normally helps to suppress cell growth. A person who inherits certain mutations (changes) in a <u>BRCA1</u> gene has a higher risk of getting breast, ovarian, prostate, and other types of cancer.

NOT TO BE DISSEMINATED OR REFERENCED

2774	
2775	Recommendation: Where specific genetic sensitivities can be identified at the individual
2776	level, consideration be given to appropriate dose levels for treatment or imaging regimes
2777	for that individual.
2778	
2779	References (Section 6.4)
2780	
2781	ICRP (1998). Genetic Susceptibility to Cancer, ICRP Publication 79 Ann. ICRP 28 (1-2).
2782	NAS/NRC (2006). BEIR VII
2783	Sankaranarayanan K, Chakraborty R (2001). Impact of cancer predisposition and radiosensitivity
2784	on the population risk of radiation-induced cancers. Rad Res 156: 648-656.
2785	UNSCEAR (2001). United Nations Scientific Committee on the Effects of Atomic Radiation.
2786	Hereditary Effects of radiation. UNSCEAR 2001 Report to the general Assembly, with
2787	Scientific Annex, No. E.01.IX.2 (United Nations Publications, New York).
2788	UNSCEAR (2006). Effects of ionizing radiation, Volume I, UNSCEAR 2006 report to the
2789	General Assembly, Annex A: Epidemiological studies of radiation and cancer.
2790	Weinberg RA (2013). The Biology of Cancer. Garland Science: New York.
2791	
2792	6.5 Cardiovascular Effects
2793	The literature regarding cardiovascular disease (CVD) after radiation exposure is complicated by
2795	a number of important factors
2796	
2797	First, CVD is not a single entity and is a term used to describe a myriad of very disparate
2798	conditions with different causes. Even the division of CVD into heart disease or stroke is
2799	inadequate. As an example, heart disease includes disorders such as valvular abnormalities,
2800	capillary and blood vessel lesions, aneurysms, effusions, muscle abnormalities, arrhythmia,
2801	endocarditis, and malformations. Stroke can either be hemorrhagic or ischemic and both have
2802	multiple different causes. Hypertension is often included in the category CVD but generally has
2803	no etiological relationship to the heart itself.
2804	The second issue that must be considered is the large number of confounding causes of CVD
2806	These include smoking hereditary or genetic factors and dietary factors Concurrent diseases
2807	and conditions also raise the risk of CVD (particularly diabetes and obesity)
2808	
2809	Third is the issue of disease diagnosis and classification. There are clear examples of death
2810	certificates which list the cause of death as "cardiac failure" when a person is found dead with no
2811	other apparent cause. The criteria used to diagnose hypertension also vary widely among
2812	different medical practices, in different countries and over time causing additional confusion in
2813	interpretation of results. Unless all these issues are carefully spelled out and controlled for,
2814 2815	results of published studies about low-dose radiation and CVD can be misleading.
2816	The fourth issue is that while there are a number of hypotheses, at present there is no clear
2817	understanding of the biological mechanisms for cardiovascular diseases at low doses and there is
2818	no clear understanding of the target cells or tissue. Without this, application of a linear dose-

response model at low doses or the assumption that this is a stochastic or deterministic process 2819 remains debatable. 2820 2821

Increased risk of CVD (including myocardial infarction, coronary artery disease and stroke) are 2822 well documented effects after high radiation doses (>30 Gy) to the heart or neck that may occur 2823 with radiation therapy. 2824 2825

There are several reports of increased risk of CVD in atomic-bomb survivors. In the Life Span 2826 2827 Study (LSS) cohort (Shimizu et al., 2010) researchers found an approximately linear dose 2828 response over the dose range 0 to \sim 3 Gy. The dose response over the dose range 0 to 1 Gy was statistically significant but over the range 0 to 0.5 Gy it was not. Excess relative risk was only 2829 2830 clear above ~ 5 Gy. The nature and magnitude of the risk at acute doses < 0.5 Gy is unresolved (Takahashi et al., 2013).

2831 2832

Interestingly, it is only the mortality data that shows a possible linear association with heart 2833 2834 disease, whereas the incidence data as reflected in the adult health study is more consistent with

2835 a quadratic dose-response model for myocardial infarction and hypertension (Yamada, 2004).

The high proportion of ill-defined heart conditions is problematic. A change in coding practices 2836

for causes of death in 1995 may have resulted in misclassifications of heart disease as "heart 2837 failure" being avoided as an underlying cause of death; cerebral infarction and acute myocardial 2838 infarction causes of death jumped dramatically. 2839

(Note: A new follow-up of the atomic-bomb survivor population from 1950 to 2008 has 2840 been completed and should be available shortly. These new data will be considered in the 2841 2842 next Report revision.) 2843

The vast majority of occupational studies are either nonsignificant or marginally significant with 2844 regard to CVD (Little, 2013). For U.K. radiologists who worked from 1987-1997 the mortality 2845 from circulatory disease was lower compared with other medical practitioners (Berrington et al., 2846 2001). 2847 2848

There are many studies of nuclear workers that have examined the issues of mortality from heart 2849 2850 disease and stroke. The vast majority of these have standardized mortality ratios (SMRs) below 2851 that of the general population (perhaps due to the healthy worker effect) as well as a number that have SMRs below 100 when comparing radiation workers to nonradiation workers or when 2852 2853 comparing high-dose to low-dose groups (Boice et al., 2016; Howe, et al., 2004). Studies of nuclear workers showing a statistically significant increase in CVD are very rare. 2854

2856 There are a number of studies of CVD in populations around nuclear facilities. These do not show a relationship to radiation exposure and typically have SMRs that reflect those in the 2857 regional or national population (Boice et al., 2007; 2010). Positive results would not be expected 2858 on the basis of the very low doses and the nuclear worker literature. 2859 2860

There are very few studies concerning natural background radiation and correlation with CVD. 2861

2862 Those studies that do exist do not show a relationship and some even show a negative trend, 2863 likely due to population age differences and lifestyles. Similar results are found for studies of

2864 airline crews exposed to higher than normal levels of cosmic radiation (Blettner et al., 2003).

2865

A recent study of tuberculosis patients in Massachusetts who received up to several hundred 2866 chest fluoroscopic examinations over a period of several years failed to reveal an overall increase 2867 in radiation-related circulatory disease (Little et al. 2015). These findings were consistent with 2868 2869 an earlier report for the same population (Davis et al. 1989). A similar but larger study of Canadian tuberculosis patients also did not find a significant association between estimated 2870 radiation doses to lung and all cardiovascular disease although subgroup analyses indicated 2871 significant associations with ischemic heart disease, a condition not increased in studies of 2872 Japanese atomic-bomb survivors (Zablotska et al 2014). 2873 2874 Recommendation: The literature is insufficient to derive an estimate of any potential 2875 cardiovascular detriment at the low doses typically associated with occupational and public 2876 2877 exposure. 2878 2879 Recommendation: Close attention to the results of research related to CVD at low and 2880 moderate doses is warranted. 2881 2882 **References** (Section 6.5) 2883 Berrington A, Darby SC, Weiss H et.al. (2001). 100 years of observation on British Radiologists: 2884 Mortality from cancer and other causes.1987-1997. Brit. J Radiol 74:507-519. 2885 Blettner M, Zeeb H. ... Tzonou A (2003). Mortality from cancer and other causes among male 2886 airline cockpit crew in Europe. Int. J Cancer 106(6):946-952. 2887 2888 Boice JD, Mumma MT, Blot WJ (2007). Cancer and noncancer mortality in populations living near uranium and vanadium mining and milling operations in Montrose County, Colorado, 2889 1950-2000. Radiat Res 2007; 167(6):711-726. 2890 Boice JD, Mumma MT, Blot WJ (2010). Cancer incidence and mortality in populations living 2891 near uranium milling and mining operations in grants, New Mexico, 1950-2004. Res 2010; 2892 174(5):624-636. 2893 Boice et al. (2016) (in press) Million person worker study early results 2894 Davis FG, Boice JD Jr, Hrubec Z, Monson RR. Cancer mortality in a radiation-exposed cohort of 2895 2896 Massachusetts tuberculosis patients. Cancer Res. 1989;49(21):6130-6. 2897 Howe GR, Zablotska LB. ... Buchanan J (2004). Analysis of the mortality experience amongst U.S. nuclear power industry workers after chronic low-dose exposure to ionizing 2898 2899 radiation. Radiat Res 162(5):517-526. 2900 Little, M.P. (2013). A review of non-cancer effects, especially circulatory and ocular diseases. Radiat. Environ. Biophys. 52(4):435-449. 2901 Little MP, Zablotska LB, Brenner AV, Lipshultz SE. Circulatory disease mortality in the 2902 Massachusetts tuberculosis fluoroscopy cohort study. Eur J Epidemiol. 2015 Aug 9. Epub 2903 ahead of print] 2904

- Shimizu, Y., K. Kodama, N. Nishi et al. (2010). Radiation exposure and circulatory disease risk:
 Hiroshima and Nagasaki atomic bomb survivor data, 1950-2003. Br Med J 340: b5349.
- Takahashi I and W, Ohishi, FA Mettler et. al. (2013). Radiation and Cardiovascular Disease:
 Meeting Report, J. Radiol Prot., 33(4): 869-880.
- 2909 Yamada Radiat Res 2004
- 2910 Zablotska LB, Little MP, Cornett RJ. Potential increased risk of ischemic heart disease mortality

77

Comment [M100]: MR and Mettler ... This is a placeholder. Boice says it is true and in the process of publication.

<mark>Boice</mark>

- with significant dose fractionation in the Canadian fluoroscopy cohort study. Am J Epidemiol. 2014;179(1):120–31. 2911
- 2912

2914 **6.6 Central Nervous System Effects** 2915 The central nervous system (CNS) is very resistant to the effects of low and medium doses of 2916 2917 radiation. Noncancer CNS damage can include necrosis, loss of myelin, white matter necrosis, cortical atrophy and significantly reduced cognitive function. All of these changes have been 2918 observed after extremely high doses of radiation (usually after aggressive radiation therapy or 2919 accidents). For reasons that are unclear (possibly due to hormonal effects or sexual dimorphism 2920 in brain development) cognitive decline after radiation therapy is greater in females. The above 2921 mentioned changes have not been observed at doses below about 12 to 20 Gy. 2922 2923 There is known to be an increase in the incidence of certain brain tumors after cranial irradiation, 2924 2925 but again this is seen only after high absorbed doses and typically when those doses are received 2926 during childhood. There are a few scattered reports of changes in mental function at lower doses from low linear energy transfer (LET) radiation, primarily in children treated for tinea capitis or 2927 hemangiomas as well as occasional reports related to multiple sclerosis and schizophrenia. 2928 These reports are often based upon vague criteria and poor dosimetry and do not meet most of 2929 the Bradford-Hill criteria for causality. The incidence of dementia was examined among atomic-2930 bomb survivors within the Adult Health Study cohort (Yamada et al., 2009), but no association 2931 with radiation exposure was found. 2932 2933 Recent experiments have shown a number of early and delayed deleterious effects in animals 2934 exposed to high atomic number, high-energy (HZE) particles and at radiation levels lower than 2935 previously suspected as being damaging. Evidence for the deleterious effects of low-dose 2936 charged-particle radiation has been reviewed in Cucinotta et al., (2014), Nelson (2009), NCRP 2937 Report No. 153 (NCRP, 2006b), and NCRP Commentary No. 23 (NCRP, 2014d). Anatomical 2938 connectivity and neurophysiological dynamics involving networks of interacting neuronal 2939 systems throughout the brain yield the properties that we associate with cognition, perception, 2940 affect, and consciousness. Ultimately, it is impairment in these higher functions of the CNS that 2941

Recommendation: Radiation effects on the CNS not be considered a major factor in evaluation of radiation protection for workers and the public with the possible exception for exposure to HZE particles.

the embryo and fetus (Section 6.2.4.2).

2952 **References** (Section 6.6)

2942

2943

2944

2945

2946 2947

2951

2953

CUCINOTTA, F.A., ALP, M., SULZMAN, F.M. and WANG, M. (2014). "Space radiation risks to the central nervous system," Life Sci. Space Res. 2, 54–69.

are of concern with respect to galactic cosmic radiation effects on human performance, health, and disease during and after extended deep space missions (NASA, 2009; NCRP (2016b). A

REF). In utero exposure and CNS effects are discussed in the Special Exposure Group section on

NASA exposure standard based on cancer and certain noncancer effects is in place (NASA

- NASA (2009). National Aeronautics and Space Administration. <u>Human Health and Performance</u>
 <u>Risks of Space Exploration Missions, Evidence Reviewed by the NASA Human Research</u>
 <u>Program</u>, NASA SP-2009-3405,
 - . 51 2007 5105,

2959	http://humanresearchroadmap.nasa.gov/Evidence/reports/EvidenceBook.pdf (accessed
2960	January 12, 2015) (National Aeronautics and Space Administration, Washington).
2961	NASA REF (exposure standard)
2962	NCRP (2006b) NCRP Report No. 153
2963	NCRP (2014d). NCRP Commentary No. 23
2964	NELSON, G.A. (2009). "Neurological effects of space radiation," Gravit. Space Biol. Bull.
2965	22(2), 33–38.
2966	NCRP (2016b) NCRP Commentary 25 (SC 1-24)
2967	YAMADA, M., KASAGI, F., MIMORI, Y., MIYACHI, T., OHSHITA, T. and SASAKI, H.
2968	(2009). "Incidence of dementia among atomic-bomb survivors-Radiation Effects Research
2969	Foundation Adult Health Study," J. Neurol. Sci. 281(1–2), 11–14.
2970	
2971	6.7 Thyroid (Noncancer Effects)
2972	
2973	This section refers to tissue reactions on thyroid function and possible thyroiditis. Thyroid cancer
2974	and nodules are discussed elsewhere (Section 6.2.1). There are many large sources of human
2975	data on thyroid function and autoimmune issues including atomic-bomb survivors, fallout,
2976	external radiation therapy, and radionuclide treatment for thyroid conditions. At high absorbed
2977	doses the main concern is reduced production of thyroid hormone (hypothyroidism) and at lower
2978	doses the issue of thyroiditis is of greater concern.
2979	
2980	Studies of atomic-bomb survivors showed a questionable increase in hypothyroidism in the 0.01
2981	to 0.49 Gy group but not in the 0.05 to 0.99 Gy group (Nagataki et al., 1994). Morimoto et al.,
2982	(1987) reported that in survivors under the age of 20 y at exposure and with doses 1 Gy or more
2983	there was no increase in either hypothyroidism or autoimmune thyroiditis.
2984	
2985	Fallout from nuclear testing resulted in significant deposition of radioiodine in the Marshall
2986	Islands and caused subclinical hypothyroidism in about 30 % of children who received thyroid
2987	doses of >2 Gy.(Lessard et al., 1985). Long-term follow-up of those with thyroid doses up to 4
2988	Gy did not show an increase in autoimmune thyroiditis. Conflicting results have been reported in
2989	the United States for fallout from atomic tests in Nevada. Rallison et al. (1991) reported an
2990	increase in thyroiditis but a later study by Kerber et al. (1993) did not find any thyroid effects.
2991	
2992	There are quite a number of studies related to Chernobyl with various methodologies, different
2993	dose sources and often with conflicting results. The studies of thyroiditis are also complicated by
2994	the availability of nonradioactive iodine. A study by Ostroumova et al. (2013) reported an
2995	increase in hypothyroidism (based on thyroid-stimulating hormone not thyroxine levels) but no
2996	evidence of autoimmune thyroiditis, based on a linear model even though the best fit to the data
2997	was not linear and there was no statistical significance at doses <4 Gy. The largest study of the
2998	Chernobyl population was performed by the Sasakawa Foundation and reported by Ito et al.
2999	(1995) and Yamashita and Shabita (1996). The study included 160,000 children and did not find
3000	any increase in thyroid antibodies, hypothyroidism or hyperthyroidism that could be related to
3001	ionizing radiation. In an analysis of fallout from Hanford, Davis et.al. (2002) found a negative
3002	dose-response curve for both hypothyroidism and autoimmune thyroiditis.
3003	
	80

NOT TO BE DISSEMINATED OR REFERENCED

Clinical and subclinical hypothyroidism are well-documented complications after external beam 3004 radiation therapy to the head, neck and upper chest for malignancies. Reports of the doses 3005 needed to cause hypothyroidism from fractionated exposures range from 20 to 50 Gy. The risk of 3006 subclinical (or biochemical hypothyroidism is about 40 % 20 y after receiving 10 to 30 Gy. 3007 3008 Iodine-131 has been used for over half a century to treat hyperthyroidism. With high 3009 administered activities (typically 100 to 600 MBq), hypothyroidism can be evident within 3010 months. Considering the high uptake of ¹³¹I in a hyperfunctioning gland the absorbed dose is 3011 usually in excess of 100 Gy. 3012 3013 In summary, fractionated thyroid doses above a few gray can induce subclinical hypothyroidism 3014 3015 and at doses >20 Gy clinical hypothyroidism may occur. The incidence increases with time and 3016 is quite variable among individuals. Autoimmune thyroiditis and hypothyroidism are not likely 3017 to increase to any significant extent at dose criteria recommended for occupational or public 3018 exposure. 3019 3020 **References** (Section 6.7) 3021 3022 Davis, S., K.J. Kopecky and T.E. Hamilton. (2002). Hanford thyroid disease study final report. 3023 CDC Contract Number 200-89-0716. Fred Hutchinson Cancer Center. 3024 Morimoto, I., Y. Yoshimoto, K. Sato et al. (1987). Serum TSH, thyroglobulin, and thyroidal 3025 3026 disorders in atomic bomb survivors exposed in youth: 30-year follow-up study. J Nucl Med 3027 28(7): 1115-1122. Ito, M., et al. (1995). Childhood thyroid diseases around Chernobyl evaluated by ultrasound 3028 examination and fine needle aspiration cytology. Thyroid 5(5): p. 365-368. 3029 Kerber, R.A., J.E. Till, S.L. Simon et al. (1993). A cohort study of thyroid disease in relation to 3030 3031 fallout from nuclear weapons testing. J Am Med Assoc 270(17): 2076-2082. 3032 Lessard ET, Miltenberger RA, Conard RA et.al. (1985). Thyroid absorbed dose for people at Rongelap, Utirik and Sifo on March 1, 1954, BNL-51882 U.S. Dept of Energy.Nagataki S, 3033 Shibata Y, ... Shimaoka K (1994), Thyroid diseases among atomic bomb survivors in 3034 Nagasaki. JAMA 1994 Aug 3; 272(5):364-70 3035 Ostroumova E, A Rozhko, M. Hatch et.al. (2013). Measures of thyroid function among 3036 3037 Belarussian children and adolescents exposed to iodine-131 from the accident at the 3038 Chernobyl nuclear plant. Environ Health Perspect. 121(7):865-871. Rallison, M.L., B.M. Dobyns, A.W. Meikle et al. (1991). Natural history of thyroid 3039 3040 abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med 91(4): 363-370. 3041 Yamashita, S. and Y. Shabita. (1996). Chernobyl: A decade later, in Proceedings of the 5th 3042 3043 Chernobyl Sasakawa Medical Cooperation Symposium 1996. Kiev, October 14-15, 1996: Elsevier Science B.V., Amsterdam. 3044 3045

Comment [M101]: Miller ... This material needs to be condensed into no more than one paragraph, which might be heavily referenced.

Mettler

3046

3047 The major radiation damage response of the clear crystalline lens of the eye is the loss of lens 3048 clarity resulting in clouding or opacification known as a cataract that in an extreme case (usually 3049 after high doses > 5 Gy in a single exposure) can cause significant visual impairment. However, 3050 exposure to low doses of radiation can lead to minor opacifications many years later. The impact 3051 of cataract outcomes on vision following either high- or low-doses are highly dependent on the 3052 type of radiation, the time over which the exposure was delivered, the genetic susceptibilities of 3053 the individual exposed, and also the actual location of the opacity within the lens that may form 3054 relative to the visual axis of the individual. 3055 3056 3057 Vision-impairing cataracts occurring after high doses to the lens of the eye have been known for 3058 many decades. Acute, fractionated doses over weeks that exceed several gray can cause obvious cataracts within a few years. Radiation induced cataracts have been reported following radiation 3059 therapy with doses of 10 to 18 Gy (Merriam and Focht, 1957). More recently, with more 3060 sophisticated technology, it has become apparent that lens opacities can be seen after doses as 3061 low as 0.5 Gy. 3062 3063 However,, there is still considerable uncertainty surrounding the relationship between dose and 3064 radiation cataract development (ICRP, 2012). Consequently, several reviews of recent radiation 3065 cataractogenesis epidemiologic studies have been published [see NCRP (2016a) for detailed 3066 review of this literature]. In general, these reviews have concluded that there is a strong 3067 likelihood of an association between exposure to ionizing radiation and initiation or development 3068 of various cataracts (NCRP, 2016a). Overall, the data were consistent with an association 3069 between exposure to ionizing radiation at 1 Gy and initiation or development of post-subcapsular 3070 cataracts, mixed, and cortical cataracts (NCRP, 2016a). 3071 3072 3073 The apparent simplicity of the association between ionizing radiation exposures and the 3074 formation of lenticular opacities belies the complex underlying biological factors and mechanisms. The reviews of mechanistic studies by several authors as summarized by NCRP 3075 (2016a) suggests that radiation-induced opacities could be stochastic in nature and perhaps not a 3076 tissue reaction, as long thought. However, the link between the induction of any, even minor, 3077 opacities in animal models and the occurrence of clinically-relevant, vision-impairing cataracts 3078 3079 in humans is still far from clear. Because of the incoherence of the mechanistic and epidemiologic evidence, it is not vet known if radiation cataractogenesis can be classified as 3080 strictly a stochastic effect or a tissue reaction in nature. The epidemiologic evidence to date 3081 indicates a threshold model, and NCRP has determined that this model should continue to be 3082 used for radiation protection purposes at this time. The specific value of the threshold for 3083 detectable opacities or vision-impairing cataracts is less clear. The epidemiologic evidence has 3084 large associated uncertainties, but currently indicates a threshold dose in the region of 1 to 2 Gy 3085 for vision-impairing cataracts. . However, NCRP has concluded that it is not possible to make a 3086 3087 specific quantitative estimate of lens effect thresholds at this time. 3088 Recommendation: A threshold model for formation of lens opacities continue to be used for 3089

6.8 Lens of the Eye (Cataract)

3099

radiation protection purposes.

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

3091	
3092	Recommendation: An absorbed dose threshold for detectable lens opacities or vision
3093	impairing cataracts not be specified at this time.
3094	
3095	The effects of LET, dose rate, acute or protracted dose delivery on cataract induction and
3096	progression are not clear. Vision-impairing cataracts could be considered the endpoint of greatest
3097	concern in terms of lens radiation protection. Cataracts are not life threatening but may affect
3098	individuals' ability to carry out their occupations or other daily tasks.
3099	
3100	Epidemiologic studies of the effect of radiation on the lens of the eye indicate that there is an
3101	association between exposure to ionizing radiation and initiation or development of post-sub-
3102	capsular cataracts, mixed and cortical vision-impairing cataracts in humans for various exposure
3103	situations. The systematic review of the current eye epidemiology data has shown that the
3104	probable risks for vision-impairing cataracts are likely increased for doses in the region of 1 to 2
3105	Gy. However, the preponderance of evidence appears to suggest the possibility that effects (e.g.,
3106	iens opacities and/or cataracts) could occur at lower doses.
3107	Therefore NCDD has determined that it is product for long of the are to recommend in the second
3108	I nerefore, NCRP has determined that it is prudent for tens of the eye to recommend an annual
3109	refers to the selection of an annual dose criterion that would not result in an individual
3110	refers to the selection of an annual dose criterion that would not result in an individual
3111 2112	accumulating an exposure in excess of the fikery fange of threshold values.
2112	The annual absorbed dose criterion for control of lens of the eye exposure recommended for
3113	members of the nublic at should be 15 mGy and is adequately protective
3115	includers of the public at should be 15 moy and is adequately protective.
3116	Recommendation: The annual absorbed dose criterion for occupational exposures for the
3117	lens of the eve he set at 50 mGy.
3118	
3110	Recommendation: The annual absorbed dose criterion for the public for exposure to the
3120	lens of the eve he set at 15 mGy.
3121	· · · · · · · · · · · · · · · · · · ·
3122	Recommendation: Evaluation and additional research should continue in the following
3123	areas: comprehensive evaluation of the overall effects of ionizing radiation on the eve.
3124	dosimetry methodology and dose-sparing optimization techniques. additional high-quality
3125	epidemiologic studies, and a basic understanding of the mechanisms of cataract
3126	development (NCRP, 2016a).
3127	
3128	References (Section 6.8)
3129	
3130	ICRP (2012). International Commission on Radiological Protection. ICRP Statement on Tissue
3131	Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs –
3132	Threshold Doses for Tissue Reactions in a Radiation Protection Context, ICRP Publication

3133 118, Annals of the ICRP **41** (1/2) (Elsevier Science, New York).

3134 3135 3136 3137 3138 3139 3140 3141	 NCRP (2016a). National Council for Radiation Protection and Measurements. Guidance on Radiation Dose Limits for the Lens of the Eye. NCRP Commentary No. 2x (National Council on Radiation Protection and Measurements, Bethesda, Maryland). Merriam, G.R. and E.F. Focht, (1957). A clinical study of radiation cataracts and the relationship dose. AJR, 1957. 77: p. 759-785. 6.9 Skin Effects
3142 3143	There are both stochastic effects and tissue reactions of ionizing radiation on the skin. The biologic basis for dose restriction for the skin was reviewed by the ICRP (1991a).
3144 3145 3146 3147 3148 3149 3150 3151 3152 3153 3154 3155	The stochastic effects are induction of non-melanoma skin cancers (most commonly basal cell and less commonly squamous cell types). There are some differences with basal cell cancers occurring at lower dose levels and squamous cell cancers being more common after higher doses associated with radiation therapy. There are anatomic differences with basal cell cancers occurring on the face and neck and squamous cell cancer more commonly on the hands. For basal cell cancer the relative risk decreases with increasing age at exposure. The interaction with ultraviolet and ionizing radiation for induction of skin cancers appears more than additive and there is a clear increase in skin cancers after ionizing radiation exposure in skin areas exposed to sunlight and in persons with faulty DNA repair (<u>e.g.</u> , xeroderma pigmentosa). There is no significant evidence that melanoma is induced by ionizing radiation.
3156 3157 3158 3159 3160 3161 3162 3163 3164	The normal incidence of non-melanoma skin cancer is difficult to assess since these cancers are commonly removed by dermatologists and are often not reported to tumor registries. The mortality rate of both types is low (usually <0.3 %). The incidence of non-melanoma skin cancers after irradiation has been assessed in atomic-bomb survivors, occupationally exposed groups and after medical exposures. In the atomic-bomb survivors the ERR of basal cell carcinoma was significantly elevated at 0.74 Gy ⁻¹ [95 % confidence interval (CI) 0.26 to 1.6] and for squamous cell carcinoma the ERR was 0.71 Gy ⁻¹ (95 % CI 0.063 to 1.9) (Sugiyama et al., 2014). There was no significant dose response for melanoma. There are major variations in the skin cancer risk reported among epidemiologic studies particularly regarding age at exposure as
3165 3166 3167 3168 3169 3170	well as excess absolute risk (EAR). These differences may be due to variation in ascertainment of the cancers, variation in genetic makeup of the populations, whole-body acute exposures versus partial-body fractionated exposures, lack of suitable controls in some studies, increased detection in groups with increased dermatological surveillance, and variations in handling of the latent period.
3171 3172 3173 3174	Regardless of the variable estimated risks among the epidemiologic studies, the low fatality and morbidity rate for non-melanoma skin cancers means that for radiation protection purposes, the effective dose restriction provides sufficient protection against stochastic skin effects.
3175 3176 3177	The tissue reactions from ionizing radiation on the skin include a number of different effects due to the various layers of skin which have different cell types, functions and radiosensitivities (ICRP, 2013).

3179 3180 3181 3182 3183 3183 3184 3185 3186	The threshold doses for these effects are shown in Table 6.3 (ICRP, 2012). Note however that the thresholds and time course for these effects are better shown as ranges than as specific values (ICRP, 2013). Table 6.3 is for single acute exposures, however a number of these effects (such as skin atrophy) can be seen with significantly higher but fractionated or chronic exposures. Field size is also a crucial factor in determining outcome with smaller fields tolerating higher doses. For a small (6 x 4 cm) field the dose of x-rays required for an effect may be twice as high as that for a large field (15 x 20 cm).
3187	Recommendation: For radiation protection purposes the dose criteria for skin exposure is
3188	designed to avoid significant adverse tissue reactions.
3189	
3190	Special radiation protection considerations arise from the issue of tiny radioactive "hot particles"
3191	which range from a few microns to a millimeter or two and which can produce very high
3192	localized doses to the skin and cause a small acute ulceration which develops over 2 weeks, has a
3193	bullseye appearance and can heal to a small dimple The pathology of these small ulcers is
3194	different from larger field irradiation and does not cause loss of reproduction of the basal cells.
3195	Another special circumstance is irradiation with beta particles which may or may not affect the
3196	basal cells and typically do not cause long-term reduction in the underlying vasculature. Both of
3197	these special cases may cause significant variations in effects for different parts of the body
3198	depending upon the thickness of the epidermis (e.g., \sim 40 um for the eyelid and \sim 450 um for the
3199	finger).
3200	
3201	
3202	6.10 Psycho-Social Effects (Pending)
3203	
3204	
3205	6.11 Summary and Recommendations [Pending (if a summary of Section 6 is wanted)]
3206	

3207

3208

3209 3210

3211 3212

3213 3214 $\frac{\text{considered to be near to ED}_1 \text{ (the estimated dose for 1\% incidence). Note that the threshold doses}{\text{are given as absorbed dose in gray (ICRP, 2012)}.}$

 Table 6.3 --- Approximate threshold single doses and time of onset for the reaction of human skin to ionizing radiation delivered in fluoroscopy exposures. These threshold doses are

Effect	Approximate Threshold Dose (Gy)	Time of Onset
Early transient erythema (skin reddening)	2	2–24 h
Main erythema reaction	6	~1.5 weeks
Temporary epilation (loss of hair)	3	~3 weeks
Permanent epilation	7	~3 weeks
Dry desquamation (dry scaling skin)	14	~4–6 weeks
Moist desquamation (weeping loss of skin)	18	~4 weeks
Secondary ulceration (open skin sore)	24	>6 weeks
Late erythema	15	8–10 weeks
Ischaemic dermal necrosis (tissue death caused by loss of blood supply)	18	>10 weeks
Dermal atrophy (first phase) (wasting away of skin)	10	>52 weeks
Telangiectasia (red blotches on skin)	10	>52 weeks
Dermal necrosis (late phase)	>15?	>52 weeks

3215 3216

3218

3217 **References** (Section 6.9)

- ICRP (1991a). The biological basis for dose limitation in the skin, Publication 59, Annals of the
 ICRP Vol 22 No.2.
- 3221 ICRP (2012). International Commission on Radiological Protection. ICRP Statement on Tissue
 3222 Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs –
- 3223Threshold Doses for Tissue Reactions in a Radiation Protection Context, ICRP Publication3224118, Annals of the ICRP 41 (1/2) (Elsevier Science, New York).
- 3225 ICRP (2013). Radiological protection in cardiology. ICRP Publication 120. Annals of the ICRP
 3226 42(1), 1-125.
- Sugiyama et.al. (2014). Skin cancer incidence among atomic bomb survivors from 1958 to
 1996, Rad Res.181:531-539.
- 3229

3230 7. Radiation Risk Estimates, Detriment and Uncertainties

3231

3232

3233

3234 **7.1.1** <u>Introduction</u> 3235

The concept of detriment for radiation protection purposes was originally introduced by ICRP in 3236 Publication 26 (ICRP, 1977) where it was defined as the mathematical 'expectation' of the harm 3237 incurred from an exposure to radiation. The effects included in harm were cancer and hereditary 3238 3239 effects. This harm included not only the probability of each type of deleterious effect but also the adjudged severity of the effect. In ICRP Publication 60 (ICRP, 1991b), the definition of 3240 3241 detriment was reconsidered to include fatal cancer risk for a specific organ, a weighted 3242 allowance for nonfatal cancers plus an estimate of severe hereditary effects, all of which were also weighted for the relative length of life lost. The primary use of detriment estimates from 3243 3244 Publication 26 (ICRP, 1977) onwards is for producing tissue weighting factors (Section 7.2.5) 3245 for use in calculating nominal risk estimates and ultimately effective dose and dose criteria for radiation protection purposes. This general concept of detriment was continued in ICRP 3246 3247 Publication 103 (ICRP, 2007a). However, the use of cancer incidence values and the inclusion of new epidemiologic data resulted in revised values for radiation detriment and tissue weighting 3248 factors. The resulting detriment adjusted nominal risk coefficients for cancer were very similar to 3249 those in ICRP Publication 60 (ICRP, 1991b), namely, $5.5 \times 10^{-2} \text{ Sv}^{-1}$ for the whole population and $4.1 \times 10^{-2} \text{ Sv}^{-1}$ for adult workers [compared to $6.0 \times 10^{-2} \text{ Sv}^{-1}$ and $4.8 \times 10^{-2} \text{ Sv}^{-1}$, respectively, 3250 3251 in Publication 60 (ICRP, 1991b)]. The overall measure of relative detriment is almost 3252 exclusively for cancer with heritable effects being a very minor component based on relative 3253 risk. The detriment for heritable effects is included in the tissue weighting factor for the gonads. 3254 3255

7.1 Measure of Detriment

Thus, for radiation protection purposes, ICRP has utilized the concept of health detriment as an
expansion of overall health impact of radiation beyond cancer and noncancer risks. The
calculation of detriment is both complex and has a number of associated uncertainties and
assumptions. Section 7.1 provides an overview of this usage and discusses NCRP's
recommendations for its application in their dose criteria.

3262 7.1.2 <u>Risk of Effect</u>

3261

3263

For radiation protection purposes as recommended by ICRP, cancer risks are converted to 3264 3265 nominal risk coefficients, based upon sex-averaged risk values and averaging over the range in age at the time of exposure.. Clearly this in itself leads to uncertainty in the risk coefficients 3266 (hence the designation as "nominal"). The first step in the development of these nominal risk 3267 coefficients is to determine lifetime cancer incidence risk estimates for radiation-associated 3268 cancers, largely based on the atomic-bomb survivor cohort. Excess relative risk (ERR) and 3269 excess absolute risk (EAR) models were used to estimate male and female lifetime excess cancer 3270 3271 risks for 14 tissues or organs. These values were then averaged across sexes. These lifetime risk estimates were adjusted downward by a dose and dose-rate effectiveness factor (DDREF) (a 3272 value of 2 was selected by ICRP). The risk estimate for leukemia is not adjusted for DDREF 3273

because the linear-quadratic (LQ) model for risk accounts for any DDREF. A discussion of the
 uncertainty in the value of DDREF is provided in Section 7.2.3.

3276

3293

3302

3277 These lifetime risk estimates, as mentioned, rely on atomic-bomb survivor data for a Japanese population, but background cancer rates differ across different populations. Thus, the risk 3278 estimates need to be adjusted when being transported across populations. ICRP Publication 103 3279 (ICRP, 2007a) states that for risk transfer across populations for each cancer site a weighting 3280 factor of the ERR and EAR lifetime risk estimates was established that provided a reasonable 3281 basis for generalizing across populations with different baseline risks. When these weighted risk 3282 estimates were averaged across seven western and Asian populations, the resulting nominal risk 3283 coefficients were those used by ICRP in their calculation of radiation detriment. 3284

3285 3286 **7.1.3** Lethality of Effect

The ICRP nominal risk coefficients for each cancer site were based on lifetime risks of cancer
incidence, whereas detriment is based on the risk of fatal cancer. The excess cancer incidence
values were converted to fatal cancer risks by multiplying by the appropriate lethality fraction
derived from selected national cancer survival data. The uncertainty for this adjustment is largely
in the accuracy of the lethality fractions used and is relatively large.

3294 7.1.4 <u>Reduction in Quality of Life</u>

The ICRP judged that cancers should be weighted not only by lethality but for cancer survivors
also for pain, suffering and any adverse effects of cancer treatment. By a somewhat complex
process, the nonlethal fraction of cancers is adjusted by a factor to account for the quality of life
loss to give an adjusted lethality fraction. In practice, a value of 0.1 was chosen for all sites, so
that in effect the greatest impact would be on relatively nonlethal cancers, such as breast or
thyroid. The nominal risk coefficients were adjusted for the quality of life reduction.

3303 7.1.5 Life Shortening (Years of Life Lost)

The nominal risk coefficients were also adjusted for the adjudged "harm" from years of life lost.
The age distribution differs for the different cancer types used in the calculation of detriment.
Thus, years of life lost can vary with cancer type. To account for this, the average ages at death
for several types of cancer were estimated from national cancer data and converted to <u>average</u>
years of life lost from when a cancer is diagnosed. These averaged values were applied to the
nominal risk coefficients that had been adjusted for lethality and quality of life, as above.

The result of adjusting the nominal cancer risk coefficients for lethality, quality of life and years
of life lost is an estimate of radiation detriment associated with each type of radiogenic cancer.
These values were normalized to sum to unity for deriving a set of relative radiation detriment
values.

NOT TO BE DISSEMINATED OR REFERENCED

NCRP CC 1 Draft of April 2016

3317 **References** (Section 7.1)

- 3318
- ICRP (1977). Recommendations of the International Commission on Radiological Protection,
 ICRP Publication 26. Annals of the ICRP, 1.
- ICRP (1991b). ICRP Publication 60: 1990 Recommendations of the International Commission
 on Radiological Protection, Elsevier Health Sciences.
- 3323 ICRP (2007a). ICRP publication 103. Annals of the ICRP, 37, 1-332.
- 3324 3325 3326

3327

7.2 Risk Estimates and Uncertainty: Addressing the Issue

3328 7.2.1 Introduction

3329 For setting radiation protection dose criteria, there are several essential, and linked, factors that 3330 3331 are currently considered to be quite uncertain. The quantitation of adverse health effects at low 3332 doses and low dose rates uses the DDREF for which there is a significant uncertainty. The adverse outcomes that are used (other than acute radiation syndromes) are phenotypically the 3333 same whether they are radiation induced or assumed to be part of the background, making it 3334 impossible to separate them for assessing low-dose effects through epidemiologic studies. To be 3335 able to attribute a specific outcome to radiation there is a need to develop some form of 3336 radiation-specific disease signature or bio-indicator. NCRP Commentary No. 24 (NCRP, 2015b) 3337 3338 describes one such approach based on key events and adverse outcome pathways. The low dose and low dose-rate risk estimate is proposed to be based on the use of biologically-based dose-3339 response (BBDR) models that utilize key events as parameters. This approach is potentially 3340 viable as indicated by recent publications describing risk assessments for environmental 3341 chemicals (e.g., Adeleye et al., 2015; Preston, 2015). As part of this approach, it is proposed that 3342 key events can be selected as radiation-specific signatures in the process of attribution. The 3343 issues associated with attributability together with considerations of the use of DDREF and 3344 3345 weighting factors in risk estimation are discussed in Sections 7.2.2 and 7.2.3, respectively. 3346 Possible approaches for addressing the uncertainties associated with low dose and low dose-rate risk estimates are discussed in Section 7.2.6. 3347 3348 **References** (Section 7.2.1) 3349 3350

- 3351 ADELEYE, Y., ANDERSEN, M., CLEWELL, R., DAVIES, M., DENT, M., EDWARDS, S.,
- 3352 FOWLER, P., MALCOMBER, S., NICOL, B., SCOTT, A., SCOTT, S., SUN, B.,
- 3353 WESTMORELAND, C., WHITE, A., ZHANG, Q. and CARMICHAEL, P.L. (2015).
- "Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using
 toxicity pathways and progress in a prototype risk assessment," Toxicology 332, 102–111.
- 3356NCRP (2015b). NCRP Commentary No. 24
- PRESTON, R.J. (2015). "Integrating basic radiobiological science and epidemiological studies:
 Why and how," Health Phys. 108(2), 125–130.
- 3359

3360 7.2.2 <u>Attributability</u>

3361

For purposes of radiation protection and establishing public and occupational dose criteria it is important to understand the scientific process of determining whether a specific health effect can be attributed to radiation exposure and if so, with what certainty. In addition it is necessary to determine what risks might occur in the future after radiation exposure of a person or a

3366 population. These issues have been dealt with in the past in NCRP Statement No 7 (NCRP,

3367 **1992**) and more recently in Annexes A and B in UNSCEAR (2012).

3368

For purposes of this document on radiation protection and for absorbed doses of <1 Gy, the 3369 discussion of attribution, inferring risks and uncertainties is limited to radiation-induced cancer. 3370 3371 Regardless of the level of exposure, a specific cancer or cancers in an individual or population 3372 cannot be unequivocally attributed to radiation exposure since at present there are no biomarkers specific to radiation-induced cancer and there are always competing causes and confounding 3373 factors. If there is a significant increase in cancer incidence in those tissues known to be 3374 3375 radiosensitive following a significant radiation exposure then attribution is plausible. The probability of causation depends upon the type of cancer, organ equivalent dose (not effective 3376 dose), radiation type and quality, age at exposure, latent period and other risk factors. In general, 3377 an increase in health effects in an individual or population cannot reliably be attributed to 3378 chronic low-LET doses in the range of average natural background radiation. This is due to 3379 uncertainties in dose assessment, insufficient statistical power of most epidemiologic studies at 3380 low doses and lack of radiation-specific biomarkers. There does appear to be an increased cancer 3381 risk from radon at or near background levels, but this is high -LET radiation. 3382 3383

Future risks from radiation exposure of an individual or population cannot and should not be 3384 inferred from effective doses that are above or below effective dose criteria for radiation 3385 protection. Effective dose criteria are not threshold levels at which stochastic health effects may 3386 or may not occur, nor are they a designated "safe" versus "unsafe" criteria. The Council 3387 3388 understands that there are substantial uncertainties in multiplying very low doses by large numbers of individuals to estimate numbers of radiation-induced health effects in an exposed 3389 population. The Council understands that such projections have been made to allocate resources 3390 or to compare potential risks from various practices. 3391 3392

Recommendation: Future risks from radiation exposure of an individual or population not
be inferred from effective doses that are above or below effective dose criteria for radiation
protection.

Recommendation: Effective dose criteria not be interpreted as threshold levels at which stochastic health effects may or may not occur, nor as a designated "safe" versus "unsafe" criteria.

3400

3396

Uncertainties in risk estimates can be classified as random nonsystematic (aleatory) or as due to
 lack of knowledge about true, but unknown, variables that are constants shared by members of
 cohort subgroups (epistemic). For estimation of radiation-induced cancers, the major

uncertainties arise from dosimetry, transfer across populations, effect of low dose and low dose

rate, radiation quality and other physical and biological confounding factors. When a detailed 3405 analysis for a specific situation is performed, the 95 % CI is generally a factor of about 2 to 3 3406 about a central estimate of risk based on a uniform whole-body exposure. 3407 3408 3409 **References** (Section 7.2.2) 3410 Berrington, Gonzales et al 2012 (not yet cited in text) 3411 NAS/NRC (2006). BEIR VII (not yet cited in text) 3412 NCI RadRAT (not yet cited in text) 3413 3414 NCRP (1992). Statement No. 7 UNSCEAR (2012). United Nations Scientific Committee on the Effects of Atomic Radiation, 3415 3416 UNSCEAR 2012 Report to the General Assembly, Annex A Attributing Health Effects to 3417 ionizing radiation exposure and inferring risks, Annex B Uncertainties in risk estimates for radiation induced cancer, United nations New York 2015. 3418 3419 3420 7.2.3 Dose and Dose-Rate Effectiveness Factor 3421 3422 3423 It has been considered necessary, based on a range of biological studies and selected epidemiologic studies, to include a DDREF for converting cancer risks obtained at relatively 3424 high absorbed doses and absorbed dose rates for predicting risks at low doses (<100 mGy) and 3425 low dose rates (<5 mGy h⁻¹). The use of DDREF has been restricted to the development of low-3426 dose and low dose-rate cancer risk estimates for calculating detriment values to be used in 3427 establishing recommendations for dose criteria for radiation protection purposes. It is not a 3428 definitive, measured value but rather a derived one based upon a selected data set that varies 3429 according to the organization making the recommendations. For example, after considering 3430 various human and experimental data, a value of 2 was selected by ICRP in Publication 60 3431 (ICRP, 1991b). A considerable amount of discussion has ensued since this time on what are the 3432 3433 appropriate data sets upon which to base a selection of DDREF and the methods for calculating a specific value. ICRP in its most recent set of recommendations (ICRP, 2007a) retained a value of 3434 2; BEIR VII (NAS/NRC, 2006) using a Bayesian approach for data analysis selected a value of 3435 1.5; and UNSCEAR (2006) most recently elected not to use a DDREF. A number of 3436 epidemiologic studies for populations exposed at low dose rates have proposed values consistent 3437 with a value of 2 and as low as 1 for DDREF conversion [reviewed, for example, in NCRP 3438 Report No.171 (NCRP, 2012b)]. 3439 3440 It has been proposed by a number of sources that it is more appropriate and more correct, based 3441 on the available literature, to consider separately a low-dose effectiveness factor (LDEF) and a 3442 dose-rate effectiveness factor (DREF) for risk estimate calculations (reviewed in Ruhm et al., 3443 2015). 3444 3445 Recommendation: Separate LDEF and DREF values be used once the necessary data are 3446 available for accurately establishing values. 3447 3448

Comment [M102]: MR ... need to indicate where these **three** references should be called out in the text of Section 7.2.2. Also need full citations for Berrington et al. (2012) and NCI RadRAT.

Mettler

These two quantities (LDEF and DREF) represent outcomes of different underlying processes 3449 and rely upon quite different data sets for their calculation. These aspects are considered below 3450 in Sections 7.2.3.1 and 7.2.3.2. Both of these factors must be determined for use in radiation 3451 3452 protection. Targeted research is needed to obtain the required data set (human, laboratory animal or cellular). There are international (e.g., ICRP, Multidisciplinary European Low Dose Initiative, 3453 and UNSCEAR) and national organizations (e.g., Public Health England, NCRP, and Electric 3454 Power Research Institute) that are currently addressing this issue and the associated necessary data 3455 3456 sets. 3457

7.2.3.1 Low-Dose Effectiveness Factor. A LDEF is necessary when extrapolating linearly from 3458 high-dose to low-dose effects for an adverse health effect dose-response curve that is essentially 3459 3460 linear-quadratic (LQ). The LDEF is calculated as the ratio of the slope of the linear extrapolation from a point on the LQ curve and the slope of the linear component of this LQ curve. For 3461 acceptance of this approach, the need is to establish if, for example, the dose-response for 3462 3463 radiation-induced cancer (particularly that for the atomic-bomb survivors) is described by an LQ 3464 curve. There has been an active discussion on this topic with opinions for and against an LQ curve for all solid cancers for the atomic-bomb survivor cohort. While it is difficult to reach a 3465 3466 definitive conclusion because of the uncertainties associated with effects at low doses, the recent report by Ozasa et al. (2012) provides a convincing argument that there is no threshold for all 3467 solid cancers. 3468 3469

Recommendation: At this time, the use of a separate LDEF for radiation protection purposes does not appear to be warranted.

7.2.3.2 Dose-Rate Effectiveness Factor. The DREF is calculated as the ratio of the slope of the 3473 dose response at low acute doses to that at low doses and low dose rates. For a linear non-3474 threshold model application, the slope for acute doses is described by the slope of the curve over 3475 the entire dose range of epidemiologic assessment. If the dose-response curve is best described 3476 by an LO application, then the low-dose slope is that for the linear component of the LO curve. 3477 The greatest uncertainty in calculating a DREF arises from the relative lack of epidemiologic 3478 data for low-dose and low dose-rate exposures. The data for occupational and environmental low 3479 dose-rate exposures of human populations together with the associated uncertainties were 3480 reviewed in NCRP Report 171 (NCRP, 2012b). The general conclusion was that a (D)DREF of 1 3481 3482 is feasible but that higher values cannot be excluded. Thus, to help reduce this uncertainty, additional reliance has to be placed on animal and cellular data. A concern is that there is a lack 3483 of direct association between the non-epidemiologic data and human cancer induction. It might 3484 well be possible to strengthen this relationship through the design of research to develop data 3485 bases that more directly address this relationship (NCRP, 2015b). Given these uncertainties, the 3486 selection of a DREF for radiation protection purposes is somewhat subjective and values of 1, 3487 3488 1.5, 2 or greater can be defended.

3490Recommendation: NCRP adopt the existing ICRP recommendation for a (D)DREF of 2 for3491radiation protection purposes.

3492

3489

3472

Comment [M103]: Bushberg ... Below what dose is dose rate not a factor? Medical exposure low dose but very high dose rate

Preston ... Tricky – if response is linear quadratic then dose at which essentially no quadratic component would be independent of dose rate. However, for LNT hypothesis used for radiation protection, dose rate is included by reducing slope and so there is no dose at which there would be no theoretical dose rate effect. This is intended to have been addressed in the text. Changes if needed.

3494

3511 3512

3514

3493 **References** (Section 7.2.3)

- 3495 NAS/NRC (2006). BEIR VII
- 3496 NCRP (2012b). NCRP Report No.171
- 3497 NCRP (2015b). NCRP Commentary No. 24
- 3498 ICRP (1991b). ICRP Publication 60: 1990 Recommendations of the International Commission
 3499 on Radiological Protection, Elsevier Health Sciences.
- 3500 ICRP (2007a). ICRP publication 103. Annals of the ICRP, 37, 1-332.
- OZASA, K., SHIMIZU, Y., SUYAMA, A., KASAGI, F., SODA, M., GRANT, E.J., SAKATA,
 R., SUGIYAMA, H. and KODAMA, K. (2012). "Studies of the mortality of atomic bomb
 survivors, Report 14, 1950–2003: An overview of cancer and noncancer diseases," Radiat.
 Res. 177(3), 229–243.
- Rühm W, Woloschak GE, Shore RE, Azizova TV, Grosche B, Niwa O, Akiba S, Ono T, Suzuki
 K, Iwasaki T, Ban N, Kai M, Clement CH, Bouffler S, Toma H, Hamada N. (2015). Dose
 and dose-rate effects of ionizing radiation: a discussion in the light of radiological protection.
 Radiat Environ Biophys. 54(4):379-401. doi: 10.1007/s00411-015-0613-6. Epub 2015 Sep 5.
- UNSCEAR (2006). <u>Effects of ionizing radiation</u>, Volume I, UNSCEAR 2006 report to the
 General Assembly, Annex A: Epidemiological studies of radiation and cancer.

3513 7.2.4 Radiation Weighting Factors

In the definition and calculation of equivalent dose, the recommended radiation weighting 3515 factors (\underline{w}_R) allow for the differences in the effect of various radiations in causing stochastic 3516 effects. The w_R values for high-LET radiation are derived for stochastic effects at low doses. 3517 **ICRP** (2007a) updated the previously recommended \underline{w}_{R} values (**ICRP**, 1991b) for neutrons and 3518 protons. The changes were based on reviews of the range of available data on the RBE of 3519 different radiations, together with biophysical consideration. Values for neutrons were given as a 3520 3521 continuous function of neutron energy (Equation. 7.1), and include a value for charged pions. 3522 Г

3523
3524
3525
3526

$$\underline{W}_{R} = \begin{bmatrix} 2.5 + 18.2 \ exp - \{ [\ln (\underline{E}_{n})]^{2}/6 \}; & \underline{E}_{n} < 1 \ MeV \\ 5.0 + 17.0 \ exp - \{ [\ln (2 \ \underline{E}_{n})]^{2}/6 \}; & 1 \ MeV \le \underline{E}_{n} \le 50 \ MeV \\ 2.5 + 3.25 \ exp - \{ [\ln (0.04 \ \underline{E}_{n})]^{2}/6 \}; & E_{n} > 50 \ MeV \end{bmatrix}$$
(7.1)

3527The \underline{w}_R values are selected to give a representative value for the known data and to be3528sufficiently accurate for application in radiation protection. The values of \underline{w}_R are selected by3529judgment for use in the determination of radiation protection quantities; as such they have fixed3530values and are not associated with any uncertainty.

3532 Values of \underline{w}_{R} for photons, electrons, muons, and alpha particles remained unchanged.

3533 All \underline{w}_R values relate to the radiation incident on the body or, for internal radiation sources, 3534 emitted from the incorporated radionuclide(s).

3535

3531

Over the years there has been a concern that the RBE for very low-energy photons and electrons may be greater than that for higher-energy photons such as the gamma rays from 60 Co or 137 Cs.

3538	(NCRP Scientific Committee 1-20 has been reviewing the available scientific information on this
3539	issue and is developing a report of their findings. The Council recommendations on the
3540	biological effectiveness of these lower-energy radiations will be based on the conclusions of that
3541	report.)
3542	
3543	Recommendation: NCRP adopt the <u>w_R</u> values in Table 7.1 provided by ICRP (2007a).
3544	
3545	7.2.5 <u>Tissue Weighting Factors</u>
3546	
3547	In the definition and calculation of effective dose, tissue weighting factors (\underline{w}_T) allow for the
3548	variations in radiation sensitivity of different organs and tissues to the induction of stochastic
3549	effects. Effective dose is calculated using age- and sex-averaged \underline{w}_{T} values.
3550	
3551	ICRP (2007a) advanced the concept of \underline{w}_T and recommended basing values of \underline{w}_T primarily on
3552	the incidence of radiation-induced cancer rather than on mortality, as well as on the risk of
3553	heritable disease over the first two generations. The values of \underline{w}_{T} , are based on epidemiologic
3554	studies of cancer induction as well as on experimental genetic data after radiation exposure, and
3555	on expert judgment. The \underline{w}_{T} values represent mean values for humans, averaged over both sexes
3556	and all ages. Effective dose is calculated for a Reference Person and not for an individual (ICRP
3557	<mark>2007a</mark>).
3558	
3559	The tissue weighting factors recommended by ICRP (2007a) (Table 7.2) are sex- and age-
3560	averaged values for all organs and tissues, including the male and female breasts, the testes, and
3561	the ovaries. This averaging implies that the application of this approach is restricted to the
3562	determination of effective dose in radiation protection and, in particular, cannot be used for the
3563	assessment of individual risk.
3564	
3565	Recommendation: NCRP adopt the \underline{w}_{T} values in Table 7.2 provided by ICRP (2007a).

3566

Recommendation: NCRP adopt the <u>w_T</u> values in Table 7.2 provided by ICRP (2007a).

3567 3568 3569	Table 7.1 Recommended radia	tion weighting factors (ICRP 2007a).
3570		······································
	Radiation type	Radiation weighting factor (\underline{w}_R)
	Photons	1
	Electrons and muons	1
	Protons and charged pions	2
	Alpha particles, fission fragments, heavy ions	20
	Neutrons	A continuous function of neutron
		energy (Equation 7.1)

3571

3573

3574

3575	
3576	

3577

3578

3579 3580

3581

3589

Table 7.2	Recommended tissue	weighting factors	(WT) (ICRP 2007a)
1 4010 7.2	Recommended fibbae	worghting fuotors		10101 2007u	,

Tissue	$\underline{\mathbf{W}}_{\mathrm{T}}$	$\sum \underline{\mathbf{W}}_{\mathrm{T}}$
Active (red) bone marrow, colon, lung, stomach, breast, remainder tissues ^a	0.12	0.72
Gonads	0.08	0.08
Bladder, esophagus, liver, thyroid	0.04	0.16
Bone surface, brain, salivary glands, skin	0.01	0.04
Total		1.00

^a Remainder tissues: adrenals, extrathoracic (ET) region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate (male), small intestine, spleen, thymus, uterus/cervix (female).

3582

3583 **References** (Section 7.2.4 and 7.2.5) 3584

ICRP (1991b). ICRP Publication 60: 1990 Recommendations of the International Commission
 on Radiological Protection, Elsevier Health Sciences.

3587 ICRP (2007a). ICRP publication 103. *Annals of the ICRP*, 37, 1-332.

3588 NCRP Scientific Committee 1-20 Report (in progress)

3590 7.2.6 Biologically-Based Dose-Response Models

3591 There are well-documented limitations to the reliance on epidemiologic data for estimating 3592 cancer and noncancer risks at low radiation doses and dose rates (NCRP, 2012b). In cases where 3593 such direct use has been presented (e.g., Kendall et al., 2013; Pearce et al., 2012), it is clear that 3594 low statistical power, possible confounders and uncertainties in dose and assessed health 3595 3596 outcome make any conclusion quite preliminary. A way forward is to develop and utilize 3597 approaches that integrate radiation biology data into available or proposed radiation epidemiologic studies in support of a risk assessment process. The specific application is to 3598 enhance the extrapolation from available high or medium dose epidemiologic data to the dose 3599 levels and dose rates relevant for radiation protection purposes. In this regard, it has been 3600 proposed that some form of BBDR modeling could meet this need (e.g., Conolly et al., 2004; 3601

3602	Curtis et al., 2002; Little et al., 2008; NCRP, 2012b; Shuryak et al., 2010). However, modeling
3603	on such a biological basis is also uncertain outside the range of the available data that are used as
3604	input parameters to a biologically-based model. For risk assessment for environmental
3605	chemicals, because of the paucity of epidemiologic data, it has been proposed that a BBDR
3606	model approach be used for predicting adverse health outcomes under low-dose chronic
3607	exposure scenarios (EPA, 2005). However, the approach has been used very sparingly in the
3608	regulatory arena itself, largely because of the lack of availability of the appropriate data sets to
3609	provide input parameters to a BBDR model. The need for expanded use of BBDR models has
3610	been concisely expressed in NCRP Report No. 171 (NCRP 2012b):
3611	
3612	"The challenge of developing a biologically-based computational model to minimize uncertainty
3612	in dose response modeling can be summarized as understanding a sufficient amount of the
2614	in dose-tesponse inducting can be summarized as inderstanding a summerical another of the
2014	computer of the second se
3615	computational model.
3616	
3617	Of course, this simple statement hides a degree of complexity that must be addressed. For
3618	example, how much of the detailed biology do we need to know and when are there sufficient
3619	data to sustain model development? This situation can be significantly alleviated if research is
3620	directed towards the data requirements identified by BBDR models; research targeted to the risk
3621	assessment process is needed.
3622	
3623	It is to be noted that no viable BBDR model has been proposed and applied to radiation risk
3624	assessment, with the possible exception of the multistage model developed by Shuryak et al.
3625	(2010) for the analysis of cancer risk patterns as a function of age-at-exposure in Japan atomic-
3626	bomb survivors.
3627	
3628	The development of realistic BBDR models is a viable goal for enhancing the current risk
3629	assessment approach for radiation-induced cancer and quite possibly for noncancer diseases. The
3630	ranid advancements in our understanding of the basis of a range of adverse health outcomes
3631	(cancer and noncancer) and the equally rand technological advances (whole genome analysis:
3633	(value in a holicance) and the equally replaced use of BBDR models a realistic goal
2622	processings, systems biology) make the emaneed use of BBBR models a realistic goal.
2624	Pataroneas (Section 7.2.6)
2024	References (Section 7.2.0)
3035	Constitution D. Kimball IS. Janagan D. Saklassar DM. Kalisak D. Draster, I. Millar El 2004. Human
3030	Coholiy KB, Klinden JS, Janszen D, Schossel PM, Kansak D, Pleston J, Miller FJ 2004. Human
2027	respiratory fact cancer risks of initiated romanderlyde, dose-response predictions derived from biologically metisyster and purchased and an and align of a combined rodent and burget from a second
2020	so a combined rode in putational modeling of a combined rodent and numan dataset. Toxicol Ser
2640	02. 2/7-290. Curtis SP. Lushack EG. Hazaltan WD. Maalaaukar SH 2002. A new paraparties of agrain against from
3640	rotracted bioh. I ET radiation arises from the two stage clouel experience model. Adv Space Bes 20:
3641	937-944
3643	EPA (US Environmental Protection Agency) 2005 Guidelines for carcinogen risk assessment. In:
3644	EPA/630/P 03/001F Washington, DC: US Environmental Protection Agency 1-166
3645	Kendall GM, Little MP, Wakeford R, Bunch KJ, Miles JC, Vincent TJ, Meara JR, Murphy MF 2013 A
3646	record-based case-control study of natural background radiation and the incidence of childhood
3647	leukaemia and other cancers in Great Britain during 1980-2006. Leukemia 27: 3-9

- Little MP, Vineis P, Li GQ. 2008. A stochastic carcinogenesis model incorporating multiple types of
 genomic instability fitted to colon cancer data (vol 254, pg 229, 2008). Journal of Theoretical Biology
 255: 268.
- 3651 NCRP (2012b). NCRP Report No. 171
- Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Lee C, Craft AW, Berrington de Gonzalez
 A, Parker L 2012. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia
 and brain tumours: a retrospective cohort study. Lancet 380: 499-505.
- Shuryak I, Sachs RK, Brenner DJ. 2010. Cancer risks after radiation exposure in middle age. J Natl
 Cancer Inst 102: 1628-1636.
- 3657

8. Recommendations

3658

3659

3660 8.1 Introduction 3661 NCRP published its most recent complete set of recommendations for the limitation of exposure 3662 to ionizing radiation as NCRP Report No. 116 (NCRP, 1993a). ICRP published its most recent 3663 set of recommendations for a system of radiological protection as ICRP Publications 103 and 3664 118 (ICRP, 2007a; 2012). The recommendations made in this Report are similar to those made 3665 previously by NCRP and ICRP. However, some changes have been made for clarity in language 3666 and terminology, and in some cases the dose values recommended for control of exposure have 3667 been changed. 3668 3669 3670 8.1.1 Principles of Radiation Protection 3671 3672 Historically the System of Radiation Protection (the NCRP System) has incorporated the three 3673 principles of justification, optimization (the ALARA principle) and dose limitation. In this Report, NCRP has restated the principle of dose limitation as restriction of individual dose. 3674 Consequently, NCRP recommends Dose Criteria for optimization and control (Section 4.3). The 3675 NCRP System is applied here to the three exposure situations (Section 2.1) and exposure 3676 categories (Section 2.2). 3677 3678 Recommendation: NCRP reaffirms the Principles of radiation protection stated as 3679 3680 justification, optimization (the ALARA principle), and restriction of individual dose. 3681

ICRP (2007a) applied its concepts of dose constraint and reference level in conjunction with the
 optimization of protection (the ALARA principle) to restrict individual doses. NCRP does not
 use the dose constraint and reference level terminology in this context. Instead NCRP has
 recommended that individual Dose Criteria be used in optimization of planning and exposure
 control. The similarities and differences are discussed in the subsections of Section 8, and are
 summarized in Tables 8.1 and 8.2.

Recommendation: Restriction of individual dose be stated as individual Dose Criteria for
 optimization.

3692 The dose recommendations in Table 8.1 are subject to various conditions as stated in the footnotes to Table 8.1. It is also expected that the ALARA principle will be applied to reduce the 3693 actual dose received to as low a value as is reasonably achievable. However, in NCRP Report 3694 No. 116 (NCRP, 1993a) the Council also recommended that an annual effective dose of 0.01 3695 mSv be considered a Negligible Individual Dose (NID) per source or practice. This 3696 recommendation is reaffirmed in this Report. The NID corresponds to a risk for adverse health 3697 effects of less than 5 in 10 million. The recommendations in this Report are related to the 3698 broader recommendations as given in Table 8.3. 3699

3700

3691

Dose Criteria are recommended to restrict dose based on two adverse health outcomes, tissue
 reactions and stochastic effects (primarily cancer mortality). The Council no longer recommends

99

Comment [M104]: Ansari ... see Ansari comments at Table 8.2 and Section 4.3.

Cool (refer to Table 8.2 and Section 4.3) ... Good question. One of the many places where we need to be clear, and as yet are not.

I think we are recommending two things. The recommendation here refers to ALARA, and so rightfully use the dose criteria for optimization. We also have recommended dose criteria for control, which is related to "limits" that all us regulators (past and present) refer to. As the draft developed the two terms have become very similar, which is no doubt contributing to potential confusions.
	NCRP (1993a)	ICRP (2012) and ICRP (2007a)	This Report
Tissue or Organ	Annual Equivalent Dose (mSv)	Annual Equivalent Dose (mSv)	Annual Absorbed Dose (mGy)
Crystalline lens of the eye.	150	20 (average over 5 y) ^a 50 (single year) ^a	50
Skin	500 (localized areas)	500 (at a depth of 70 μm averaged over 1 cm ²) ^b	500 (at a depth of 70 μ m from any external source of irradiation and averaged over the most highly exposed 10 cm ² of skin.)
Hands and feet.	500 (localised areas)	500 (at a depth of 70 μ m) ^b	500 (at a depth of 70 μm averaged over area exposed.)

Table 8.1 --- Summary of recommendations for occupational exposure (adverse tissue reactions).

^a From <mark>ICRP (2012)</mark>. ^b From <mark>ICRP (2007a)</mark>.

3709 3710

Table 8.2 --- Summary of basic recommendations (adverse stochastic health effects).

Situation ^a \rightarrow	(Effe	Planned Annual	mSv)	(Effe	Emergency Exposure	mSv)	(Effec	Existing Annual	mSv)
Category	(LIIC	cuve Dose,	111.5 V)	(LIIC		, 1115 V)	(Litte	tive Dose,	111.5 V)
	NCRP (1993a)	ICRP (2007a)	This Report	NCRP (1993a)	ICRP (2007a)	This Report	NCRP (1993a)	ICRP (2007a)	This Report
Occupational	50 ^b	20 ^c	50 ^d	500 ^e	None ^e 1,000 or 500	500 ^f	none	none	50 ^d
Public	1 ^g	1 ^h	1 ⁱ	5 ^j	20- 100 ^k	20 ⁱ	none	1-20	5 ⁱ

3711

- ^a These situations were defined in ICRP (2007a) and are not strictly applicable to the
- 3713 recommendations in NCRP (1993a).

^b Subject to a cumulative dose not to exceed 10 mSv times age.

- 3715 \int_{1}^{c} Averaged over 5 y, not to exceed 50 mSv in any one year.
- ^a Dose Criterion for optimization with a Dose Criterion for control of 20 mSv annually.
- 3717 ^e For life saving or equivalent purposes.
- 3718 ^f Dose Criterion for optimization with a Dose Criterion for control of 50 mSv annually.
- 3719 ^g Continuous or frequent exposure.
- $\frac{h}{h}$ Recommended limit.
- 3721 ⁱ Dose Criterion for control.
- ³⁷²² ^J Intended for infrequent exposure.
- 3723 ^k Reference level

3724

optimization is 50 mSv/y while criterion for control is 20 mSv/y. I found that confusing and would have thought them to be the other way around. **Comment [M106]: Ansari** ... the comment above may apply here also.

Comment [M107]: Ansari ... the comment above may apply here also.

Comment [M105]: Ansari ... criterion for

NOT TO BE DISSEMINATED OR REFERENCED

ICRP, 2007a). 3727 3728 Dose criteria^a Characteristics of the Exposure Radiological Protection Examples (mSv) Situation Requirements Greater than 20 to 100^{b,c} Individuals exposed by sources Consideration should be given Dose criterion set for the that are not controllable, or where to reducing doses. Increasing highest planned residual dose actions to reduce doses would be efforts should be made to from a radiological disproportionately disruptive. reduce doses as they approach emergency. Exposures are usually controlled 100 mSv. Individuals should by action on the exposure receive information on pathways. radiation risk and on the actions to reduce doses. Assessment of individual doses should be undertaken. Where possible, general Dose criteria set for Greater than 1 to 20 Individuals will usually receive benefit from the exposure information should be made occupational exposure in planned situations. situation but not necessarily from available to enable individuals the exposure itself. Exposures to reduce their doses. Dose criteria set for may be controlled at source or, comforters and caregivers of For planned situations, alternatively, by action in the patients treated with radiopharmaceuticals. exposure pathways. individual assessment of exposure and training should Dose criterion for the highest take place. planned residual dose from radon in dwellings. 1 or less Individuals are exposed to a General information on the Dose criteria set for public source that gives them little or no level of exposure should be exposure in planned individual benefit but benefits made available. Periodic situations. society in general. checks should be made on the exposure pathways as to the Exposures are usually controlled level of exposure. by action taken directly on the source for which radiological protection requirements can be planned in advance.

3725 Table 8.3 --- Framework for source-related effective dose criteria with examples for single dominant sources for all exposure situations that can be controlled. (Adapted from Table 5, 3726

3729

3730 ^a Acute or annual dose.

^bIn exceptional situations, informed volunteer workers may receive doses above this band to save lives, 3731

3732 prevent severe radiation-induced health effects, or prevent the development of catastrophic conditions.

3733 ^cSituations in which the dose threshold for tissue reactions in relevant organs or tissues could be

3734 exceeded should always require action.

the use of dose equivalent or equivalent dose for assessing adverse tissue reactions because these
quantities were developed for stochastic (no threshold dose) effects. The Dose Criteria for tissue
effects is now stated as absorbed dose. Dose Criteria for stochastic effects continue to be given
as effective dose or equivalent dose to a specific organ.

8.1.2 <u>Ethical principles</u>

The NCRP System is based primarily on the ethical principles (Section 3): 3744

- beneficence,
- non-maleficence,
- autonomy, and
- justice.

3745

3746

3747

3748

3749

3759

3760

3765

The uncertainties associated with establishing the relationship between radiation dose and
adverse stochastic health effects at radiation doses approaching those delivered by the ubiquitous
natural background radiation have resulted in a fifth principle, that of precaution, being added to
the NCRP System. Thus, the recommendations continue to be based on the radiation dose-effect
model termed linear-no-threshold (LNT) for exposure to doses above approximately 1 mSv.

3756Recommendation: The NCRP System continue to be based on the LNT model to describe3757the dose-effect relationship for stochastic adverse health effects.3758

8.2 Tissue Reactions

Recommendations are given in this section for Dose Criteria related to exposure of the skin and
extremities, and the lens of the eye for planned and existing exposure situations (Sections 8.2.1
and 8.2.2). Special considerations are necessary for occupational exposures during emergency
situations, which are covered in Section 8.2.3.

3766 **8.2.1** <u>Skin, Including Extremities</u> 3767

Both NCRP (1993) and ICRP (2007a) have stated that discrete limits are necessary to protect 3768 3769 localized areas of skin including the extremities against tissue reactions because these tissues will not necessarily be protected by limits on effective dose. The recommended limits were given 3770 3771 in equivalent dose because, as explained by ICRP (2007a), "the relevant RBE values for the 3772 deterministic effects are always lower than w_R values for stochastic effects. It is, thus, safely 3773 inferred that the dose limits provide at least as much protection against high-LET radiation as against low-LET radiation". NCRP (1993a) and ICRP (1991b) recommended that for 3774 occupational exposure the annual limit be set at 500 mSv. This recommendation was reaffirmed 3775 by ICRP in Publication 103 (ICRP, 2007a), which specified that the limit applied to the 3776 equivalent dose averaged over 1 cm² area of skin regardless of the area exposed. ICRP (2007a) 3777 3778 also provided a recommended annual limit for public exposure of 50 mSv.

3780 3781	NCRP (2001b) has recommended a somewhat different approach to assessing skin dose relevant to radiation protection. Following a detailed report on biological effects for "hot particles" on the
3782 3783	skin (NCRP, 1999) the Council reassessed its recommendation for skin exposures.
3784 3785	The Council then made the following recommendation (NCRP, 2001b):
3786	"For skin, limitation of occupational radiation exposure from external sources be based
3787	on ensuring that irradiation from any source would not be expected to result in
3788	breakdown of skin barrier function with the consequent possibility of infection. The
3789	absorbed dose in skin at a depth of 70 µm from any external source of irradiation be
3790	limited to 0.5 Gy (500 mGy) averaged over the most highly exposed 10 cm ² of skin.
3791	This can be viewed as a per-irradiation event limit so long as the exposed areas of skin do
3792	not overlap in such a way that the total absorbed dose to the most highly exposed 10 cm^2
3793	of skin exceeds the limit during a given year. In the event that the areas of exposed skin
3794	overlap, then the limit applies to the calendar year, consistent with the annual general
3795 3796	skin limit of 0.5 Gy y^{-1} , rather than to the individual events."
3797	If it is necessary to apply the skin limit to high-LET radiations, the Council recommends the
3798	approach taken in NCRP Report No. 132 (NCRP, 2000) in which the absorbed dose is multiplied
3799	by the biological effectiveness of the radiation to obtain a radiation-weighted absorbed dose (in
3800	gray). This may then be compared to the limit expressed in gray. Values of biological
3801 3802	effectiveness for the various high-LET radiations are given in Table 8.4.
3803	It is not likely that radiation exposure outside of the occupational setting or certain medical
3804	procedures will approach any of the threshold doses cited in Table 6.3. Consequently NCRP
3805	makes no recommendation of Dose Criteria related to exposure of the skin and extremities for
3806 3807	members of the public.
3808	Recommendation: For planning and dose control during operations the absorbed Dose
3809	Criterion in skin at a depth of 70 µm from any external source of irradiation be 0.5 Gy (500
3810	mGy) averaged over the most highly exposed 10 cm ² of skin.
3811	
3812	Recommendation: There be no Dose Criteria recommended for the skin for exposure of the
3813	public.
3814	
3815 3816	8.2.2 Lens of the Eye
3817	NCRP has determined that it is prudent to reduce the current recommended annual lens of the
3818	eye occupational absorbed Dose Criterion to 50 mGy (NCRP, 2016a). If it is necessary to apply
3819	the recommended lens Dose Criterion to high-LET radiation, NCRP recommends the approach
3820 3821	described in Section 8.2.1 for skin exposures.
3822	Recommendation: The annual absorbed Dose Criterion for occupational exposure to the
3823	lens of the eye be 50 mGy.
3824	· · ·
3825	Recommendation: The annual absorbed Dose Criterion for members of the public lens of
3826	the eye exposure be 15 mGy.
	· - ·

3828 3

3828	Table 8.4 Biological effectiveness values for converting absorbed dose in tissue (gray) to
3829	radiation-weighted absorbed dose in tissue (gray) for tissue reactions (adapted from ICRP,
3830	<u>1989).</u> ^a
3831	

Radiation Type	Recommended Biological Effectiveness Values ^b	Range ^b
1 to 5 MeV neutrons	6.0 ^b	(4-8)
5 to 50 MeV neutrons	3.5 ^b	(2-5)
Heavy ions (helium, carbon, neon, argon)	2.5 ^c	(1-4)
Proton >2 MeV	1.5	

3832

3833 ^aRBE values for late tissue reactions are higher than for early effects in some tissues and are influenced by the doses used to determine the RBE. 3834

^bThere are not sufficient data on which to base RBE values for early or late effects induced by 3835

neutrons of energies <1 MeV or greater than about 25 MeV. However, based on the induction of 3836

chromosome aberrations, using 250 kVp x rays as the reference radiation, the RBE for neutrons 3837

<1 MeV are comparable to those for fission spectrum neutrons. It is reasonable to assume that 3838

3839 the RBE values for >50 MeV will be equal to or less than those for neutrons in the 5 to 50 MeV 3840 range.

^cThere are few data for the tissue reactions of ions with a $\underline{Z} > 18$ but the RBE values for iron ions 3841

 $(\underline{Z} = 26)$ are comparable to those for argon. Based on the available data a value of 2.5 for the 3842

RBE of heavy ions is reasonable. One possible exception is cataract of the lens of the eve 3843

because high RBE values for cataracts in mice have been reported. 3844

3879

3883

3847 8.2.3 <u>Acute Organ Effects</u> 3848

NCRP CC 1

Draft of April 2016

The principal organ effects that could lead to serious injury or death from radiation exposure are 3849 given in Table 8.5. ICRP has established a maximum value for its reference level of 100 mSv. 3850 Further ICRP stated, "Exposures above 100 mSv incurred either acutely or in a year would be 3851 justified only under extreme circumstances, either because the exposure is unavoidable or in 3852 exceptional situations such as the saving of life or the prevention of a serious disaster" (ICRP, 3853 2007a). Nevertheless, in footnotes b and c associated with Table 8.3 ICRP stated, "In exceptional 3854 situations, informed volunteer workers may receive doses above this band (above 100 mSv) to 3855 3856 save lives, prevent severe radiation-induced health effects, or prevent the development of 3857 catastrophic conditions." and, "Situations in which the dose threshold for tissue reactions in 3858 relevant organs or tissues could be exceeded should always require action." Within that framework, guidance can be given for specific emergency situations. 3859 3860 The Council has made specific recommendations related to emergency situations in NCRP 3861 Report No. 165 (NCRP, 2010a). NCRP has not recommended a dose limit for emergency 3862 responders performing time-sensitive, mission critical activities such as lifesaving. Instead, the 3863 Council recommended that decision dose points (Dose Criteria) be established based upon 3864 operational awareness and mission priorities. A 0.5 Gy decision absorbed Dose Criterion was 3865 recommended to keep an emergency responder's individual dose from unintentionally surpassing 3866 1 Gy, below which clinically-significant early health effects are not likely to occur. 3867 3868 Recommendation: For planning and dose control during operations the absorbed Dose 3869 3870 Criterion for exposure to a significant portion of a critical organ, such as active bone marrow, be 1 Gv. 3871 3872 3873 Recommendation: For dose control during operations the absorbed Dose Criterion for 3874 exposure of the whole body be 0.5 Gy for occupationally exposed individuals engaged in 3875 critical emergency situations. 3876

Recommendation: For planning and dose control during operations the absorbed Dose
Criteria for exposure of the lens of the eye and skin be adjusted accordingly.

Recommendation: In exceptional situations, informed volunteer workers may receive doses
 above these Dose Criteria to save lives, prevent severe radiation-induced health effects, or
 prevent the development of catastrophic conditions.

The recommendations for annual occupational absorbed Dose Criteria for the various tissue reactions for planned, emergency and existing exposure situations are summarized in Table 8.6.

3888 3889 Table 8.5. --- Estimates of the threshold doses for mortality^a in adults exposed to acute irradiation (adapted from Table 4.5 in ICRP, 2012).

Absorbed Dose^b Resulting in Effect (Mortality) Organ/Tissue Time to Develop Effect Approximately 1 % Incidence for an Acute Exposure (Gy) Bone marrow syndrome Without 30–60 d Bone marrow ~1 good medical care With medical care 30-60 d 2-3 Bone marrow Gastrointestinal syndrome Without medical care Small intestine 6–9 d ~6 6–9 d With conventional Small intestine >6 medical care Pneumonitis – mean 1-7 months 7-8 Lung lung dose Cardiovascular Heart >10-15 y ~0.5 disease – whole-body exposure Cerebrovascular Carotid artery >10 y ~0.5 disease

3890

3891 ^a Some of these diseases may not be fatal, if good medical care or biological response modifiers 3892 are used. In the cases of cardiovascular disease and cerebrovascular disease, from the evidence currently available, the values given here are also assumed to apply to morbidity from these 3893 diseases.

3894

^b Most values rounded to nearest 1 Gy; ranges indicate area dependence for skin and differing 3895 medical support for bone marrow. 3896

NOT TO BE DISSEMINATED OR REFERENCED

3898 3899	Table 8.6 Recommendations for annual occupational absorbed Dose Criteria for tissue reactions (Gy).				
3900	Exposure Situation				
-	Planned	Emergency	Existing	Critical Organ	
-	0.05	1.0	0.05	Active bone marrow	
	0.05	0.5	0.05	Total body	
	0.05	1.0	0.05	Crystalline lens of the eye	
	0.5	1.0	0.5	Localized areas of the skin	
	0.5	1.0	0.5	Hands and feet	

Table 8.6 D. dati 1.04 wheed Do se Criteria for tie f .1

3902	8.3 Stochastic Effects
3903	The Council has reviewed the estimated risks for radiation exposure and the uncertainties in
3904	these risk estimates. As a result the Council has determined that there is no basis for changing the
3906	fundamental ICRP (2007a) recommendations for controlling doses (based on stochastic effects)
3907	as expressed in Table 8.3. The differences are that the Council does not use the ICRP
3908	terminology of dose constraints and reference levels, but has established a single general term,
3909	individual effective Dose Criteria, for optimization and control to apply adequate protection for
3910	various situations. The Council has retained its basic recommendations for restriction of annual
3911	effective dose (NCRP, 1993a), but has placed those recommendations within the three exposure
3912	situations (planned, emergency and existing.) using the flexibility provided by ICRP (2007a) as
3913	stated in footnotes b and c to Table 8.3.
3914	
3915	It should be noted that the recommended dose criteria depend upon the exposure situation. When
3916	the exposure can be reasonably expected to be under the control of the party responsible for the
3917	radiation source causing the exposure, the recommended dose criteria are more restrictive than in
3918	emergency or existing exposure situations in which the source of the exposure is not
3919	controllable. However, in all situations the recommended dose criteria represent adequate
3920	protection within the NCRP System.
3921	The dose recommendations, based on the health detriment related to stochastic effects, for
3922	occupational, public and medical exposures are discussed for each of the three exposure
3923	situations in Sections 8.4 through 8.6. Summaries of the recommended dose criteria for
3924	occupational exposure are given in Table 8.7, and for exposure to members of the public, to
3925	comforters and caregivers, and to medical research volunteers are given in Table 8.8.
3926	9 4 Diama di Francesco Sitera tian
3927	8.4 Planned Exposure Situation
3920	8 4 1 Occupationally Exposed Individuals
3930	or the <u>occupationally Exposed individuals</u> .
3931	Occupational exposure is discussed in Section 2.2.1. The Council continues to endorse the
3932	annual effective dose recommendation of 50 mSv for occupationally exposed individuals stated
3933	in NCRP Publication No.116 (NCRP, 1993a) for planned occupational exposure.
3934	
3935	Recommendation: For planning and design of radiation protection the annual effective
3936	Dose Criterion for optimization be 50 mSv.
3937	D raviously NCDD (1002a) recommended that the sumulative lifetime does for an individual not
3030	exceed 10 mSy multiplied by the individual's age. The Council no longer recommends a limit on
3939	the cumulative lifetime dose for an individual Instead the Council recommends that for
3941	occupational exposure the average annual effective Dose Criterion for control for an individual
3942	be 20 mSv over any consecutive 5 y period.
3943	5 51
3944	Recommendation: During operations the Council recommends the average annual
3945	effective Dose Criterion for control for an individual be 20 mSv.

NOT TO BE DISSEMINATED OR REFERENCED

3946

Table 8.7 --- Recommendations for occupational exposure.

3947

Exposure Situation	Purpose	Individ	ual Effective Dose (mSv)	e Criteria
		Planned	Emergency	Existing
<u>General</u> Annual	- Optimization Control	50 20	500 50	50 20
Pregnancy Annual	Control (during pregnancy)	5	5	5
<u>Minors under 18 y</u> Annual	Control	1	20	5
<u>Negligible</u> <u>individual dose</u> Annual	Optimization	0.01	0.01	0.01

3950Table 8.8 --- Recommendations for exposure to members of the public, to comforters and3951caregivers, and to medical research volunteers.

Exposure Situation	Purpose	Individ	ual Effective Dose (mSv)	Criteria
		Planned	Emergency	Existing
General	-			
Annual	Optimization For the first year of occupancy (existing)	5	20	20
	Control For continued occupancy (existing)	1	20	- 5
Comforters and				
caregivers				
Annual-adults	Optimization	5	-	-
(not pregnant) Annual-adults (pregnant)	Optimization	1	-	-
Medical research				
volunteers				
Societal benefit			-	-
minor	Optimization	< 0.1		
intermediate	Optimization	0.10-01	-	-
moderate	Optimization	1 - 10	-	-
substantial	Optimization	>10	-	-
Negligible				
individual dose				
Annual	Optimization	0.01	0.01	0.01

As in the past, the Council continues to recommend that minors who are employed in an 3953 occupation in which exposure to radiation is possible be treated as members of the public for 3954 radiation protection purposes. 3955 3956 3957 Recommendation: For dose control during operations the annual effective Dose Criterion 3958 for individuals under the age of 18 y be guided by the recommendations for exposure to the public. 3959 3960 3961 As discussed in Section 8.1 the Council reaffirms its NID as the effective dose at which efforts to 3962 reduce radiation exposure to the individual may not be warranted (NCRP, 1993a). 3963 3964 Recommendation: An annual effective dose of 0.01 mSv be considered a Negligible 3965 Individual Dose (NID) per source or practice 3966 8.4.1.1 Special Considerations and Dose Criteria for Medical Staff. In some circumstances it 3967 may be necessary for a health care worker to exceed the recommended annual effective Dose 3968 Criterion in order to save a patient's life or to prevent severe and irreparable injury to a patient. 3969 As an example, Table 5.3 in NCRP (2010) describes situations where this may be necessary in 3970 3971 fluoroscopically guided interventional procedures. In such situations policies and procedures should be in place so that in the event of a reasonably 3972 foreseeable time-critical urgent or emergent situation, advanced provision exists for exceeding 3973 3974 the annual occupational effective Dose Criterion. However, the average annual effective Dose 3975 Criterion for an individual of 20 mSv over any consecutive 5 y period still applies. 3976 8.4.1.2 Embryo and Fetus. The sensitivity of the embryo and fetus for both mental retardation 3977 and cancer should be considered in all situations involving irradiation of an embryo or fetus 3978 (NCRP, 1993a). This is a special consideration for occupationally exposed pregnant workers. 3979 3980 For the risk of cancer induction from prenatal exposure, ICRP (2007a) indicates that it is prudent 3981 to assume that the risk of induction of childhood solid tumors is similar to that of leukemia and 3982 the risk of cancer later in life is similar to that of childhood irradiation and is, at most, about 3983 three times that of a population as a whole (ICRP, 2007a). ICRP (1991b) indicated that while 3984 there is no need to differentiate between male and female occupational exposure, when a worker 3985 is known to be pregnant, it is appropriate that a higher more stringent standard of protection is 3986 afforded to the fetus. ICRP (2007a) also indicated in the 2007 recommendations (Publication 3987 103, paragraph 299) that "prenatal exposure would not be a specific protection case, i.e. would 3988 not require protective actions other than those aimed at the general population". 3989 3990 3991 This situation can be thought of as occupational exposure to the mother while the unborn child is treated as a member of the public. In the context of occupational exposure consideration must be 3992 given to the right of the mother to retain her job. The ethical principles of autonomy and justice 3993 (Section 3.2.2) permit the mother to accept risks for her unborn child. In the context of exposure 3994 to a member of the public, exposure to the unborn child would normally be governed by the 3995

3996 Dose Control criteria for planned exposure (Section 8.4.2). Within the framework presented in

2007	Table 8.3, a reasonable compromise would be to consider the exposure to the unborn child as an
2000	infraquent occurrence and establish the Dose Criterion for the program worker at 5 mSy for the
2000	nariod of her pregnancy. This is a slight change from the previous NCRP (1003a)
3999	recommendation of an aguivalant dasa agual to 0.5 mSv par month to the davalaring ambrua
4000	and fatus, and the programmer is dealared
4001	and refus, once the pregnancy is declared.
4002	December 1 for East least a december 1 decime and the second for the second off of the
4003	Recommendation: For planning and dose control during operations the annual effective
4004	Dose Criterion for an occupationally-exposed pregnant worker be 5 mSv for the period of
4005	ner pregnancy. Exposure control based on this Dose Criterion should begin when the
4006	pregnancy is declared
4007	
4008	This recommendation reflects the need to limit the total lifetime risk of leukemia and other
4009	cancers in individuals exposed in utero. At doses below the recommended Dose Criterion the
4010	risk of all tissue reactions is expected to be negligible. It also reflects the fact that monitoring the
4011	dose to the mother during her pregnancy is more practical than attempting to determine the dose
4012	to the embryo/fetus.
4013	
4014	8.4.2 Exposure of the Public
4015	
4016	The public is familiar with the effective dose value of 1 mSv as the annual dose limit under
4017	current regulations. NCRP (1993a) recommended this value as a public dose limit for continuous
4018	or frequent exposures. However, NCRP also recommended a maximum annual effective dose
4019	limit of 5 mSv for infrequent exposures. ICRP (2007a) establishes an upper dose constraint of 20
4020	mSv for members of the public under certain circumstances.
4021	
4022	It is prudent and practical for NCRP to establish the effective Dose Criterion for control for
4023	planned exposure situations at 1 mSv y ⁻¹ for members of the public. In all situations a process of
4024	optimization shall be applied to reduce the actual exposures below the recommended Dose
4025	Criterion consistent with the ALARA principle.
4026	
4027	The <u>Dose Criterion for control</u> for a planned exposure situation should be the design objective
4028	for any individual source of radiation exposure. The design objective may be reduced below 1
4029	mSv y ⁻¹ based on the application of the ALARA principle. Periodic estimates of exposures to
4030	members of the public should be made to confirm that the design objective is being met. This
4031	should assure that for possible exposure to multiple sources, the exposure of any individual
4032	would likely not exceed the Dose Criterion for optimization of 5 mSv in any one year.
4033	
4034	Recommendation: For planning and design of radiation protection systems the annual
4035	effective Dose Criterion for optimization be 5 mSv.
4036	
4037	Recommendation: For dose control during operations the annual effective Dose Criterion
4038	for control related to any individual source of radiation be 1 mSv.
4039	v

4049

4066

4073

4077

Information regarding potential radiation effects on children has become clearer over the last
decade, especially with regard to specific tumor types and the temporal pattern of risk expression
for different tumors (Section 6.2). However, the overall risk coefficient has not changed
significantly since the Council's prior recommendation (NCRP, 1993a). The greater sensitivity
of children was already factored into that recommendation. The Dose Criteria for public
exposure provide responsible consideration for the sensitivity of infants and children, as well as
the developing fetus for all exposure situations.

4048 8.4.3 Exposure Related to Certain Medical Activities

Certain medical procedures and research activities involve radiation exposure to individuals who 4050 4051 are not patients, but rather members of the public. Because of the benefits of these exposures and 4052 the possibility that they could expose an individual to an effective dose that exceeds the Dose Criteria for control for planned exposures, special consideration is required. These individuals 4053 can be grouped into two classifications: Comforters and Caregivers, and Human Studies 4054 Research subjects. ICRP (2007a) recommended that the dose constraint for caregivers be 5 mSv 4055 per episode. The recommendation for the dose constraint for volunteers for biomedical research 4056 is based on the expected benefit to society and ranges from less than 0.1 mSv to greater than 10 4057 4058 mSv. 4059

8.4.3.1 Comforters and Caregivers. ICRP (2007a) and NCRP (2006) addressed radiation
exposure to comforters and caregivers, particularly family members. These exposures are
infrequent and normally of low dose and short-term. For example, a parent may elect to stay by a
child's side during an imaging procedure, such as a CT scan or a FGI procedure. This is
generally permissible for a family member. Appropriate radiation protection measures shall be
employed, such as shielding with lead aprons or screens.

Procedures involving administration of radionuclides may result in exposure of the patient's
family members and friends. These exposures occur infrequently and merit special consideration.
ICRP (2007a) recommends a dose constraint of 5 mSv per episode. Based on NCRP (2006) the
Council recommends an annual effective Dose Criterion of 5 mSv be applied for adult members
of the family of a patient, other than pregnant women. An annual effective Dose Criterion equal
to 1 mSv is recommended for pregnant women and children.

4074Recommendation: For planning the annual effective Dose Criterion for control be 5 mSv4075for adult members of the family of a patient, other than pregnant women, and 1 mSv for4076pregnant women and children.

Hired caregivers such as healthcare aides or nurses are not generally considered to be
occupationally exposed. The radiation exposure they receive in the course of caring for their
patients should reflect effective Dose Criteria recommended for members of the public in
planned exposure situations.

For the purpose of applying radiation exposure Dose Criteria, other patients, visitors to the medical facility, and staff who are not specifically trained in radiation safety should be

	Dian of April 2010
4085	considered members of the public and their dose restricted within the recommended effective
4086	Dose Criteria for planned exposure.
4087	
4088	Recommendation: The effective Dose Criteria for hired caregivers, other patients, visitors
4089	to the medical facility, and staff who are not specifically trained in radiation safety reflect
4090	Dose Criteria recommended for members of the public in planned exposure situations.
4091	
4092	8.4.3.2 <u>Human Studies Research</u> . The radiation dose a human subject receives specifically
4093	through participation in a research protocol, which would not have been received otherwise, is
4094	considered separately from that received in the normal course of medical treatment.
4095	
4096	The use of ionizing radiation modalities must be justified and should be assessed against the
4097	potential use of other modalities that utilize nonionizing radiation (such as ultrasound and
4098	magnetic resonance imaging), to minimize radiation exposure to the human subject. A key
4099	consideration in the process of justification is whether or not the radiation study adequately
4100	assesses a given clinical trial measure, and whether it does so while delivering the lowest
4101	reasonable radiation dose.
4102	As in standard medical case investing studies in a measure much subtract through the autimized to
4103	As in standard medical care, imaging studies in a research protocol should be optimized, to
4104	designers and Institutional Daview Deard reviewers must consider:
4105	designers and institutional Review Board reviewers must consider.
4100	• whather or not the clinical trial measures are appropriate and are affectively obtained:
4107	 whether or not the clinical trial measures are obtained using the lowest radiation dose that
4100	• whether of not the enhicit that measures are obtained using the lowest radiation dose that is reasonably achievable: and
4105	 whether the estimated radiation risk is appropriate within the context of other protocol
4110	risks and any potential benefits
4112	Tisks and any potential benefits.
4113	ICRP (2007a) recommends effective doses to volunteers from biomedical research, if the
4114	research is a benefit to society be restricted to a range from <0.1 mSv for minor benefit to >10
4115	mSv for substantial benefit. Table 8.8 contains recommendations based on ICRP (2007a) Table
4116	8.
4117	
4118	In the United States, for clinical research involving radioactive drugs conducted under the
4119	auspices of a Radioactive Drug Research Committee, specific limitations apply under Federal
4120	Regulations [21 CFR 361.1(b)(3)] (FDA, 2015). Subjects must receive the smallest radiation
4121	dose with which it is practical to perform the study without jeopardizing the scientific benefits of
4122	the study. Under no circumstances can the radiation dose to an adult subject from a single study,
4123	or cumulatively from a number of studies conducted within 1 y, exceed the limits shown in Table
4124	8.9. For subjects under 18 y of age, the radiation dose cannot exceed 10 % of the adult values.
4125	(NCRP recommendations will be based on the report of SC 4.7 and PAC 4.)
4126	

4127

Comment [KK108]: NCRP recommendations will be based on the report of SC 4.7 and PAC 4.

4128 Table 8.9 --- Limits for conducting Radioactive Drug Research Committee studies on adult 4129 research subjects.^a

4130

Portion of Body	Dosing	Dose
Whole body	Single dose	30 mSv (effective dose)
	Annual and total dose commitment	50 mSv (effective dose)
Active blood-forming organs, lens of the eye, gonads	Single dose	30 mGy (organ dose)
	Annual and total dose commitment	50 mGy (organ dose)
Other organs	Single dose	50 mGy (organ dose)
	Annual and total dose commitment	150 mGy (organ dose)

4131 4132

4133

4134 4135

4136

4140

4142

8.5 Emergency Exposure Situation

^aAdapted from 21 CFR 361.1(b)(3) (FDA, 2015), separating specific organ dose from the whole-

Following an accident or malicious event that introduces a source of radiation, the radiation dose
may be rapidly changing and is not under any controls. Protection may be based upon controls
placed on individuals and individual actions.

body dose and basing the organ dose limits on the tissue reactions (Section 8.2).

4141 8.5.1 Occupationally Exposed Individuals

The first responders to an emergency must be considered as occupationally exposed. They may
be exposed to radiation dose rates that are much greater than those typically encountered in an
occupational setting. Consequently there is a potential for accumulating a high dose in a short
time. Under these conditions special considerations should be given to the Dose Criteria.
Guidance for dose control for first responders is given in NCRP Report No. 165 (NCRP, 2010a).

4148 4149 During the early response phase there may be individuals who need immediate rescue and 4150 evacuation to treat injuries and reduce the probability of fatalities. There also may be actions 4151 required to control the spread of the radiation source, prevent access to the area and limit the 4152 possibility of continuing exposure to high dose rates. Dose Criteria that are higher than those 4153 recommended for planned exposure situations should apply only to volunteers and should

4154 provide the flexibility needed for responders to accomplish these tasks.

4155

4179

4182

4189

NCRP (1993a) previously recommended, "Exposures during emergency actions that do not 4156 involve lifesaving should, to the extent possible, be controlled to the occupational dose limits. 4157 4158 Where this cannot be accomplished, it is recommended that a limit of 0.5 Sv effective dose and an equivalent dose of 5 Sv to the skin be applied." ICRP (2007a) recommends for life saving, 4159 "no dose restrictions if benefit to others outweighs rescuer's risk". For other urgent rescue 4160 operations the recommendation is 1,000 or 500 mSv and for other rescue operations, 100 mSv. 4161 NCRP (2010a) does not recommend a dose limit for emergency responders performing time-4162 sensitive, mission critical activities such as lifesaving. Rather the recommendation is made to 4163 adopt an absorbed dose of 0.5 Gy as a decision point at which the benefit of further exposure is 4164 evaluated. 4165 4166 4167 Dose control for life-saving and other urgent rescue activities should be based on the potential acute effects of radiation and specifically on preventing death of the responders by limiting the 4168 4169 absorbed dose to the active bone marrow. This can be done by selectively shielding a portion of 4170 the active bone marrow and by controlling the absorbed dose to the total body. For this purpose

the Dose Criteria for avoiding adverse tissue reactions (Table 8.6) should be applied.

4173 Recommendation: For operations in life-saving and other urgent rescue activities the 4174 effective Dose Criterion be 500 mSv.

4175
4176 For activities that do not involve life-saving and other urgent rescue actions, NCRP recommends
4177 that the Dose Criteria be based on adverse health outcomes of a stochastic nature and that the
4178 effective Dose Criterion be 0.5 Sv.

4180 Recommendation: During activities that do not involve life-saving and other urgent rescue 4181 activities the effective Dose Criterion be 0.5 Sv.

Following the immediate response, emergency operations may continue for some time. During this period the Dose Criteria should be based on those for a planned exposure situation and the recommended effective Dose Criterion is 50 mSv.

4186 4187 **Recommendation**

4187 Recommendation: For dose control the effective Dose Criterion be 50 mSv for extended
4188 activities during the emergency.

4190 **8.5.2** <u>Members of the Public</u>

4191
4192 During the emergency there is likely to be some possibility of controlling dose to members of the
4193 public by certain actions. These actions could include sheltering in place, evacuation, or
4194 distribution of radioprotective drugs. The beneficial effects of applying any of these controls
4195 should be evaluated and justified as quickly and completely as possible. Guidance for protection
4196 of the public in emergency situations is given in NCRP Report Nos. 138 (NCRP, 2001a) and 165
4197 (NCRP, 2010a). No dose limits are recommended.

NCRP (1993a) made no specific recommendation related to exposure to the public in emergency 4199 situations, or when the dose to individual members of the public might exceed the normal dose 4200 limits. Presumably the applicable limit was understood to be 5 mSv because the exposure would 4201 be infrequent. ICRP (2007a) states, "Reference levels for the highest planned residual doses in 4202 emergency situations are typically in the 20 mSv to 100 mSv band of projected dose." 4203 4204 4205 During the early stages of an emergency it will be extremely difficult to control and assess the dose to any individual member of the public. The Council accepts the statement of ICRP (2007a) 4206 concerning the range of doses estimated in emergency situations and recommends that the 4207 effective Dose Criterion for a member of the public be 20 mSv during the period of the 4208 4209 emergency. 4210 4211 Recommendation: For planning and dose control during emergency situations the effective Dose Criterion for optimization and control be 20 mSv for a member of the public. 4212 4213 **8.6 Existing Exposure Situation** 4214 4215 As discussed in Section 2.1, in an existing exposure situation there may be limited means to take 4216 any protective actions based on modifying the source itself, and the levels of exposure may not 4217 warrant urgent actions to achieve the objectives of radiation protection. 4218 4219 NCRP (1993a) did not define an existing exposure situation in Report No. 116. However, the 4220 Council did provide recommendations for remedial actions for naturally occurring radiation. This 4221 4222 is a limited case of an existing exposure situation. In this situation NCRP (1993a) recommended 4223 "that remedial action be undertaken when continuous exposures from natural sources, excluding 4224 radon, are expected to exceed five times the average, or 5 mSv annually". ICRP (2007a) 4225 recommends that reference levels for existing exposure situations should be set typically in the 1 mSv to 20 mSv band of projected dose. 4226 4227 Naturally Occurring Radioactive Material (NORM) poses unique challenges to The NCRP 4228 System because of the ubiquitous nature of the radioactive material, and the difficulties in 4229 providing protection by actions taken on the source. In general, action can only be taken on the 4230 pathways of exposure, or upon the presence and actions of individuals. Nevertheless, the 4231 fundamental approach of protection through optimization (the ALARA principle) with individual 4232 dose criteria can, and should be applied. 4233 4234 Because of the widespread nature of NORM in the environment, the exposure is usually 4235 considered to be an existing exposure situation. Human activities often change the prevailing 4236 circumstances of exposure, in some cases enhancing the concentration of NORM materials. It is 4237 4238 these circumstances that warrant particular attention from a radiation protection standpoint. 4239 Recommendation: There be a systematic, graded approach to NORM, based on 4240 4241 characterization of the exposure conditions, the level of dose received by individuals, and 4242 the possibilities for taking action to reduce exposures. 4243

NCRP CC 1 NOT TO BE DISSEMINATED OR REFERENCED Draft of April 2016 There also may be some instances of potential radiation exposure in areas that have been 4244 contaminated by activities that result in accidental or intentional release of radioactive materials. 4245 Potential exposure to the public may be elevated over the normal level expected from the 4246 4247 ubiquitous background radiation. In situations such as this remedial actions, which may involve active public participation, are taken to reduce this exposure. However, an elevated radiation 4248 4249 dose may exist for some time during this process. 4250 8.6.1 Radon and Naturally Occurring Radioactive Material 4251 4252 4253 High levels of radon may be found in both homes and in workplaces. In this situation the equivalent dose to the lung is the important radiation protection quantity. However, it is difficult 4254 4255 to determine on an individual basis and is not practicable to use for radiation protection. 4256 Consequently, a Criterion has been established for the radon concentration in air at 300 Bq m⁻³ (NCRP, 1993a; ICRP 2014). This represents an annual effective dose of 4257 approximately 20 mSv. This criterion applies to both occupational and public exposure. 4258 4259 In almost all cases, radon mitigation actions based on concentration will be sufficient, and further 4260 actions are generally not warranted under the optimization principle. 4261 4262 4263 Recommendation: Radon levels be assessed, and the Air Concentration Criterion be 300 4264 Bq m⁻³ 4265 **8.6.2** Occupationally Exposed Individuals 4266 4267 4268 In situations in which occupational exposure is being controlled, the contribution of radon should be included if it comprises more than 20 % of the total occupational effective dose. 4269 Organizations and regulatory authorities may choose to use the relevant requirements for 4270 occupational exposure, including monitoring and record keeping, when it is not possible to 4271 4272 maintain radon levels below the recommended concentration control target. 4273 4274 Recommendation: The contribution of radon should be included if it comprises more than 20 % of the total occupational effective dose. 4275 4276 4277 Many industrial applications may use materials that contain natural radioactivity, or processes that concentrate the natural radioactivity. In most of these cases, the radioactive materials are 4278 Comment [M109]: Cool edit not the subject of the industrial process. The possibilities for concentration and significant levels 4279 of dose have been seen, for example, filters for gas extraction activities. These industrial 4280 processes should be examined for the possible presence of radioactive materials, and an 4281 assessment made of concentrations and exposures. If necessary actions should be taken to 4282 control, and properly dispose of waste streams that contain radioactive materials, to prevent 4283 4284 exposure and possible environmental damage. The Dose Criteria for planning and control of occupational exposure under planned exposure situations apply. 4285

4287	Recommendation: The effective Dose Criteria for optimization and control of occupational
4288	exposure under planned exposure situations apply.
4289	
4290	Occupational exposure would occur during remedial actions to institute controls on exposure for
4291	an existing situation. Previous NCRP (1993a) recommendations imply that the limit for annual
4292	occupational dose applies in this situation. ICRP (2007a) applies its reference levels to
4293	occupational exposures. The Council recommends that the protection for occupational exposure
4294	in planned exposure situations be applied.
4295	
4296	Recommendation: For planning and design of a remedial action the annual effective Dose
4297	Criterion for optimization be 50 mSv.
4298	
4299	Recommendation: For dose control during operations the annual effective Dose Criterion
4300	101 condoi 101 an muividual de 20 mSv.
4301	967 Mambara of the Dublic
4302	3.0.2 <u>Members of the Public</u>
4303	Consistent with previous NCRP recommendations (NCRP, 1993a) and ICRP recommendations
4304	(ICRP 2007a) summarized in Table 8.3, the Council recommends that the effective Dose
4306	Criterion be 20 mSy in the first year following identification of the situation. The Council further
4307	recommends that the annual effective Dose Criterion be set at 5 mSy for later years
4308	
4309	Recommendation: For planning purposes the effective Dose Criteron for optimization for a
4310	member of the public be 20 mSv in the first year following identification of the situation.
4311	
4312	Recommendation: For dose control nurposes the annual effective Dose Criteron for control
4313	for a member of the public be 5 mSy for later years.
4314	
4315	
4316	References (Section 8)
4317	
4318	FDA (2015). Federal Regulations [21 CFR 361.1(b)(3)]
4319	http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=361.1 (accessed
4320	January 27, 2016) (U.S. Food and Drug Administration, Silver Spring, Maryland).
4321	ICRP (1989). Publication 58
4322	ICRP (1991b). International Commission on Radiological Protection. 1990 Recommendations of
4323	the International Commission on Radiological Protection, ICRP Publication 60, Annals of
4324	the ICRP 21 (1-3) (Elsevier Science, New York).
4325	ICRP (2007a). International Commission on Radiological Protection. The 2007
4326	Recommendations of the International Commission on Radiological Protection, ICRP
4327	Publication 103, Annals of the ICRP 37 (2-4) (Elsevier Science, New York).
4328	ICRP (2012). International Commission on Radiological Protection. ICRP Statement on Tissue

- Threshold Doses for Tissue Reactions in a Radiation Protection Context, ICRP Publication
 118, Annals of the ICRP 41 (1/2) (Elsevier Science, New York).
- ICRP (2014). Radiological Protection against Radon Exposure. ICRP Publication 126. Ann.
 ICRP 43(3).
- NCRP (1993a). National Council on Radiation Protection and Measurements. Limitation of
 Exposure to Ionizing Radiation, NCRP Report No. 116 (National Council on Radiation
 Protection and Measurements, Bethesda, Maryland).
- NCRP (1999). National Council on Radiation Protection and Measurements. Biological Effects
 and Exposure Limits for "Hot Particles," NCRP Report No. 130 (National Council on
 Radiation Protection and Measurements, Bethesda, Maryland).
- NCRP (2000). National Council on Radiation Protection and Measurements. Radiation
 Protection Guidance for Activities in Low-Earth Orbit, NCRP Report No. 132 (National
 Council on Radiation Protection and Measurements, Bethesda, Maryland)
- NCRP (2001a). National Council on Radiation Protection and Measurements. Management of
 Terrorist Events Involving Radioactive Material, NCRP Report No. 138 (National Council
 on Radiation Protection and Measurements, Bethesda, Maryland)
- NCRP (2001b). National Council on Radiation Protection and Measurements. Extension of the
 Skin Dose Limit for Hot Particles to Other External Sources of Skin Irradiation, NCRP
 Statement No. 9 (National Council on Radiation Protection and Measurements, Bethesda,
- Maryland).
 NCRP (2006). National Council on Radiation Protection and Measurements. Management of
 Radionuclide Therapy Patients, NCRP Report No. 155 (National Council on Radiation
- 4352 Protection and Measurements, Bethesda, Maryland).
- NCRP (2009) National Council on Radiation Protection and Measurements. Ionizing Radiation
 Exposure to the Population of the United States, NCRP Report No. 160 (National Council on
 Radiation Protection and Measurements, Bethesda, Maryland).
- NCRP (2010a) National Council on Radiation Protection and Measurements. Responding to a
 Radiological or Nuclear Terrorism Incident: A Guide for Decision Makers, NCRP Report
 No. 165 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
- NCRP (2010b) National Council on Radiation Protection and Measurements. Radiation Dose
- Management for Fluoroscopically-Guided Interventional Medical Procedures, NCRP Report
 No. 168 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
 NCRP (201X) Report of SC 1-23.

4364 9. Protection of the Environment 4365 The principal aim of NCRP in Section 9 is to provide both a factual basis and coherent 4366 4367 philosophy from which to establish a framework for an appropriate level of protection of the environment against the detrimental effects of radiation exposure. These recommendations are 4368 consistent with other radiation protection recommendations of NCRP in that they are intended to 4369 prevent the occurrence of adverse radiation-induced effects while still enabling those activities 4370 which provide benefit to society from such exposures. 4371 4372 4373 Within the United States, radiologic impacts to the environment because of human activities have resulted from past intentional or accidental releases and continue through periodic regulated 4374 4375 intentional releases of radioactive substances. These impacts have been modest in almost all 4376 cases. However, NCRP in its advisory capacity has an obligation to provide guidance to regulators, industry, and the public on radiation doses and their effects to nonhuman biota. This 4377 4378 guidance is intended to provide a defensible technical foundation for those organizations and 4379 individuals tasked with the responsibility of assessing radiologic impacts on the environment. 4380 4381 NCRP recognizes that the ultimate determination of what constitutes an appropriate or allowable environmental impact requires much more than adherence to a single numerical value of dose 4382 rate. Particularly in environmental assessments, many factors need to be considered, such as the: 4383 4384 presence of threatened or endangered species; 4385 . 4386 • spatial extent of the impact; 4387 abundance and diversity of species present; necessity of the action to be taken; and 4388 • 4389 • inherent value of the environment being evaluated. 4390 4391 Those considerations are, appropriately, outside the purview of NCRP. 4392 4393 9.1 Philosophical Basis of Environmental Radiation Protection 4394 The NCRP has long supported the philosophy that radiation protection is more than simply the 4395 4396 development of limits. It requires justification for exposure and optimization of dose such that potential harm is minimized (Lindell, 1966; NCRP, 1993). Radiation protection of the 4397 environment readily fits within this philosophical framework (Higley, 2016). In the last 20 y 4398 there has been considerable effort expended globally to examine the philosophical basis of 4399 4400 environmental protection in an effort to develop a consensus on what constitutes an appropriate 4401 framework for protection (Dicus, 2003; Pentreath, 1999; Robinson, 2003). Most recent

- recommendations focus on environmental endpoints which impact population maintenance, such
 as reproductive success (Andersson <u>et al.</u>, 2008; ICRP, 2007a; UNSCEAR, 2008).
- 4404

the most vexing issue in regard to protection of the environment or protection of non-human species. which are not necessarily the same thing, is that we haven't clarified our objective. For human protection, we have been pretty clear that the objective is to prevent deterministic effects and minimize (ALARA) stochastic effects for individuals sorry for the "old" terminology. Can we be more specific for this section in regard to our views on individual protection versus some collective level of protection (e..g., community, species, or habitat)? think that this would help convey a better understanding of why dose control targets are not recommended and why the use of screening criteria is practical and protective (i.e., in meeting the defined objective).

4405 4406

4412

9.2 Scientific Basis for Radiation Protection Guidance

Past efforts on environmental radiation protection assumed that humans were the most
radiosensitive species, and that by protecting them all other organisms would be protected,
although not necessarily at the level of the individual (ICRP, 1977). For more than 20 y it has
been recognized that while humans are radiosensitive, other organisms are as sensitive, or very
nearly so (Rose, 1991).

Unlike plants and animals, humans are able, under most circumstances, to intentionally limit 4413 their radiation exposure by controlling pathways or duration of exposure. The accident at 4414 Fukushima-Daiichi has been evaluated by several international organizations, including the 4415 4416 World Health Organization (WHO), the United Nations Scientific Committee on the Effects of 4417 Atomic Radiation (UNSCEAR) and International Atomic Energy Agency (IAEA). WHO has concluded that the radiation doses received by the Japanese population following the accident, 4418 4419 while substantial, are unlikely to result in measurable excesses of cancer in the human population 4420 (WHO, 2012). However, in contrast, a recent publication has matched field observations of impacts on birds in the vicinity of Fukushima with a rigorous assessment of dose (Garnier-4421 Laplace et al., 2015). This assessment has concluded that dose rates and doses experienced by 4422 4423 numerous avian species at Fukushima were within the range where adverse population level are expected to occur. Because pathways of exposure and dose, even within the same environment, 4424 differ markedly amongst organisms, steps taken to limit human exposures may not restrict doses 4425 of nonhuman biota to levels that would prevent adverse population effects, particularly in the 4426 wild (Higley, 2016). 4427

4428

Radiation protection of the environment, as a concept distinct from protection of people has been 4429 vigorously debated for more than 20 y (Higley, 2016). ICRP, UNSCEAR, IAEA and many 4430 governments have reviewed the radiobiological data, recommended screening criteria, and 4431 4432 written legislation or guidance to address this concern. Consequently, systems for radiation 4433 protection of the environment have been widely developed and implemented both within and outside the United States. A comparison of recent recommendations is shown in Table 9.1. 4434 DOE, in the absence of guidance from advisory bodies, and after considerable stakeholder 4435 consultation, issued a technical standard (DOE, 2002) which explicitly addressed radiation 4436 protection of the environment. In addition to setting radiation protection criteria, the DOE 4437 technical guidance included a graded approach to screening sites for impact. DOE also 4438 commissioned the creation of computer software to streamline the assessments (RESRAD, 4439 2016; this system has been used at DOE facilities for more than a decade. 4440 4441

ICRP has recommended a framework for consideration of environmental radiation protection 4442 (ICRP, 2008). ICRP published its derived consideration reference levels (DCRLs) (ICRP, 4443 2007a), dose conversion factors (ICRP, 2008), and guidance for application of the ICRP 4444 methodology (ICRP, 2014). Within the European Union, both guidance and computational tools 4445 4446 have been broadly applied (Andersson et al., 2009; Brown et al., 2008). None of these systems of guidance have proven particularly burdensome, and they have provided regulators with 4447 concrete, defensible, and scientifically based criteria from which to conduct assessments of 4448 4449 radiologic impact.

4450

4451

Table 9.1	Comparison of reported effects and absorbed dose-rate screening levels for
	<u>nonhuman biota</u> . ^a

Organization	Dose Rate (mGy d ⁻¹)	Criteria	Reference
DOE	1	Recommended dose rate criteria for terrestrial mammals	DOE (2002)
ICRP	0.1	Lower level, DCRL ^b , mammals	ICRP (2008)
UNSCEAR	2	Lowest reported value for chronic ecosystem level effects	UNSCEAR (2008)
EU Protect	0.2	Screening level for all species set at a predicted no effects dose rate	Andersson <u>et al.</u> (2009)
UK	0.1	Screening level	
Russia (suggested)	0.07	Long-lived warm blooded mammals	Sazykina and Kryshev (1999)
EU Protect	0.05	Vertebrate screening level	Andersson <u>et al.</u> (2009)

^a Dose rates as published are in a variety of units. Units have been standardized and reported to one significant figure for clarity. ^b DCRL is derived consideration reference level.

4452

4455	
4454	9.3 Recommendations
4455	
4456	Dose limits per se are not appropriate in the context of environmental protection, as it is not
4457	feasible to monitor individual organism dose against a limit. However, as previously noted,
4458	scientific data provide an indication of the levels of absorbed dose rate likely to cause
4459	measurable impacts in nonhuman species. Bradshaw et al. (2014) has provided a qualitative
4460	comparison of current radiation guidance and dose rates resulting from anthropogenic and
4461	natural sources in comparison with measured, predicted and observed effects (Figure 9.1).
4462	Although not shown on Figure 9.1, the DOE recommendations would align with the upper level
4463	of the ICRP recommendations.
4464	
4465	While dose limits are not appropriate for environmental protection, NCRP believes that
4466	establishing screening values is an appropriate task for this advisory body. Consequently, NCRP
4467	acknowledges that the current science on radiation impacts on organisms and the environment
4468	warrants a screening level of 0.1 mGy d ⁻¹ . Below this level, no additional analysis should be
4469	considered. Conversely, absorbed dose rates exceeding this level may require additional
4470	evaluation.
4471	
4472	Recommendation: An absorbed dose criterion for screening of 0.1 mGy d ⁻¹ be established
4473	for organisms and the environment.
4474	
4475	
4476	

Comment [AA(111]:

Ansari ... It is clear how this section's discussion and this recommended screening level apply to Existing Exposure situations. But do they apply to other exposure situations? If not, we should specify it. But if the principles of protection for non-human species do apply to other exposure situations, it would make this section even more helpful if we can elaborate on how:

- For Emergency Situations, a good example from Fukushima is mentioned in the text – doses to avian species high enough to expect tissue reactions. We also know the dreadful consequences (not directly due to radiation) for mammalian farm animals that were left behind as people were evacuated. Should we comment on how these factors should be balanced in emergency response situations? How do we allocate scarce resources when taking action to reduce dose or assist non-human species may mean taking resources away from humans. [of course related to ethics as well] But in practice, do we have a recommendation for these situations or a practical guide to follow?

 In a Planned Exposure Situation (although I can't think of a good example at this moment), dose rates to non-human species may exceed this screening level for a period of time. Accumulated dose to non-human species can also exceed dose limits for humans because of protection measures humans take and non-humans can't. How should we approach those situations?



- 44814482 Fig. 9.1. A qualitative comparison of radiation guidance and doses from anthropogenic and
- 4483 natural sources in comparison with measured, predicted and inferred effects (Bradshaw et al.,
- **2014**).

4486 **References** (Section 9)

- ANDERSSON, P., BEAUGELIN-SEILLER, K., BERESFORD, N., COPPLESTONE, D.,
 DELLA VEDOVA, C., GARNIER-LAPLACE, J., HOWARD, B., HOWE, P., OUGHTON,
- D. & WELLS, C. 2008. Numerical benchmarks for protecting biota against radiation in the
 environment: proposed levels, underlying reasoning and recommendations.
- ANDERSSON, P., GARNIER-LAPLACE, J., BERESFORD, N. A., COPPLESTONE, D.,
 HOWARD, B. J., HOWE, P., OUGHTON, D. & WHITEHOUSE, P. 2009. Protection of the
 environment from ionising radiation in a regulatory context (protect): proposed numerical
 benchmark values. *Journal of Environmental Radioactivity*, 100, 1100-1108.
- Bradshaw, Clare, Lawrence Kapustka, Lawrence Barnthouse, Justin Brown, Philippe Ciffroy,
 Valery Forbes, Stanislav Geras' kin, Ulrik Kautsky, and François Bréchignac. "Using an
 Ecosystem Approach to complement protection schemes based on organism-level
 endpoints." *Journal of environmental radioactivity* 136 (2014): 98-104.
- BROWN, J., ALFONSO, B., AVILA, R., BERESFORD, N. A., COPPLESTONE, D., PRÖHL,
 G. & ULANOVSKY, A. 2008. The ERICA tool. *Journal of Environmental Radioactivity*,
 99, 1371-1383.
- DICUS, G. 2003. A regulatory framework for environmental protection. *Protection of the Environment from Ionising Radiation*, 12.
- DOE, U. S. 2002. A Graded Approach for Evaluating Radiation Doses to Aquatic and Terrestrial
 Biota. *In:* ENERGY, U. S. D. O. (ed.). Washington, D.C.
- GARNIER-LAPLACE, J., BEAUGELIN-SEILLER, K., DELLA-VEDOVA, C., MÉTIVIER, J. M., RITZ, C., MOUSSEAU, T. A. & PAPE MØLLER, A. 2015. Radiological dose
 reconstruction for birds reconciles outcomes of Fukushima with knowledge of dose-effect
 relationships. *Scientific Reports*, 5, 16594.
- Higley, Kathryn (2016). "Radiation Protection of the Environment A Case for US Standards,"
 (in preparation, for submittal to Health Physics, February 2016).
- ICRP (1977). Recommendations of the International Commission on Radiological Protection,
 ICRP Publication 26. Annals of the ICRP, 1.
- 4515 ICRP (2007a). ICRP publication 103. Annals of the ICRP, 37, 1-332.
- ICRP (2008). ICRP Publication 108. <u>Environmental protection-the concept and use of reference</u>
 animals and plants. Annals of the ICRP, 38, 4-6.
- ICRP (2014). ICRP Publication 124: Protection of the Environment under Different Exposure
 Situations. *Annals of the ICRP*, 43, 1-58.
- LINDELL, B. 1996. The Risk Philosophy of Radiation Protection. *Radiation Protection Dosimetry*, 68, 157-163.
- 4522 NCRP 1993. *Limitation of exposure to ionizing radiation*, NCRP Report No. 116.
- 4523 PENTREATH, R. 1999. A system for radiological protection of the environment: some initial
 4524 thoughts and ideas. *Journal of Radiological Protection*, 19, 117.
- 4525 RESRAD (2016). <u>RESRAD-BIOTA</u>, part of the RESRAD Family of Codes,
 4526 <u>https://web.evs.anl.gov/resrad/home2/biota.cfm</u> (accessed January 25, 2016) (Argonne
 4527 National Laboratory, Argonne, Illinois).
- ROBINSON, C. 2003. Development of an international framework for the protection of the
 environment from the effects of ionizing radiation. *Protection of the Environment from*
- 4530 *Ionising Radiation*, 110.

ROSE, K. 1991. Lower limits of radiosensitivity in organisms, excluding man. *Journal of Environmental Radioactivity*, 15, 113-133.

- 4533 SAZYKINA, T. & KRYSHEV, I. 1999. Radiation protection of natural ecosystems: Primary and 4534 secondary dose limits to biota. *Health and Environmental Criteria and Standards*, 115.
- 4535 UNSCEAR 2008. Effects of ionizing radiation: report to the General Assembly, with scientific
 4536 annexes, United Nations Publications.
- 4537 WHO (2012). World Health Organization. "Preliminary dose estimation from the nuclear
- 4538 accident after the 2011 Great East Japan Earthquake and Tsunami."

10. Communication of NCRP's System of Radiation Protection to Stakeholders 4539 4540 **Key Points** Effectively communicating the guidance is as important as the guidance itself. A tangible benefit to open, transparent, and effective communication is the establishment and maintenance of trust and confidence in the system of radiation protection for stakeholders. Professionals, patients, the media, and the public have various perceptions of radiation risk and thus different information needs and communication best practices. • Public perception of radiation risk can evoke some of the highest levels of concern – special risk and crisis communication best practices are needed to effectively deliver key information and encourage helpful behaviors. 4541 4542 Communication has always been an integral part of NCRP's mission as prescribed in its Charter 4543 (see below). However, the need for communication of its recommendations has changed 4544 dramatically over time and the tools available for communication have evolved rapidly over the 4545 past decade. An objective of Section 10 is to clearly articulate NCRP's role in communicating its 4546 recommendations and to provide guidance on how this can be accomplished. 4547 4548 4549 Another objective of Section 10 is to provide guidance for the communication of the Council's 4550 recommendations encompassed in this Report to all of its stakeholders. Stakeholders in this context are defined as all parties that would have an interest in the Council's recommendations. 4551 4552 A tangible benefit to open, transparent, and effective communication is the establishment and 4553 maintenance of trust and confidence in the NCRP system of radiation protection (The NCRP 4554 System). Part of this communication effort should be directed to fostering an understanding of 4555 The NCRP System, its underlying science and philosophy, and the accompanying regulatory 4556 mechanisms. Depending on the type of exposure situation, stakeholders may include the 4557 4558 relevant scientific and professional organizations, industry, medical workers, the media, and the general public (including patients and their caregivers). A variety of training, educational, 4559 outreach, and collaborative opportunities can promote this understanding among these 4560 stakeholders. 4561 4562

The sections below review how communication has been achieved historically, how NCRP currently communicates with its stakeholders, and how to incorporate available new technologies for the future. The section also discusses various types of stakeholders that may have an interest in the Council's recommendations and provides examples of how The NCRP System can be effectively communicated through different degrees of interaction to these stakeholders. Finally, the section provides a general discussion on the challenges of communicating radiation protection and the risks and benefits of the use of radiation in our everyday lives.

Comment [M112]: Kase ... I read through Section 10 quickly. At this point I think we should include it as is, but eventually I think that it can be condensed somewhat, perhaps by 30% or so.

Hyer et al.

4571 Section 10 is not meant to prescribe the details of how to communicate, rather it is a high level
4572 view of principles that can be employed, the various groups of stakeholders involved, and new
4573 areas to explore in the future. It is clear that NCRP must give more emphasis to communicating
4574 its recommendations in the future and this section is meant to provide a guide. The Council
4575 believes this topic is critical to the understanding, acceptance, and implementation of these
4576 recommendations. Therefore, this section is the beginning of a renewed area of focus for NCRP
4577 the future.

4578 4579 4580

10.1 NCRP's responsibility to communicate its System of Radiation Protection

NCRP specifically recommends the following principles when communicating radiation guidance:

- Inclusiveness one should engage all relevant stakeholders in the dialogue and dissemination of information
- Culture of safety an effective culture of safety should be cultivated and maintained to facilitate radiation protection
- Accountability there should be clear accountability for radiation protection responsibilities, including responsiveness to feedback on safety from internal and external stakeholders
- Transparency all communication should be transparent with accurate, open, user-friendly and easily understandable information for the individuals and groups that need to access and use it
- Use of all channels communications should utilize the wide range of mechanisms that are available for reaching all professionals, stakeholders, media, and especially the public; social media outlets can be a key resource to help reach specific populations.

4582	Communication has always been an integral part of NCRP's mission and is clearly stated in the
4583	first article of its Congressional Charter (NCRP, 1964). It is to:
4584	
4585	"Collect, analyze, develop, and disseminate in the public interest information and
4586	recommendations about (a) protection against radiation (referred to herein as
4587	radiation protection) and (b) radiation measurements, quantities and units,
4588	particularly those concerned with radiation protection:"
4589	
4590	This element of NCRP's Charter has been manifested in many different forms over its existence,
4591	including reports, commentaries, annual meetings, topical meetings, media interaction,
4592	professional society participation, Congressional testimony, and in many other forms.
4593	
4594	Nevertheless, the Council's policies on communication have taken a much more proactive
4595	direction over the past decade by including experts on communication as members of the

4614

4616

Council. Knowledge from these professionals is dramatically influencing not only the substance 4596 of NCRP products and their clarity but also how the information is disseminated and 4597 communicated. Although communication has always been a foundation of NCRP's mission, the 4598 Council is moving to strengthen and expand the role of communication of its work in the future. 4599 This Report, in particular, is an example of how communication has been incorporated into 4600 NCRP's work from the very beginning of the organization of this committee and the evolution of 4601 the Report from its earliest draft to the final product. 4602 4603 The Council recognizes its responsibility to communicate to its stakeholders but it also realizes 4604 the limitations inherent in this goal. Stakeholders span a broad spectrum of government and 4605 4606 private organizations, professionals, and members of the general public. Therefore, the degree to

private organizations, professionals, and members of the general public. Therefore, the degree to
which we can effectively communicate directly with stakeholders and the methods employed
differ. Section 10.2 addresses who our stakeholders are and how we plan to strengthen our
communication role to each.

The following sub-sections provide a general overview of the comprehensive process involved in the development of NCRP's work products and the communication of these products to a broad scope of interested persons and organizations.

4615 10.1.1 Standards of Scientific Excellence and Quality Required by NCRP

Effective communication begins with the highest standards of science. NCRP recommendations 4617 are produced primarily in the form of reports and are the product of a high-standard peer review 4618 4619 and publication process. The intensive internal and external peer review process that is required 4620 by each NCRP report is one of the most extensive and thorough of any scientific organization. This standard of excellence ensures that the recommendations of the Council are founded on the 4621 best available science and are clearly presented. A brief summary of the peer review process is 4622 described below along with a discussion of the different types of publications NCRP uses to 4623 communicate its recommendations to its stakeholders. 4624 4625

4626 **10.1.2** <u>Peer Review Process for NCRP Reports</u> 4627

NCRP reports carry the full weight and authority of the Council. A draft report being prepared 4628 by an NCRP committee undergoes essentially continuous review by the committee, but NCRP 4629 4630 also employs an extensive review process that begins when the committee has finished its drafting work. When the committee has produced what is deemed to be the penultimate draft, the 4631 4632 report is sent to a Program Area Committee (PAC) that is expected to provide suggestions and 4633 advice on how the draft publication might be improved prior to submission to the full Council 4634 membership. Frequently, the committee identifies expert reviewers outside of the Council membership who could also provide valuable comments. The comments of the PAC and expert 4635 4636 reviewers, as well as any comments resulting from review by the committee members are collected, they are made available to the committee, considered, and modified if needed. 4637 4638

With the critical review process completed, the draft publication, as revised on the basis of the comments generated during the PAC and expert review process, is sent to the full Council (100

4656

4658

4674

4679

members), Distinguished Emeritus members, and Collaborating and Special Liaison 4641 Organizations for review. The publication may also be sent, as a draft, to other interested and 4642 informed individuals and organizations both in the United States and abroad, with requests for 4643 4644 comments. 4645 The comments resulting from the review are collected and the process of examination and 4646 modification by the committee begins again. The goal of this iteration is to reconcile significant 4647 scientific differences between the scientific committee and the reviewers. In the end, NCRP 4648 4649

reports require the approval of essentially 100 % of the Council's members. If any differences of
opinion between Council members and the scientific committee remain, they are resolved by the
Board of Directors.

The rigorous peer review process described above is required for all NCRP reports. However, the Council has other forms of communication of its recommendations available that may be used depending on the circumstances involved.

4657 **10.1.3** Other Forms of Communication of NCRP Recommendations to Stakeholders

In addition to NCRP reports, the Council uses other forms of communicating with its
stakeholders, each incorporating varying forms of peer review and publication. These
publications give NCRP the ability to respond quickly to specific requests or emerging issues.
Examples of these forms of communication are described below.

- Commentaries provide preliminary evaluations, critiques, or reviews and results of
 exploratory studies, and are approved by the Board of Directors rather than the Council
 membership.
- Supplements, which are approved by the Board of Directors, are additions to existing
 reports and commentaries, allow new information to be provided on a previously reported
 topic.
- Statements are concise documents that succinctly address topics of contemporary interest and importance for radiation protection.
- Proceedings of the annual meetings.
- Proceedings of NCRP sponsored symposia.
 - Lauriston S. Taylor lectures.
- Presidential Reports, which are documents on specific issues in radiation protection that are developed by a scientific committee, reviewed by members of Council and other subject area experts as needed, and approved for publication by the President and Board of Directors.

In addition to these avenues, supplemental mechanisms (such as presentations at scientific
meetings, speaking to public groups, and responses to media requests) are also used to
communicate NCRP recommendations with stakeholders. Regardless of the form of
communication used, the Council incorporates a rigorous and extensive review process to meet
its standards of excellence for communicating The NCRP System.

10.1.4 Recent New Initiatives of NCRP Related to Communication of its Recommendations
(Text pending; some topics listed below)
• Transmission of annual meetings over the web
• PAC-7
• CC-1 report
10.1.5 Future Initiatives in Communication of NCRP Recommendations
NCRP will need to evaluate its communication strategy with respect to newer technologies and
practices. It is key that NCRP adapts to these changes to ensure that its quality product and
guidance reach their intended audiences.
6
Radiation is one of the least understood and most frightening matters. The media attention to
radiation is one of the reast and recent large scale disasters. like Fukushima serve to approvate these
challenges and further weaken trust. Thus the challenge for anyone trying to communicate
radiation topics and risk will be to overcome people's concerns, such that correct and accurate
information can be exchanged. If knowledgeable authorities do not communicate this
information effectively, the information gap will be filled by other sources of information that
may or may not serve the public interest
Today, nearly everyone is inundated with information and it has become increasingly difficult to
be heard. These challenges apply almost everywhere. Moreover, the internet and the concept of
"Web 2.0" are rapidly changing how people create and receive information. Web 2.0 represents
the movement from passive viewing of content (downloading documents, charts, graphs,
photographs) to actively viewing and creating content by many users. This is the very nature of
social media. Web 2.0 also heralds the movement of the internet from static text to dynamic
video. A recent Nielsen report predicts 90 % of web traffic will be video by 2020 and it is
expected that 1,000,000 minutes of video will cross the internet every minute!
Change is inevitable and people and organizations either move with change or are at risk for
being left behind. The trends in the internet are such that there will be a movement towards
quality of message and content. The dominance of video will favor stories, vignettes, personal
accounts, and anecdotal reports over statistics and figures.
Sharing ideas and recommendations with others, particularly in high detail, will likely continue
to take place in written reports. There has been a long standing trends to make written reports
more visually interesting and attractive. Use of tables, graphs, call-out boxes, photographs, and
colors can greatly increase reader interest and retention of key materials.
Social media outlets can be very useful in providing users with access to credible, science-based
health information when, where and how users want it. One must accept the concept of bringing
information to where the end users are. A recent Nielsen study showed that Americans doubled
their time spent on social media channels in a single year (Nielsen, 2015). A variety of social
media tools can be employed to reinforce and personalize messages, reach new audiences, and

4731 4732	build a communication infrastructure based on open information exchange. There are three key attributes of social media channels that are believed to make them highly effective as health	
4733 4734 4735 4736 4737	 Personalization: content tailored to individual needs. Presentation: timely and relevant content accessible in multiple formats and contexts. Participation: partners and the public who contribute content in meaningful ways. 	
4738 4739 4740 4741	Additionally, many social media channels facilitate social engagement, viral sharing of information and trust (CDC, 2011).	[
4742 4743 4744 4745 4746 4747	NCRP will need to evaluate its communication strategy with respect to newer technologies and practices. It would be challenging to make specific recommendation here. What is known is that how and where people receive and process information is rapidly changing. It is key that NCRP adapts to these changes to ensure that its quality product and guidance reach their intended audiences.	
4748 4749	10.2 Communication Strategies for Stakeholders	
4750 4751 4752	The stakeholders of The NCRP System include:	
4753 4754 4755 4756 4757 4758 4759 4760	 agencies or organizations responsible for regulating radiation exposures of the public, the workers, and the environment; individuals or groups of individuals occupationally or accidentally exposed to radiation; public or private entities responsible for appropriations or expenditure of funds for control of radiation exposures; and anyone interested or otherwise affected by the nation's governing system of radiation protection and its underlying scientific principles. 	
4760 4761 4762 4763 4764 4765	The information needs of various stakeholders vary. So does the nature of NCRP's relationship and the extent of its direct engagement with each group of stakeholders. Consequently, the content and means of communication to address the information needs of each group need to be examined carefully. In this section, a number of specific NCRP stakeholders and their information needs are briefly described along with communication strategies for each.	
4760 4767 4768 4769 4770 4771 4772 4773 4774 4775	Government, legislators and scientific or professional organizations often have direct communication links with the NCRP. Radiation workers and the general public typically have indirect links to the NCRP. While they may go to the NCRP guidance documents for information and to answer their questions, it is more likely that they obtain information about radiation protection from other subject matter experts such as radiation protection agencies, radiation safety trainers, radiological health researchers and educators, radiation protection leadership within organizations for whom they work, and medical professionals providing patient care involving radiation.	

Comment [AA(113]: Ansari ... John, if you have a more recent 2016 version, please substitute. I think you are referring to the Health Communicators' Social Media Toolkit? That is a 2011 reference found here: http://www.cdc.gov/socialmedia/tools/guidelines/p df/socialmediatoolkit bm.pdf I edited the reference list to include this.

Till

4776 10.2.1 Governmental Agencies

To enhance the communications exchange, it is recommended that government agencies have representatives with the expertise and time to evaluate NCRP guidance on the System of Radiological Protection, and translate it into working regulatory practices.

4777

4778 Government agencies, at both the federal and state levels, are responsible for establishing and enforcing the system of radiation protection as it applies in their respective jurisdictions. These 4779 agencies include the Nuclear Regulatory Commission (NRC), the Environmental Protection 4780 4781 Agency (EPA), the Department of Energy (DOE), the Department of Defense (DOD), the Occupational Safety and Health Administration (OSHA), the Food and Drug Administration 4782 (FDA), the National Aeronautics and Space Administration (NASA), and each of the state 4783 4784 radiation control programs. These government agencies can use the guidance and 4785 recommendations of the NCRP as the scientific foundation to inform their regulatory practices. 4786 Other federal and state government agencies engaged in protection of the people and the 4787 environment including the Centers for Disease Control and Prevention (CDC) and Department of Homeland Security (DHS) can use the guidance and recommendations of the NCRP to inform 4788 their activities in promoting public health. As such, the NCRP often has a direct relationship with 4789 4790 government agencies and is responsive to specific needs which these agencies may express for scientific guidance and recommendations. 4791

4792

Government organizations in turn need to communicate their findings, practices, and regulations
 to their stakeholders. It is worth noting that radiation protection regulations may not necessarily
 reflect the latest NCRP guidance and recommendations. Government agencies consider societal,

4796 practical, and other factors to develop new regulations, and the regulatory process by nature
 4797 takes time.

Government agencies often obtain their knowledge of The NCRP System directly from the
reports and commentaries of the NCRP. As described in Section 10.1, members of the NCRP
may testify before Congress and other lawmakers. Government agencies also request the NCRP
to provide evidence-based recommendations to fill a radiation protection gap. Some
representatives from government agencies are members of NCRP committees. In this capacity,
they engage in research on radiation protection issues and help formulate new or updated
guidance.

4806 **10.2.2** Lawmakers

Although the NCRP is a congressionally chartered organization, it receives no appropriations
from Congress and the scientific activities it conducts within its Charter are not managed by
Congress. However, the NCRP is occasionally called upon to provide information on specific
scientific topics to congressional staff or to offer testimony at congressional hearings. These
congressional requests may be part of legislative activities, government oversight functions, or
response to particular constituents. The NCRP communication with congressional staff is direct,
and the content is responsive to specific requests from congressional staff.

4814
NCRP guidance is typically brought to lawmakers by government agencies during rulemaking. It 4815 is valuable to both the agency and lawmakers when the objective perspectives of the NCRP are 4816 used to support regulations. The agency representative must thoroughly research NCRP 4817 perspectives before sharing them with lawmakers. NCRP Report executive summaries provide a 4818 brief overview of the findings. The documents also have a comprehensive index which makes 4819 finding specific evidence more efficient. The agency representative may have to translate some 4820 of the scientific evidence used by the NCRP into more common language. Educating legislative 4821 staff assigned to committees or individual representatives is valuable as they may have more 4822 time to read and understand technical information for summaries they provide lawmakers. 4823 4824

The scientific findings of the NCRP may also be used to clarify positions of interest to the constituents whom lawmakers represent. There may be debate about a radiation protection issue within a community or in a certain industry that can be improved with recommendations from the NCRP. This Report characterizes these exposures in Section 2. Fact-based guidance to restrict dose for planned, existing and emergency exposure situations is found in Section 8.

4831 The answers to questions about existing situations are often not as straightforward as with

planned and even emergency situations. ICRP Publication 103 describes the complexities when
high levels of radon or other naturally occurring radioactive materials contribute significantly to
public dose, or when an incident at a nuclear facility or other site can cause radiological

4835 contamination to the environment (ICRP, 2007a).

4836

4830

As described in NCRP Report No. 175, the circumstances of exposure and criteria for control of
that exposure following a radiological or nuclear emergency may not fit neatly into The NCRP
System without site-specific optimization (NCRP, 2015). This optimization must be conducted
in collaboration with the community members who may be displaced, and with those who may
return to once abandoned locations.

4842

More so than in any other exposure situation, agencies must listen to the concerns and suggestions of the people exposed when radioactive materials and radiation are newly discovered or introduced into a community.

4844	As important as listening is to the communication process, so too are the steps of sharing the
4845	initial information so the listener receives the message as intended. The National Library of
4846	Medicine provides excellent guidance for readable health materials
4847	(https://www.nlm.nih.gov/medlineplus/etr.html). The speaker must know the audience and
4848	determine the objectives of the message for each audience. A message can be scored for
4849	readability with word processing software. The speaker must also demonstrate proficiency with
4850	the science, especially since it is likely he or she will have to answer questions about the initial
4851	message. Subject matter expert is a designation more easily lost than gained.
4852	
4853	Reading press coverage or other accounts after the message is delivered can provide feedback
4854	about message delivery and reception. Effective organizations have public information officers

that perform this and similar tasks to measure the success of communications activities. Shouldthere be misconceptions a clarification should be published to mitigate them.

4857

4858 **10.2.3** <u>Scientific and Professional Organizations</u> 4859

Scientific and professional organizations represent a pool of subject matter experts who
contribute, directly or indirectly, to development and implementation of the system of
radiological protection. Their work practices in areas of radiation research or radiation safety are
often influenced by regulatory decisions. Furthermore, senior members of these organizations
are often engaged by media outlets to disseminate information on issues of public interest.
Representatives of these organizations are consulted by legislative bodies and decision makers at
state and federal levels.

4867 As such, these organizations should be regarded as stakeholders themselves and as important 4868 partners in the context of communicating The NCRP System to other stakeholders. In the last 4869 several decades, the NCRP has fostered close relationships with national and international 4870 organizations engaged in science and the practice of radiation protection. These organizations 4871 include the Radiation Research Society (RRS), the Health Physics Society (HPS), the 4872 Conference of Radiation Control Program Directors (CRCPD), the International Radiation 4873 Protection Association (IRPA), the International Commission on Radiological Protection 4874 (ICRP), and the International Commission on Radiation Units and Measurements (ICRU), the 4875 American Association of Physicists in Medicine (AAPM), the American College of Radiology 4876 (ACR), the American Nuclear Society (ANS), Radiological Society of North America (RSNA), 4877 4878 and the American Society of Radiation Oncology (ASTRO). Many universities have academic 4879 programs that support radiation protection and the industries requiring radiation protection. They 4880 also look to the NCRP for guidance and for reference material for teaching and research.

4881

In times of crises and emergencies, the contributions of such organizations become even more
vital. Members or representatives of scientific and professional organizations can help inform
and explain radiation protection concepts to the public through print, broadcast, or social media.
Communication material, especially if developed and coordinated in advance with these
organizations, help ensure that clear and consistent messages are available and disseminated
using risk communication science and methodology.

These entities often serve as translators. They may engage government lawmakers and radiation protection agencies during rulemaking and try to represent one or many perspectives of the public who are exposed to, or the industries which use, radiation and radioactive materials. This role is important because not every law or government position is necessarily based on facts. The role is so important that many organizations have liaisons with government officials.

4893

It is important that scientific and professional organizations maintain liaison relationships with the NCRP, so developments in our understanding of The NCRP System can be accurately translated by them for their constituents.

NCRP CC 1 Draft of April 2016

4895 **10.2.4** <u>Radiation Workers</u> 4896

As explained below, radiation workers may not be the primary and direct audience of NCRP
guidance and recommendations because the immediate information needs of radiation workers,
in both industry and medicine, focus on operational and procedural issues and the regulatory
radiation protection practices at their specific institutions. However, radiation protection
managers, radiation safety officers and instructors can use NCRP guidance and recommendations
to guide their practices, procedures, and development of educational material they use to train
and inform their workers.

An important pillar of any system of radiological protection is its safety culture in maintaining 4905 the safety of workers, the public and the environment (Classic et al., 2014; IAEA, 1991; 2002; 4906 **2013**; **IRPA**, **2014**).⁴ While the radiation protection system is promulgated and subsequently 4907 regulated by appropriate state or federal government agencies, the primary responsibility for the 4908 safe and secure use of radiation and radioactive materials is with individuals and organizations 4909 performing those regulated activities. Both industry and the regulatory community are 4910 4911 encouraged to increase the transparency of and communication about their efforts to assess and improve their safety cultures (IAEA, 2013; NA/NRC, 2014). 4912

4913

4894

4914 A model is what is called the nuclear safety culture. It is defined as "the core values and

4915 behaviors resulting from a collective commitment by leaders and individuals to emphasize safety

4916 over competing goals to ensure protection of people and the environment" (HPS, 2012; NRC,
 4917 2011).

An essential component of a positive safety culture is open and transparent communication with a focus on safety. The focus areas of communication in the context of nuclear safety culture are operational issues and procedures at the workplace, and the concept is primarily for workers in the nuclear industry. However, the concept of safety culture has broader applications and applies to all classes of workers with potential for occupational exposures. Furthermore, free and transparent communication can and should include all aspects of The NCRP System to foster trust and confidence.

Medical care providers comprise a large and important group of workers with potential for 4925 4926 radiation exposure. The concept of promoting safety-focused communication toward a positive safety culture applies to the medical exposure situation. Practitioners' understanding of the 4927 radiation protection system will help in the implementation of that system and improved safety 4928 4929 practices that benefit both the practitioners and the patients. With the growing proportion of 4930 medical doses in the overall dose to humans (NCRP, 2009), strengthening the medical worker's knowledge of the radiological protection safety culture, and promoting their discussion and use 4931 4932 of its tenets with patients is vital.

⁴ The term "safety culture" was first introduced by the International Nuclear Safety Advisory Group (**INSAG**, **1986**) and further expanded on in **INSAG** (**1988**).

4933 4934 4935 4936 4937 4938 4939 4940 4941 4942 4943	Under potential emergency exposure situations, workers are likely to encounter conditions different from their routine responsibilities, and they may be asked to undertake critical emergency response tasks with potential radiation exposures beyond applicable routine annual exposure limits (EPA, 2013; FEMA, 2013; IAEA, 2015; NCRP, 2001). Effective communication with workers about safety practices, potential risks, and the system in place to monitor and protect their safety in emergency exposure situations is most effective when included as part of the routine worker training and refresher training. This can have immediate impact in saving lives (e.g., when medical care providers are receiving contaminated or exposed patients with life-threating injuries) (NCRP, 1994; 2001; HHS, 2006a; FEMA, 2013; CDC, 2012; IAEA, 2015).
4944	Radiation workers are among the most important of people with whom NCRP guidance about
4945	The NCRP System is shared. They have agreed to earn a living at the expense of radiation dose.
4946	For many the cost is modest, a small dose accumulated slowly over a long time. For others, the
4947	cost may be much higher. For both, it is critical that fears be attended to with the same facts. This
4948	Report provides those facts with the individual Adverse Health Outcomes from Radiation
4949	Exposures described in Section 6, accounted for in the Radiation Risk Estimates, Detriment and
4950	Uncertainties of Section 7, and controlled by dose criteria in the Recommendations of Section 8.
4951	
4952	It is the responsibility of the employer to clearly share the findings in these sections of the Report
4953	at multiple opportunities. The first is at the time of employment. At this point a brief summary
4954	should be shared with prospective new hires. A common source of such guidance is required by
4955	the legal radiation protection authority for the jurisdiction.
4956	

It is recommended that the Nuclear Regulatory Commission, Agreement States, Environmental Protection Agency, Department of Energy, Department of Defense, Occupational Safety and Health Administration, and Conference of Radiation Control Program Directors review the recommendations of this Report and revise their notices, instructions and reports to workers relative to radiation protection.

4957

Once hired, personnel need radiation protection training commensurate with their level of 4958 radiation exposure. Administrative staff who work near a radiology suite need not have the same 4959 level of training as the radiologic technician in that suite. State and Federal regulations 4960 consistently provide guidance about the required level of radiation protection training. Those 4961 licensed by these authorities must periodically evaluate the effectiveness of this training. As it is 4962 important to verify the message was received as intended, the trainee should be tested for 4963 comprehension of key information. NCRP Report 134 provides guidance on radiation protection 4964 training programs (NCRP, 2000), and Appendix B of NCRP Report 162 provides a useful tool 4965 for verifying the adequacy of training for all scales of radiation protection programs (NCRP, 4966 2009). 4967 4968

Training must continue throughout employment, not simply because regulations require it, butbecause the science behind radiation protection regulation advances. In this Report, the evidence

for some risks of radiation exposure have been found to be less than measured in the past, and
some risks are now understood to be greater than previously reported. Where there is insufficient
evidence to change perspectives for other health outcomes, this can illuminate the issue of
uncertainty. The components of this uncertainty are described in Section 7.2.

4975

It is recommended that the findings of this Report be incorporated into radiation worker training programs to ensure the latest findings on risk and detriment are shared with those exposed occupationally to radiation.

4976

4978

4995

4977 10.2.5 The General Public

As was the case with radiation workers, members of the public are not the primary and direct
audience of NCRP guidance and recommendations. Information needs of the public vary
depending on where they live, where they work, and whether they or members of their family
have had medical exposures or other life experiences involving radiation. People living in
proximity to a nuclear facility or in communities where construction of new facilities are planned
would have specific needs for information on potential risk to their families and their
environment.

In an emergency exposure situation, the needs and demands of the public for information are 4987 immediate, and require clear, concise, and actionable information (NCRP, 1994; 2001). During 4988 the recovery phase of an emergency, however, communication challenges are different. When 4989 4990 the transition is made from an emergency exposure to an existing exposure situation, and members of the public are encouraged to return to homes they previously evacuated, they are 4991 likely to scrutinize and question the radiological safety criteria supporting those 4992 4993 recommendations (ICRP, 2012). Recognizing the concerns of the public and understanding their need for information are necessary for effective communication. 4994

4996 Public perception of radiation risk is often disproportionate to the actual risk. As a result, 4997 radiation safety practitioners, managers, and regulators continue to face communication 4998 challenges. Furthermore, too often traditional and social media outlets provide inaccurate or 4999 exaggerated information that increases apprehension about the subjects of radiation and 5000 radioactive materials. These outlets are growing in number, and reliance upon them for the 5001 majority of information used by members of the public is accelerating. Leveraging the same 5002 means of communication to provide accurate and contextual information is paramount. 5003

5004 In this context, medical patients and caregivers comprise an important sector of the general 5005 public. It is common for health care providers to share information with their patients getting 5006 diagnostic images or receiving radiation therapy. Radiologists and radiation oncologists can 5007 easily explain how the benefits of exposure far outweigh the adverse effects possible. Some 5008 patients who have been administered radioactive materials to treat an illness are released to 5009 caregivers despite that the materials within their bodies emit radiation. The radiological health

care provider releasing the patient to a caregiver must be capable of providing caregivers a 5010 thorough summary of the risks of their personal radiation exposure while helping another. 5011 5012 Public information personnel should have policies and plans to clearly explain the rationale 5013 supporting the system of radiation protection. Engagement with the public about The NCRP 5014 System, and how it pertains to their real everyday lives and what it means for their future helps 5015 build public trust in The NCRP System. 5016 5017 The NCRP communication efforts are not targeted at the general public. However, the guidance 5018 and recommendations and the scientific discussions that support NCRP recommendations can be 5019 the basis for developing such targeted communication materials. 5020 5021 5022 While the worker has agreed to incorporate some risk from radiation exposure, he or she has also 5023 been additionally compensated with specialized training to provide the knowledge and skills to minimize dose, and is provided detailed personal dose information through time. This bargain 5024 5025 rarely exists for members of the general public, who may find themselves suddenly and unexpectedly in a radiation exposure situation. Such is the case for homeowners who obtain 5026 radon test results that require mitigation or for a whole nation when a disaster includes 5027 widespread radioactive material contamination. For the latter, the ICRP identified radiological 5028 protection and risk communication problems were important impediments following the reactor 5029 releases at Fukushima (ICRP, 2012). The CDC has exceptional guidance that can prevent many 5030 communication problems with planning (CDC, 2012). 5031 5032 Because the audience is diverse and obtains information in many ways, communication about the 5033 relevant aspects of The NCRP System must be shared in many ways. The means by which 5034 5035 people share information change rapidly, and should be understood so accurate information is found efficiently and from those well informed by guidance such as found in this Report. In 5036 5037 radiological or nuclear emergencies, testing message templates for effectiveness is useful. 5038 FEMA has provided tested messages for an improvised nuclear device (FEMA, 2013). Many jurisdictions have developed similar products for nuclear power plant accidents (CRCPD, 2010). 5039 5040 Social media can be a force multiplier (White, 2012), and important information can reach more 5041 people more rapidly using brief comments, a photograph, an attention-grabbing video, and a web 5042 link for more details. 5043 5044

It is recommended that a diverse collection of social media outlets as well as traditional print and broadcast methods be used to communicate critical messages about radiation protection to the general public in brief, effectiveness-tested, written, audio and video formats to accommodate the multiplicity of communication devices.

NCRP CC 1 Draft of April 2016

5046 **10.2.6** The Media

5080

5081

5087

5047 5048 The media are an effective mechanism for reaching an audience. Traditional media outlets (television, radio, and print media) together with more modern media outlets (internet and social 5049 media) reach large segments of the population and are effective in forming public opinion and 5050 perceptions. Establishing and maintaining a professional relationship with members of the 5051 media can create opportunities to communicate informational and educational materials for the 5052 public regarding radiation issues of national or local concern. This relationship can be cultivated 5053 by creating scientific information in templates or formats that members of the media can use. It 5054 would be helpful to indeed work with members of the media, on an ongoing basis, to develop 5055 5056 communication materials that can be used in short notice when the need arises (e.g., when a 5057 medical overexposure occurs or when the news of a new published study generates public 5058 interest.) 5059

The NCRP is responsive to requests from the media for information, and in that context, does
have a relationship with the media. However, it is prudent for major stakeholders in the nation's
radiation protection system, namely government agencies and scientific and professional
organizations to work with media on an ongoing basis so they can have credible and accurate
information when they need it.

5065 The role of the media becomes more paramount during public health emergencies. While it is 5066 important to recognize that the role and function of the media is not the same as a public 5067 information officer (CDC, 2012), media professionals can be effective partners, through open 5068 5069 and honest communication, to provide timely information to the public and help manage a crisis. 5070 Developing media guides with basic background information that members of the media can use during public health emergencies is one such approach (HHS, 2006a). Engaging representative 5071 members of the media in the creation of communication templates used for emergencies is 5072 another and complimentary approach. For example, FEMA (2013) published an interagency 5073 guide that provides such messages for use in the aftermath of an improvised nuclear device 5074 detonation. The media professionals' knowledge of what works can be combined with learning 5075 about radiation and emergency response. If knowledgeable authorities do not communicate this 5076 information effectively, the information gap will be filled by other sources of information that 5077 may or may not serve the public interest. 5078 5079

10.3 Challenges of Communicating Concepts of Radiological Protection

Communicating radiation risk is challenge and people react differently to radiation concerns.
Since people react to and process information differently in the high-concern setting,
communication strategy must adapt as well. Effective communication is key; the better the
target audiences are able to understand and process key information, the higher the likelihood of
appropriate perception of actual risk and helpful behaviors and attitudes.

Radiation and radiation risk are some of the most complex topics. There are broad applications
 of radiation from the personal level with medical imaging and cosmic radiation to daily exposure
 with radiation workers to community concerns with a nuclear power plant. Radiation protection

5098

is, by definition, communicating risk. There is no uniform nor consistent perception of radiation
risk. Public perception and acceptance is determined by the context in which the radiation is
used. Various intended audiences will have different needs regarding not only technical content
but also best practices of communicating risk. Amongst an uninformed and unfamiliar
audiences, the inherent risk and unknowns of radiation can trigger some of the highest levels of
concern. Amongst professional audiences, familiarity with radiation does reduce the perceived
risk.

The very different reactions to different uses provide insight into the nature of perception and the 5099 determinants of acceptable risk (Slovic, 1996). In in the setting of high awareness and high trust, 5100 5101 such as radiation professionals and some stakeholders, communication and education strategies 5102 can be based on conveying data and detailed guidance in a conventional logical and organized fashion. On the contrary, for those uninformed, unfamiliar or with different priorities, a different 5103 strategy is often required. In this high-concern, low-trust setting, using best practices of risk and 5104 crisis communication is essential. These practices focus on addressing peoples' natural emotional 5105 response in a high-concern, low-trust setting. 5106 5107

There are many enhanced challenges for getting balance and useful information about radiation 5108 to people. Most situations will be non-crisis or routine. Since radiation remains a high-concern 5109 issue, many of the techniques used in risk and crisis communication will still apply in the routine 5110 setting. For example, message mapping has proven to help explain complex matters. Message 5111 mapping is a strategy to create a set of key messages (usually three) consisting of short 5112 statements that are easily understood. The three key messages when said together comprise a 5113 soundbite, or easily quoted and memorable phrase. Each key message can have more detailed 5114 5115 information available for a more informed response. These layered answers to key questions are 5116 very useful to communicate key concepts in the high-concern setting. Once people grasp the key concepts, they are more open for complexity and details. 5117 5118

The message map strategy was developed for the top 60 difficult question for pandemic 5119 5120 influenza (HHS, 2006b). For the 2014 Ebola crisis, the 50 State Health Officials developed message maps for the top 60+ questions on Ebola (Covello and Hyer, 2014). The detailed peer-5121 reviewed message maps were published in the middle of intense media coverage. Data from an 5122 independent tracking poll of Americans' perception of improved accuracy in media reporting 5123 were tightly correlated with the publication and downloading of this document (Frankovic, 5124 2014). A similar effort is now being done for communicating risk and healthy behaviors 5125 5126 associated with the Zika virus.

5127
5128 Radiation risk remains a high concern topic for many people. People simply process information
5129 differently in the high concern setting and officials must account for this. Effective
5130 communication is key; the better the target audiences are able to understand and process key
5131 information, the higher the likelihood of appropriate perception of actual risk and helpful
5132 behaviors and attitudes.

NCRP CC 1 Draft of April 2016

5135 **References** (Section 10)

- 5136
- 5137 CDC (2011). U.S. Centers for Disease Control and Prevention, The Health Communicator's
 5138 Social Media Toolkit,
- 5139 <u>http://www.cdc.gov/socialmedia/tools/guidelines/pdf/socialmediatoolkit_bm.pdf</u> (Centers for
 5140 Disease Control and Prevention, Atlanta, GA).
- 5141 CDC (2012). U.S. Centers for Disease Control and Prevention, Crisis and Emergency Risk
 5142 Communication, <u>http://emergency.cdc.gov/cerc/resources/pdf/cerc_2012edition.pdf</u> (Centers
 5143 for Disease Control and Prevention, Atlanta, GA).
- Classic, K., Bernard LeGuen, Kenneth Kase and Richard Vetter (2014). Safety and Radiation
 Protection Culture. pp. 263-277, Chapter 15 in Safety and Quality: Paradigms in leadership
 and innovation. Lau, l. and Ng, K-H., eds. Radiological Springer Science+Business Media,
 Dordrecht, 2014.
- 5148 Covello V and Hyer R. (2014). Top Questions On Ebola: Simple Answers Developed by the Association
 5149 of State and Territorial Health Officials. Association of State and Territorial Health Officials, October
 5150 31st, 2014. Arlington, Virginia. <u>http://www.astho.org/infectious-disease/top-questions-on-ebola-</u>
 5151 simple-answers-developed-by-astho/
- 5152 CRCPD (2010). Conference of Radiation Control Program Directors. Nuclear Generating Station
 5153 Plume and Post-Plume Exercises and Incidents Library of Press Releases.
- EPA (2013) U.S. Environmental Protection Agency, *Protective Action Guides And Planning Guidance For Radiological Incidents*, Draft for Interim Use and Public Comment (U.S.
 Environmental Protection Agency, Washington, D.C.)
- FEMA (2013). Federal Emergency Management Agency. Improvised Nuclear Device Response
 and Recovery: Communicating in the Immediate Aftermath. (Federal Emergency
 Management Agency, Washington, DC).
- FEMA (2013). "Improvised Nuclear Device Response and Recovery Communicating in the
 Immediate Aftermath". (Federal Emergency Management Agency, Washington, DC).
- Frankovic, K. (2014). "The Media and Ebola". Economist/YouGov Poll, 13Oct-13Nov 2014.
 https://today.yougov.com/news/2014/11/19/ebola-crisis-over-us/
- HHS (2006a) U.S. Department of Health and Human Services, *Terrorism and other Public Health Emergencies, a Field Guide for Media*, <u>https://www.hsdl.org/?view&did=33484</u>
 (Department of Health and Human Services, Washington, D.C.)
- 5167 HHS (2006b). Pandemic Influenza Pre-Event Message Maps. Department of Health and Human
 5168 Services. Washington, DC 2006.
- HPS (2012). Health Physics Society, *Radiation Safety Culture*, Position Statement of the Health
 Physics Society (Health Physics Society, McLean, VA).
- 5171 Hyer RN and Covello VT (2005). Effective Media Communication during Public Health
 5172 Emergencies: A WHO Handbook. World Health Organization, Geneva
 5173 <u>http://www.who.int/csr/resources/publications/WHO CDS 2005 31/en/;</u>
 5174 <u>http://www.who.int/csr/resources/publications/WHO%20MEDIA%20HANDBOOK.pdf?ua=</u>
 5175 <u>1</u>
- 5176 IAEA (1991). International Atomic Energy Agency, *Safety Culture*, A report by the International
 5177 Nuclear Safety Advisory Group, Safety Series No. 75-INSAG-4 (International Atomic
 5178 Energy Agency, Vienna).

- 5179 IAEA (2002). International Atomic Energy Agency, *Key Practical Issues in Strengthening Safety* 5180 *Culture*, A report by the International Nuclear Safety Advisory Group INSAG-15
 5181 (International Atomic Energy Agency, Vienna).
 5182 IAEA (2012) I. Least in LATE.
- 5182 IAEA (2012) International Atomic Energy Agency communication
- 5183 IAEA (2013). International Atomic Energy Agency, *Regulatory Oversight of Safety Culture in* 5184 *Nuclear Installations*, IAEA-TECDOC-1707 (International Atomic Energy Agency, Vienna).
- 5185 IAEA (2015). International Atomic Energy Agency, *Preparedness and Response for a Nuclear* 5186 *or Radiological Emergency*, Safety Standards Series No. GSR Part 7 (International Atomic
 5187 Energy Agency, Vienna).
- 5188 ICRP (2007a). International Commission on Radiological Protection. Recommendations of the
 5189 ICRP, ICRP Publication 103, Ann. ICRP 37(2–4) (Elsevier, New York).
- 5190 ICRP (2012). International Commission on Radiological Protection. Task Group. Report of
 5191 ICRP Task Group 84 on Initial Lessons Learned from the Nuclear Power Plant Accident in
 5192 Japan vis-à-vis the ICRP System of Radiological Protection (Elsevier Science, New York).
- 5193 INSAG (1986). International Nuclear Safety Advisory Group. Summary Report on the Post-
- Accident Review Meeting on the Chernobyl Accident (IAEA Safety Series No.75-INSAG-I).
 INSAG (1988). International Nuclear Safety Advisory Group. Basic Safety Principles for
 Nuclear Power Plants (Safety Series No.75-INSAG-3).
- 5196 Nuclear Power Plants (Safety Series No.75-INSAG-3).
 5197 IRPA (2014). IRPA Guiding Principles for Establishing A Radiation Protection Culture, Edition
 5198 2014. International Radiation Protection Association. (irpa.net)
- NAS (2014). National Academies of Sciences, *Lessons Learned from the Fukushima Nuclear Accident for Improving Safety of U.S. Nuclear Plants*, National Research Council (National
 Academies Press, Washington, D.C.).
- NCRP (1964). An Act: To incorporate the National Committee on Radiation Protection and Measurements. Public Law 88-376, 78 Stat., July 14, 1964, http://uscode.house.gov/statutes/pl/88/376.pdf
- NCRP (1994). National Council on Radiation Protection and Measurements. *Advising the Public About Radiation Emergencies*, NCRP Commentary No. 10 (National Council on Radiation
 Protection and Measurements, Bethesda, Maryland).
- NCRP (2001). National Council on Radiation Protection and Measurements. *Management of Terrorist Events Involving Radioactive Material*, NCRP Report No. 138 (National Council
 on Radiation Protection and Measurements, Bethesda, Maryland).
- NCRP (2009). National Council on Radiation Protection and Measurements. *Ionizing Radiation Exposure of the Population of the United States*, NCRP Report No. 160 (National Council on
 Radiation Protection and Measurements, Bethesda, Maryland).
- NCRP (2015). Appendix E of NCRP Report No. 175, DECISION MAKING FOR LATE-PHASE
 RECOVERY FROM MAJOR NUCLEAR OR RADIOLOGICAL INCIDENTS.
- 5216 Nielsen (2015).
- 5217 NRC (2011), U.S. Nuclear Regulatory Commission, *Final Safety Culture Policy Statement*, Federal
 5218 Register, Vol. 76, No. 114, 34773-8 (U.S. Nuclear Regulatory Commission, Washington).
- 5219 NCRP (2000). National Council on Radiation Protection and Measurements. Operational
- Radiation Safety Training, NCRP Report No. 134 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).

Comment [M114]: MR ... need full citation

- NCRP (2009). National Council on Radiation Protection and Measurements. Self Assessment of
 Radiation Safety Programs, NCRP Report No. 162 (National Council on Radiation
- 5224 Protection and Measurements, Bethesda, Maryland).
- NCRP (2015). National Council on Radiation Protection and Measurements. Decision Making
 for Late Phase Recovery from Major Nuclear or Radiological Incidents, NCRP Report No.
 175 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
- 5228 Slovic (1996). Radiat Prot Dosimetry (1996) 68 (3-4): 165-180).
- White, Connie M. Social Media, Crisis Communication, and Emergency Management. (CRC
 Press, Taylor & Francis Group, Boca Raton, Florida).

NCRP CC 1 Draft of April 2016

5232 Glossary (These Glossaries are currently under further review)

5234 [Teaching Definitions]

5233

5240

5249

5254

Absorbed dose: Not all the ionizing radiation to which we are exposed actually causes dose.
Some is reflected away, some is used up in the dead layer of skin that covers the outer layer of
our bodies and some actually passes all the way through our body without interacting at all. That
which does cause us dose is the absorbed dose. The absorbed dose in tissue is often a fraction,
sometimes a much smaller fraction of the dose in air near our bodies.

5241 Activity: Radioactive materials are made up of atoms that are unstable. In the simplest terms, this instability is a function of the number neutrons relative to the number of protons in the 5242 atom's nucleus. Unstable atoms seek to become stable, and they do so by emitting radiation. This 5243 5244 radiation is excess nuclear mass converted to energy. The transformation of unstable atoms to stable atoms has been called radioactivity, or more simply, activity. The unit of activity is the 5245 5246 becquerel which is equal to one radioactive transformation per second. The more activity, the 5247 more radioactive material that exists, the more ionizing radiation that is emitted over time. This ionizing radiation causes dose, so the more activity, the higher the possible dose. 5248

Acute and Chronic Radiation Dose: An acute ionizing radiation dose is a high dose received in
 a short time. Chronic ionizing radiation doses are accumulated in small increments over a longer
 time. Acute radiation doses risk immediate effects, while chronic doses increase the risk of
 effects later in life.

5255 ALARA: As Low As Reasonably Achievable (ALARA) is a radiation protection approach 5256 where the objective is to minimize the dose a person gets in a situations like work, medical 5257 diagnosis or treatment or from radioactive materials in the environment as with radon exposure 5258 in the home. The dose minimization or optimization effort is to as low a level as is practical, 5259 generally, to a point where the benefits are equivalent to or greater than the costs to reduce the 5260 dose.

5262 ALI and DAC: Doses from radioactive materials we breathe into our bodies are controlled to 5263 minimize health effects using the Annual Limit on Intake (ALI) and the Derived Air Concentration (DAC). The ALI is that amount of radioactive materials taken into the body that 5264 5265 will result in the person getting a dose of 0.05 sievert, a current limit for occupational exposures. The DAC is used to make it easier to control work exposures. The DAC divides the ALI by the 5266 5267 amount of air a worker breathes over the course of a year. The results are in units of radioactive material per volume of air, typically in becquerel per liter. An air sampler can measure the 5268 becquerel/liter in a work location, and a worker's dose from the air can be controlled by 5269 5270 minimizing the duration of exposure or providing the worker respiratory protection. The ALI must also account for dose from radioactive materials that are ingested, for example from 5271 consuming food or water contaminated with radioactive materials. The ALI is also used to limit 5272 5273 intakes of radioactive materials from food and water. Calculations using food and water 5274 concentrations and human ingestion rates allow comparisons to the ALI. . 5275

5276 **Background Radiation:** This is the ionizing radiation from sources not related to our

Comment [M115]: MR ... we should go with the usual NCRP style Glossary ... to be created later ... will use these input and as appropriate

MR

MR

Comment [M116]: MR ... Need to coordinate with Section 5. The formal definitions of quantities and units in

Section 5 and the Glossary should be exactly the same (and the same as the original source). The additional detail would only be in Section 5.

Comment [CD117]: Cool ... I don't think the text makes any reference to ALI and DAC.

occupation. It is from ionizing radiation used to diagnose or treat illness; from the radiations 5277 emitted by radioactive materials in our environment, like radon; from radiations entering our 5278 atmosphere from outer space, as from the sun; and from the use of ionizing radiation in a host of 5279 industrial settings. When we get ionizing radiation exposure at work, records of our dose do not 5280 include this background radiation. When we measure ionizing radiation, we typically subtract 5281 background radiation to account for that ionizing radiation from the source alone. Efforts to 5282 reduce background radiation doses are as important as reducing them from work exposures. 5283 Some people get doses from background radiations that are greater than doses from occupational 5284 exposures. 5285

Becquerel (Bq): Henri Becquerel discovered natural radioactivity in 1896. He was awarded a
Nobel Prize in Physics in 1903 for this. In his honor, the unit of activity, by which the quantity of
radioactive materials is measured, is the Becquerel. Its abbreviation is Bq. One Bq is equal to
one radioactive transformation per second.

5292 **Bioassay:** Bioassay is a means to estimate the ionizing radiation dose to an individual, by examining samples from their body (*in vitro* bioassay), or by measuring emissions of radiation 5293 from radioactive materials within their body with instruments (in vivo bioassay). With in vitro 5294 bioassay, say with a urine, fecal, blood or hair sample, the amount of radioactive material in the 5295 body is calculated based on the amount in the sample. With in vivo bioassay, the amount of 5296 radioactive material in the person's body is calculated using the number and energy of ionizing 5297 5298 radiations emitted by radioactive materials measured with an external detector and instrumentation. 5299

5300

5311

5286

5291

Biodosimetry: We can use changes in our bodies to estimate how much dose we received. For
low doses, we may look for subtle changes like those in the exposed person's chromosomes. For
higher doses, effects like skin reddening, hair loss and time until the onset of vomiting can help
us estimate the dose.

Committed effective dose: This is the dose a person receives from an intake of radioactive
materials, and to which he or she is committed based on the time it takes to eliminate the
radioactive material from the body. Generally, a maximum period of time is used for the
accumulation of this dose, because some radioactive materials take many years to be eliminated.
50 y is the duration recommended in the United States.

5312 Committed equivalent dose: The committed effective dose from internal radioactive materials may impact only a small part of the body. As an example, the thyroid gland is essentially the 5313 only part of the body that gets dose when radioactive iodine is inhaled or ingested. The different 5314 tissues or organs that may be affected have different tissue weighting factors on the basis of the 5315 detriment done to the health of the person as a whole. The thyroid, for example, has a small 5316 tissue weighting factor (0.03), because detriment to the thyroid has a small health impact on the 5317 5318 human body as a whole. Because harm to it can be more severe as an overall impact to the health of the body, the red bone marrow has a higher tissue weighting factor (0.12). 5319 5320

NOT TO BE DISSEMINATED OR REFERENCED

Deterministic effect (see tissue reaction): A deterministic effect is a dose consequence known 5321 to result when the dose exceeds a threshold. The threshold varies somewhat based on the 5322 differences among people, but the effect will not occur until that threshold is exceeded. For 5323 5324 example, erythema or reddening of the skin by ionizing radiation exposure will not occur at low doses, such as those where the skin dose limit is established. A dose of hundreds of millisieverts 5325 5326 is required before the skin reddens. 5327 **Detriment:** This is the harm possible with exposure to ionizing radiation, especially due to 5328 cancer or genetic effects. 5329 5330 Dose and Dose Rate: Dose is the generic term used in radiation protection to account for the 5331 5332 amount of radiation a person is exposed to and affected by. Dose is usually measured with an 5333 instrument, but it can also be estimated, calculated or reconstructed from facts about the duration of, and types of, radiation exposure. The dose rate tells us how rapidly someone can accumulate 5334 5335 a dose. Dose rate is usually measured with an instrument, for example a Geiger counter, in units 5336 of radiation per unit time, for example microsievert per hour. If someone is exposed to a radiation field of 0.1 microsievert per hour for 10 hours, their dose would be recorded as 1 5337 5338 microsievert. 5339 Dose coefficient: Radiation causes damage through the ionization of tissues with which radiation 5340 interacts. The radiations from different radioactive materials are all different, so the amount of 5341 5342 ionization, damage and dose they cause differs. Dose coefficients have been numerically, and often, experimentally, determined for the radiations from different radioactive materials. If you 5343 multiply the amount of activity interacting with the tissue by the dose coefficient, you obtain the 5344 expected dose to that tissue. This means knowing what type radioactive material emitted the 5345 radiation, can be as important as knowing how much is interacting with the tissue. 5346 5347 **Dose Limit:** Dose limits are used to control exposures, usually at work, to minimize health risks. 5348 5349 A common dose limit in the United States is 0.05 sievert whole body for a year. It is common to 5350 have different limits for different parts of the body, for example the lens of the eye, the extremities, and the whole body except for the eyes and extremities. 5351 5352 Dose Reconstruction: Sometimes a person's radiation exposure was not recorded by an 5353 5354 instrument, and his or her dose is reconstructed from evidence about the exposure. Such evidence includes the radiation type, an estimate of the duration of exposure, an estimate of what the 5355 5356 radiation dose rates were or how much radioactive material the person took into his or her body. 5357 **Dosimeter:** This is a way, usually a device, to measure dose. Common devices used as 5358 dosimeters are film badges, thermoluminescent dosimeters or optically stimulated luminescent 5359 dosimeters. In each, the radiation alters the material within the dosimeter, and the amount of 5360 change is proportional to the amount of radiation to which the device was exposed. A dosimeter 5361 of legal record is one that can be used, most often for workers, to record the "official" dose. 5362 5363 5364 Effective dose: Radiation-induced damage to certain tissues, for example the lung tissue, causes 5365 more harm to the health of the person as a whole than the same amount of radiation to other

Comment [DLM118]: Miller ... Tissue reaction is not defined.

Comment [M119]: MR ... see items under "simple definitions" (i.e., deterministic effect and tissue reaction).

Comment [CD120]: Cooll ... thought we were getting rid of this term for our recommendations. Comment [CD121]: Cool ... Need to be clear that this is annual occupational exposure if we use an example. To just say "a common..." does not do

it

tissues, for example the bone surfaces. To calculate the effective dose, one must not only know
how much total tissue mass has absorbed the radiation energy and the amount of that energy, but
also how sensitive the tissue is to radiation and to the overall well-being of the exposed
individual. Tissue weighting factors are available, often from empirical testing, to account for
these differences.

5371

5393

5402

5406

Equivalent dose: While the effective dose accounts for the different sensitivities of different 5372 organs, and the overall detriment to the whole body from the dose using tissue weighting factors, 5373 equivalent dose accounts for the fact that certain kinds of radiation are more harmful than others. 5374 For example, one milligray of alpha radiation dose to the tissues lining the deep lung tissues will 5375 cause roughly twenty times more damage that one milligray absorbed dose from beta radiation tp 5376 5377 those same tissues. Radiation weighting factors account for these differences. Multiplying the 5378 absorbed dose in gray by the radiation weighting factor yields the equivalent dose. Equivalent dose is measured in the unit Sievert (Sv). Tallying equivalent dose in sievert puts weight on the 5379 biological dose consequences in people no matter what type of radiation. With alpha and beta 5380 radiation, one milligray of alpha radiation results in an equivalent dose of twenty millisievert, 5381 while one milligray of beta radiation results in an equivalent dose of one millisievert. 5382 5383

External and Internal Dose: Radiation dose can be received from radioactive materials that are 5384 inside the body, perhaps from breathing in contaminated air or from drinking water with 5385 naturally occurring radium or uranium in it. This is called internal dose. When radiation dose is 5386 the result of exposure to machine generated radiation, or from radioactive materials outside the 5387 body, the dose is an external dose. The effects of a 1 millisievert dose from radioactive materials 5388 within the body or of a 1 millisievert dose from sources outside the body are equivalent. Because 5389 internal doses accumulate over the entire time it takes for the radioactive material to pass through 5390 the body, determining the dose from internal sources is often more complex than for those 5391 outside the body. 5392

5394 Genetic, Somatic and Teratogenic Risk: There are risks to health from radiation exposure. Those that affect our own tissues are called somatic risks. If the sex cells within our bodies, the 5395 sperm and ova, are exposed to the radiation, those cells may be affected increasing the risk of 5396 health effects for children conceived with those sperm or ova. These are genetic risks. If a 5397 woman is pregnant when she is exposed to radiation, and the radiation also exposes the embryo 5398 5399 or fetus simultaneously, there are risks that the child may be affected, as well as the mother. The risks to the embryo or fetus are teratogenic, and the dose to the embryo or fetus must be 5400 considered as well as the dose to the mother. 5401

5403 Gray (Gy): The gray is the unit of absorbed dose, and only for the total amount of radiation
5404 absorbed in some medium, for example air or human skin, and the total mass within which it was
5405 absorbed. The absorbed dose can be directly measured with instruments.

Half-life, including biological, physical and effective: Because radioactive materials transform
over time in a random manner, the time required for them to transform is a statistical term, the
half-life. It is the average time required for half the total amount of radioactive material to
transform. The time it takes for half the material to transform because of changes in the atomic

5418

5433

5445

NOT TO BE DISSEMINATED OR REFERENCED

5411 nucleus of the radioactive material is called the physical half-life. When radioactive materials are 5412 within our bodies, the term half-life is used to measure the time required for biological processes 5413 to eliminate half of the radioactive material from the body. This is called the biological half-life. 5414 Since radioactive materials in the body are subject to both physical radioactive transformation in 5415 the atomic nucleus and biological elimination from the body, the effective half-life is calculated 5416 to account for both the physical and the biological half-lives. When internal dose is calculated, 5417 the effective half-life must be applied.

Lifetime Risk: From the moment of conception, radiation exposure is a fact of life. Usually, the 5419 womb provides protection, but embryo and fetal dose may result in risk of teratogenic effects 5420 like microcephaly, smaller than average head size, or reduce the born child's mental function. 5421 5422 Throughout life outside the womb, there is constant radiation dose from naturally occurring 5423 radioactive materials and from machine-made radiations. Some of us experience more than 5424 others, depending on where we live, and, often, the number of medical conditions we experience 5425 where diagnostic or therapeutic doses are delivered with the care. There are also people who 5426 work with radiation, from health care providers to nuclear power plant workers, and they receive additional radiation dose beyond these "background" exposures. It is important to reduce the risk 5427 from all of these radiation doses incurred over our lifetimes. Knowing when and, where you can, 5428 to how much radiation you are exposed, for example by testing the air in your home for radon 5429 and keeping track of the number and type of radiology procedures you receive, can be as 5430 important as getting a record of occupational dose from your employer if you work in a job 5431 5432 requiring radiation exposure.

5434 Radiation: Radiation is the term often equated with x-rays from machines and the emissions of alpha, beta and gamma radiations from radioactive materials in our environment and used in 5435 various ways in occupations. Sound waves, radio waves and infrared, visible and ultraviolet light 5436 are also radiations, they move in a wave form through time and space. These though are called 5437 non-ionizing radiation, X, alpha, beta and gamma radiations are ionizing. The dose delivered by 5438 5439 non-ionizing radiations is primarily the result of physical disturbances, including some intense 5440 enough to increase tissue and whole body temperatures. Ionizing radiations deliver dose imperceptibly, imparting energy to individual atoms and molecules, even the genetic material 5441 within the nucleus of atoms. This energy can create charged particles called ions, and it is the 5442 dose delivered by these charged particles that we try to manage in traditional radiation 5443 protection. 5444

Radiation weighting factor: The different radiation types, for example, alpha, beta, gamma,
neutron and proton, cause different amounts of human tissue detriment. Radiation weighting
factors account for this. When the absorbed dose from radiation in gray is multiplied by the
weighting factor for that radiation, the product is the equivalent dose in sievert.

5451 Radioisotope and Radionuclide: Radioactive materials are unstable atoms that emit radiation to 5452 achieve stability. Otherwise, radioactive materials are chemically identical to stable atoms of the 5453 same material that do not emit radiation. Chemical identity and behavior is governed by the 5454 number of electrons possessed by an atom. The number of neutrons and protons, in simplest 5455 terms, defines the stability of the atom. Most atoms have numerous forms, and these are often Comment [M122]: Higley ... the definition of radiation weighting factor uses the word detriment. ICRP defines detriment as" Detriment The total harm to health experienced by an exposed group and its descendants as a result of the group's exposure to a radiation source. Detriment is a multidimensional concept. Its principal components are the stochastic quantities: probability of attributable fatal cancer, weighted probability of severe heritable effects, and length of life lost if the harm occurs." I'm not sure we're using the term appropriately in our definition.

In fact ICRP in 103 describes radiation weighting factor as "Radiation weighting factor, wR A dimensionless factor by which the organ or tissue absorbed dose is multiplied to reflect the higher biological effectiveness of high-LET radiations compared with low-LET radiations. It is used to derive the equivalent dose from the absorbed dose averaged over a tissue or organ."

MR ... an example of creating a newly worded definition (that confuses the issue) for a term that is clearly defined by the originating body (in this case ICRP). Section 5 and these "Glossaries" have a number of such cases.

5462

5470

NOT TO BE DISSEMINATED OR REFERENCED

referred to as different radioisotopes of the stable atom. Isotopes of an atom have the same
number of protons, but different numbers of neutrons in the nucleus. These different forms of a
chemical may also be referred to as radionuclides, radioactive materials with nuclei that are
different from isotope to another. Stable atoms deliver no radiation dose, while different
radioisotopes may actually deliver different amounts of radiation dose based upon the radiations
they emit trying to become stable.

Risk coefficient: When you correlate the radiation dose with the level of risk of an effect from that dose, it yields a risk coefficient. Typically, the risk coefficient is obtained by dividing the numeric level of risk by the radiation dose associated with it. This may yield, for example, a risk coefficient of 0.02 excess fatal cancers per gray of absorbed dose. You can see the varying level of risk with different doses on a graph where dose is plotted on the x-axis and the risk of cancer, for example, is plotted on the y-axis. Different shapes of the curve indicate doses where risk coefficients for cancer are higher or lower than for other doses.

5471 Sievert (Sv): This is the unit of equivalent dose. It account for the absorbed dose as well as the
5472 greater or lesser biological effects of that absorbed dose based on the types of radiation
5473 delivering the absorbed dose, that is, alpha, beta, gamma, neutron and proton. Radiation
5474 weighting factors are used to convert the absorbed dose in gray to equivalent dose for the type of

5475 radiation in sievert. 5476

5477 Stochastic effect: A stochastic effect is one where the level of risk for that effect is random in nature, but it generally increases with increasing dose.
5479

Tissue weighting factor: different human tissues have been shown to affect the overall health of the person to different degrees. Tissue weighting factors are used to account for these differences so the absorbed dose to one tissue can be related to the possible detriment to the person as a whole. This can be seen with the breast tissue weighting factor (0.15). It is higher than, for example, the thyroid tissue weighting factor (0.03) because the health effects from a given dose of radiation will be worse to the overall health of a person when the breast tissue absorbs it as compared to when the thyroid does. Comment [DLM123]: Miller ... And also effective dose.

NCRP CC 1 Draft of April 2016

5488 [Simple Definitions]

5495

5499

5503

5507

5514

5520

5525

Absorbed dose: The amount of radiation energy deposited in a unit mass of material such as
body tissue. It is expressed in units Gray (Gy) which equals the absorption of one joule of
energy per kilogram of material. Absorbed dose is typically used in assessing the severity of
tissue reactions due to short term (acute) radiation exposure. Absorbed dose also forms the basis
for calculating the probability of stochastic effects after accounting for the type and energy of
radiation and affected organ(s) – see "equivalent dose" and "effective dose".

Activity: The rate of transformation (decay) of radioactive materials. Activity is a measure of
the amount of radioactive material. It is expressed as the number of atoms breaking down per
second and is measured in unit of Becquerel (Bq).

Acute and Chronic Radiation Dose: An acute radiation dose is one where a high dose is
 received in a short time, and the effects result soon after. Chronic radiation doses are
 accumulated in small increments over a longer time, and the effects manifest later in life.

ALARA: As Low As Reasonably Achievable is a radiation protection approach where00 dose is
 reduced to the minimum practical level (such that the costs to reduce the dose are at least
 equivalent to the benefits).

ALI and DAC: The Annual Limit on Intake (ALI) is that amount of radioactive material (in
becquerel) taken into the body that will result in a dose of no more than 0.05 sieverts, the current
limit for occupational exposures in the United States. The Derived Air Concentration (DAC)
divides the Annual Limit on Intake by the amount of air a worker breathes in over the course of a
year to yield the radioactive material per volume of air in bequerels per liter. The Annual Limit
on Intake must also account for dose from radioactive materials that are ingested.

Background Radiation: This is the radiation not related to our occupation. It consists of dose
from medical uses of radiation, from radioactive materials in our environment, from radiations
from outer space, and from the use of radiation in industry. Occupational dose records do not
include background radiation. Reducing dose from background radiation doses is as important as
reducing them from work exposures.

5521 **Becquerel (Bq):** The special SI unit for measuring the amount of radioactivity. One Bq is a very 5522 small quantity and equals one radioactive atom disintegrating per second. It is more common to 5523 use multiples of Bq such as kBq (kilobequerel, or 1,000 Bq), MBq (megabequerel, or $1x10^6$ Bq), 5524 GBq (gigabequerel, or $1x10^9$ Bq) or TBq (terabequerel, or $1x10^{12}$ Bq).

Bioassay: An assessment of the amount of radioactive material in the body. Direct bioassay
(also called in vivo assay) measures the radiation coming directly from the body. Indirect
bioassay (also called in vitro assay) measures the amount of radioactivity in material excreted or
otherwise removed from the body such as urine, feces, or hair.

5531 **Biodosimetry:** Biodosimetry is the use of changes in our bodies, like chromosome aberrations 5532 for low doses and skin reddening for high doses, to estimate dose.

5533

5538

5542

5548

5553

5559

5566

5570

5573

Committed effective dose: The sum of the weighted committed equivalent doses to all body
organs. The committed equivalent dose to each organ is weighted by that organ's tissue
weighting factor. The accumulated dose from radioactive material inside the body is calculated
for 50 y to the future for adults and to age 70 for children.

5539 **Committed equivalent dose:** Accounts for continuing radiation exposure to body organs from 5540 radioactive material inside the body. This accumulated dose to each organ is typically calculated 5541 for 50 y to the future for adults and to age 70 for children.

5543 **Deterministic effect (see tissue reaction):** Adverse health effect to an organ or series of organs 5544 for which the severity of the effect increases with increasing radiation dose. Typically, there is a 5545 dose threshold below which deterministic effects will not occur. Examples of deterministic 5546 effects are the development of cataracts due to irradiation of the eye, erythema (reddening) of the 5547 skin due to dermal irradiation, cutaneous radiation injury and acute radiation syndrome.

5549 Detriment: An overall measure of the probability of occurrence of stochastic effects due to
5550 radiation exposure. Detriment is the sum of the probabilities of all stochastic effects (fatal
5551 cancer, morbidity from non-fatal cancer, and heritable effects) due to exposure to ionizing
5552 radiation.

Dose and Dose Rate: Dose is the term used to account for the amount of radiation a person is effected by. It is usually measured with an instrument, but it can also be estimated, calculated or reconstructed from facts about the time and types of radiation exposure. The dose rate is usually measured with an instrument in units of radiation per unit time, as in microsieverts per hour. The dose equals the dose rate multiplied the time.

Dose coefficient: A factor used to calculate radiation doses from either a) an internal exposure due to radioactive material taken into the body or b) an external exposure due to radioactive material in the environment. Dose coefficients vary depending on the particular radionuclides and the route of intake (e.g., ingestion or inhalation. Furthermore, dose coefficients may be expressed in terms of either equivalent dose or effective dose, and care must be exercised in selection of the appropriate dose coefficients for the desired result.

5567 **Dose Limit:** Dose limits are used to control occupational exposures. A common dose limit in the 5568 United States is no more than 0.05 sieverts whole body for a year. There may be other limits, for 5569 example, for the lens of the eye or the extremities.

5571 **Dose Reconstruction:** This is how a person's radiation exposure is calculate from evidence 5572 about the radiation exposure's duration, intensity and type..

5574 **Dosimeter:** This is usually a device which measures dose, like a film badge or a

thermoluminescent or optically stimulated luminescent dosimeter. The radiation alters the

5576 material within the dosimeter, and the amount of change is proportional to the amount of

Comment [DLM124]: Miller ... Circular; the definition for tissue reaction is "see deterministic effect"!

Comment [M125]: MR ... see Preston Glossary addition later in this list for tissue reaction. Need to combine these inputs into one entry (under tissue reaction)

5579

5586

5593

5597

5603

radiation to which the device was exposed. A dosimeter of legal record is one used, mostly forworkers, to record the "official" dose.

Effective dose: A quantity used in radiation protection to evaluate the overall health effects of
radiation exposure on the whole body. This quantity takes into account the absorbed doses
received by various organs and tissues and weighs them according to present knowledge of the
sensitivity of each organ to radiation. It also accounts for the type and energy of radiation and the
potential for each type to inflict biologic damage. Effective dose is expressed in units of Sievert
(Sv) or millisieverts (mSv) where 1 Sv equals 1000 mSv.

Equivalent dose: A quantity used in radiation protection to place all types and energies of
radiation on a common scale regarding the stochastic health effects that could result from
exposure to such radiations. To calculate equivalent dose, the absorbed dose (in units of Gy) is
multiplied by a unit-less factor determined by the type and energy of the radiation (see the
"radiation weighting factor"). Equivalent dose is expressed in units of Sievert (Sv) or
millisieverts (mSv) where 1 Sv equals 1000 mSv.

External and Internal Dose: Radiation dose received from radioactive materials inside the body
is called internal dose. When the radiation dose is the result of exposure to sources outside the
body, it is called external dose.

Genetic, Somatic and Teratogenic Risk: Those risks of radiation exposure that affect your own tissues are somatic risks. Genetic risks arise when the sperm cells or ova are exposed to radiation and the effects are seen in children subsequently conceived. If a pregnant woman and her embryo or fetus is exposed simultaneously, there are risks that the child may be affected, as well as the mother. The risks to the embryo or fetus are teratogenic.

5604 Gray (Gy): The SI special unit for absorbed dose. One Gy is equivalent to deposition of 1 joule
of radiation energy in 1 kilogram of material such as body tissue. (see "absorbed dose").
5606

Half-life, including biological, physical and effective: The time required for radioactive 5607 materials to transform to a stable state is its half-life, the average time required for half the 5608 radioactive material to transform. The physical half-life is the time it takes for half the material 5609 to transform with changes in the atomic nucleus. When radioactive materials are within the body, 5610 the biological half-life accounts for the time for biological processes to eliminate half of them 5611 from the body. Since the materials are subject to both physical nuclear transformation and 5612 biological elimination, the effective half-life is calculated to account for both. The effective half-5613 life must be applied when internal dose is calculated. 5614 5615

Lifetime Risk: Embryo and fetal dose may result in risk of teratogenic effects like microcephaly
 or reduced mental function. Throughout life, all of us are subject to the ionizing radiation dose
 from naturally occurring radioactive materials, and from diagnostic and therapeutic exposure in
 medical care. Some also receive occupational ionizing radiation dose beyond these "background"
 exposures. Working from the tenet that any ionizing radiation exposure increases our risk of

5631

5646

adverse health consequences, it is important to reduce all of these ionizing radiation dosesincurred over our lifetimes.

5623
5624 Radiation: Radiation is not just the term associated with x-rays from machines and the
5625 emissions of alpha, beta and gamma radiations from radioactive materials in our environment
and used in various ways in industry. It is also used for sound waves, radio waves and infrared,
visible and ultraviolet light. X, alpha, beta and gamma radiations are ionizing radiations. Ionizing
radiations impart energy to individual atoms and molecules, even the genetic material within the
nucleus of atoms, and it can create charged particles called ions. Ionizing radiation dose is
delivered by these charged particles.

Radiation weighting factor: Expresses the biological effectiveness of different ionizing
radiations when calculating equivalent doses. It is a unit-less number, and assumed to be
independent of the tissue or organ irradiated. For gamma radiation, this multiplier is 1. Some
ionizing radiations, such as high-energy beta particles, alpha particles and neutrons, cause more
damage per unit of absorbed dose than does gamma radiation, and have radiation weighting
factors ranging as high as 20.

Radioisotope and Radionuclide: Radioactive materials are unstable atoms that emit ionizing radiation to achieve stability. The number of neutrons and protons, in simplest terms, defines the stability of the atom. Isotopes of an atom have the same number of protons, but different numbers of neutrons in the nucleus. These different forms of the same chemical may also be referred to as radionuclides, radioactive materials with nuclei that are different from one isotope to another. Stable atoms deliver no ionizing radiation dose. Different radioisotopes may deliver different radiation doses based upon the radiations they emit trying to become stable.

Risk coefficient: is the probability of a stochastic health effect such as cancer per unit of
 ionizing radiation dose. Risk coefficient may also be expressed as the probability of cancer per
 unit of radioactivity taken inside the body, or per unit of radioactivity in the environment.

Sievert (Sv): The SI special unit for equivalent dose and effective dose. One Sv equals 1
joule/kilogram absorbed dose, multiplied by one or more multipliers for the organ(s) considered,
the type and energy of ionizing radiation, or both.

5654
5655 Stochastic effect: Adverse health effects to an organ or series of organs for which the
probability of occurrence increases with increasing ionizing radiation dose. An example of
stochastic effects is the development of cancer. The severity of such stochastic (random) effects
does not change with increasing dose, and their onset does not typically exhibit a dose threshold.

5660 Tissue reaction: See "deterministic effect". For protection purposes the biological effects of
 5661 radiation are separated into stochastic effects (cancer, heritable effects) and tissue reactions. The
 5662 latter had previously been termed deterministic effects but were renamed as tissue reactions in
 5663 ICRP (2007a) because of the enhanced evidence that these responses could be modified after
 5664 irradiation rather than being determined at the time of irradiation. Such tissue reactions can occur

NOT TO BE DISSEMINATED OR REFERENCED

5665	at early or late times after irradiation. In addition, they typically exhibit a threshold dose that has	
5666	been the basis for establishing recommended dose limits.	 Comment [M126]: Preston revision
5667		
5668	Tissue weighting factor: Expresses the contribution of detriment in a particular organ to total	
5669	detriment to the body as a whole. It is a unit-less number between 0 and 1, and it is assumed to	
5670	be independent of the type or energy of ionizing radiation.	
5671		

5672 Glossary (usual style) (example)

as low as reasonably achievable (ALARA**):** A principle of radiation protection philosophy that

5675 requires that exposures to ionizing radiation be kept as low as reasonably achievable,

5676 economic and societal factors being taken into account. The ALARA principle is satisfied

5677 when the expenditure of further resources would be unwarranted by the reduction in

5678 exposure that would be achieved.

5679

Abbreviations, Acronyms and Symbols

5681		
5603	ΔΙΔΡΔ	as low as reasonably achievable (the ALARA principle)
5002	REDE	hiologically based dose response (model)
5065		confidence interval
5084		
5685	CNS	central nervous system
5686	СТ	computed tomography
5687	CVD	cardiovascular disease
5688	DCRL	derived consideration reference level
5689	DDREF	dose and dose-rate effectiveness factor
5690	(D)DREF	dose and dose-rate effectiveness factor (alternate presentation)
5691	DNA	deoxyribonucleic acid
5692	DREF	dose-rate effectiveness factor
5693	E	effective dose
5694	EAR	excess absolute risk
5695	ERR	excess relative risk
5696	FGI	fluoroscopically-guided interventional (procedure)
5697	HZE	high atomic number, high-energy (particle)
5698	SI	Systeme Internationale (International System of Quantities and Units)
5699	LDEF	low-dose effectiveness factor
5700	LET	linear energy transfer
5701	LQ	linear-quadratic (model or curve)
5702	LSS	Life Span Study
5703	RBE	relative biological effectiveness
5704	SMR	standardized mortality ratio
5705 5706	The NCRP System	the System for Radiation Protection for the United States
5707	WR	radiation weighting factor
5708	$\underline{\mathbf{W}}_{\mathrm{T}}$	tissue weighting factor
5709		